ASML Holding (ASML) 20-F 12 Feb 14 2013 FY Annual report (foreign) Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Dec. 31, 2013
Document And Entity Information [Abstract]	'
Document Type	'20-F
Amendment Flag	'false
Document Period End Date	31-Dec-13
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'FY
Trading Symbol	'ASML
Entity Registrant Name	'ASML HOLDING NV
Entity Central Index Key	'0000937966
Current Fiscal Year End Date	'--12-31
Entity Well-known Seasoned Issuer	'Yes
Entity Current Reporting Status	'Yes
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	440,852,334

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (EUR €)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Income Statement [Abstract]	'		'		'
Net sales	€ 5,245,326		€ 4,731,555		€ 5,651,035
Cost of sales	-3,068,064		-2,726,298		-3,201,645
Gross profit	2,177,262		2,005,257		2,449,390
Other income	64,456		'		'
Research and development costs	-882,029		-589,182		-590,270
Selling, general and administrative costs	-311,741		-259,301		-217,904
Income from operations	1,047,948		1,156,774		1,641,216
Interest and other, net	-24,471		-6,196		7,419
Income before income taxes	1,023,477		1,150,578		1,648,635
Provision for income taxes	-7,987		-4,262		-181,675
Net income	1,015,490		1,146,316		1,466,960
Basic net income per ordinary share	€ 2.36		€ 2.70		€ 3.45
Diluted net income per ordinary share	€ 2.34	[1]	€ 2.68	[1]	€ 3.42	[1]
Number of ordinary shares used in computing per share amounts (in thousands)	'		'		'
Basic	429,770		424,096		425,618
Diluted	433,446	[1]	426,986	[1]	429,053	[1]
System sales [Member]	'		'		'
Income Statement [Abstract]	'		'		'
Net sales	3,993,129		3,801,632		4,883,913
Cost of sales	-2,233,621		-2,198,921		-2,793,931
Service and field option sales [Member]	'		'		'
Income Statement [Abstract]	'		'		'
Net sales	1,252,197		929,923		767,122
Cost of sales	-€ 834,443		-€ 527,377		-€ 407,714
[1]	The calculation of diluted net income per ordinary share assumes the exercise of options issued under our stock option plans and the issuance of shares under our share plans for periods in which exercises or issuances would have a dilutive effect. The calculation of diluted net income per ordinary share does not assume exercise of such options or issuance of shares when such exercises or issuance would be anti-dilutive.

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Income And Comprehensive Income [Abstract]	'	'	'
Net income	€ 1,015,490	€ 1,146,316	€ 1,466,960
Foreign currency translation, net of taxes:	'	'	'
Gain (loss) on foreign currency translation	-113,779	8,063	-17,473
Financial instruments, net of taxes:	'	'	'
Gain (loss) on derivative financial instruments	-5,370	214	-4,610
Transfers to net income	-2,276	-7,761	51,963
Other comprehensive income, net of taxes	-121,425	516	29,880
Total comprehensive income, net of taxes	894,065	1,146,832	1,496,840
Attributable to equity holders	€ 894,065	€ 1,146,832	€ 1,496,840

Consolidated_Balance_Sheets

Consolidated Balance Sheets (EUR €)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Assets	'		'
Cash and cash equivalents	€ 2,330,694		€ 1,767,596
Short-term investments	679,884		930,005
Accounts receivable, net	878,321		605,288
Finance receivables, net	250,472		265,167
Current tax assets	32,333		57,116
Inventories, net	2,393,022		1,856,970
Deferred tax assets	124,431		103,695
Other assets	336,421		246,005
Total current assets	7,025,578		5,831,842
Finance receivables, net	46,017		38,621
Deferred tax assets	139,513		39,443
Other assets	298,559		311,538
Goodwill	2,088,589		149,168
Other intangible assets, net	697,634		9,943
Property, plant and equipment, net	1,217,840		1,029,923
Total non-current assets	4,488,152		1,578,636
Total assets	11,513,730		7,410,478
Liabilities and shareholders' equity	'		'
Accounts payable	625,870		188,961
Accrued and other liabilities	2,216,882		1,880,370
Current tax liabilities	15,803		10,791
Current portion of long-term debt	4,385		3,610
Provisions	2,227		2,280
Deferred and other tax liabilities	3,494		271
Total current liabilities	2,868,661		2,086,283
Long-term debt	1,070,185		755,880
Deferred and other tax liabilities	364,695		88,307
Provisions	4,620		7,974
Accrued and other liabilities	283,142	[1]	405,141	[1]
Total non-current liabilities	1,722,642		1,257,302
Total liabilities	4,591,303		3,343,585
Commitments and contingencies	'		'
Cumulative Preference Shares	'		'
Ordinary Shares	40,092		37,470
Share premium	2,912,862		483,651
Treasury shares at cost	-364,702		-464,574
Retained earnings	4,376,613		3,931,359
Accumulated other comprehensive income	-42,438		78,987
Total shareholders' equity	6,922,427		4,066,893
Total liabilities and shareholders' equity	11,513,730		7,410,478
Common Class B [Member]	'		'
Liabilities and shareholders' equity	'		'
Ordinary Shares	'		'
[1]	The main part of the non-current portion of accrued and other liabilities relates to down payments received from customers regarding future shipments of EUV systems and deferrals with respect to services.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
Cumulative Preference Shares, nominal value	€ 0.09	€ 0.09
Cumulative Preference Shares, authorized (actual number of shares)	700,000,000	700,000,000
Cumulative Preference Shares, outstanding (actual number of shares)	'	'
Ordinary Shares, nominal value	€ 0.09	€ 0.09
Ordinary Shares, authorized (actual number of shares)	699,999,000	699,999,000
Ordinary Shares, outstanding (actual number of shares)	440,852,334	407,165,221
Common Class B [Member]	'	'
Ordinary Shares, nominal value	€ 0.01	€ 0.01
Ordinary Shares, authorized (actual number of shares)	9,000	9,000
Ordinary Shares, outstanding (actual number of shares)	'	'

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (EUR €)		Total		Issued and Outstanding Shares [Member]		Share Premium [Member]	Treasury Shares at cost [Member]	Retained Earnings [Member]	Accumulated OCI [Member]
In Thousands, except Share data, unless otherwise specified
Beginning Balance at Dec. 31, 2010		€ 2,773,908		€ 39,293		€ 471,253	-€ 151,672	€ 2,366,443	€ 48,591	[1]
Beginning Balance, shares at Dec. 31, 2010	[2]	'		436,593,000		'	'	'	'
Components of comprehensive income:		'		'		'	'	'	'
Net income		1,466,960		'		'	'	1,466,960	'
Foreign Currency Translation, net of taxes		-17,473		'		'	'	'	-17,473
Gain (loss) on financial instruments, net of taxes		47,353		'		'	'	'	47,353
Total comprehensive income, net of taxes		1,496,840		'		'	'	1,466,960	29,880
CCIP:		'		'		'	'	'	'
Purchase of treasury shares		-700,452		'		'	-700,452	'	'
Purchase of treasury shares, shares	[2]	'		-25,675,000		'	'	'	'
Cancellation of treasury shares		'		-1,187		'	373,801	-372,614	'
Share-based payments		12,430		'		12,430	'	'	'
Issuance of shares		34,084		248		-10,629	61,906	-17,441	'
Issuance of shares, shares	[2]	'		2,751,000		'	'	'	'
Dividend paid		-172,645		'		'	'	-172,645	'
Tax benefit/deficit from share-based payments		-11		'		-11	'	'	'
Ending Balance at Dec. 31, 2011		3,444,154		38,354		473,043	-416,417	3,270,703	78,471	[1]
Ending Balance, shares at Dec. 31, 2011	[2]	'		413,669,000		'	'	'	'
Components of comprehensive income:		'		'		'	'	'	'
Net income		1,146,316		'		'	'	1,146,316	'
Foreign Currency Translation, net of taxes		8,063		'		'	'	'	8,063
Gain (loss) on financial instruments, net of taxes		-7,547		'		'	'	'	-7,547
Total comprehensive income, net of taxes		1,146,832		'		'	'	1,146,316	516
CCIP:		'		'		'	'	'	'
Issuance of shares		3,977,368		8,691		3,968,677	'	'	'
Issuance of shares, shares	[2]	'		96,566,000		'	'	'	'
Fair value differences	[3]	-123,416		'		-123,416	'	'	'
Capital repayment	[4]	-3,728,324	[5]	-8,691		-3,845,261	125,628	'	'
Capital repayment, shares	[2]	'		-93,411,000		'	'	'	'
Purchase of treasury shares		-535,373		-198		'	-535,175	'	'
Purchase of treasury shares, shares	[2]	'		-13,478,000		'	'	'	'
Cancellation of treasury shares		'		-1,030		'	294,752	-293,722	'
Share-based payments		18,714		'		18,714	'	'	'
Issuance of shares		53,714		344		-10,222	66,638	-3,046	'
Issuance of shares, shares	[2]	'		3,819,000		'	'	'	'
Dividend paid		-188,892		'		'	'	-188,892	'
Tax benefit/deficit from share-based payments		2,116		'		2,116	'	'	'
Ending Balance at Dec. 31, 2012		4,066,893		37,470		483,651	-464,574	3,931,359	78,987	[1]
Ending Balance, shares at Dec. 31, 2012		407,165,221		407,165,000	[2]	'	'	'	'
Components of comprehensive income:		'		'		'	'	'	'
Net income		1,015,490		'		'	'	1,015,490	'
Foreign Currency Translation, net of taxes		-113,779		'		'	'	'	-113,779
Gain (loss) on financial instruments, net of taxes		-7,646		'		'	'	'	-7,646
Total comprehensive income, net of taxes		894,065		'		'	'	1,015,490	-121,425
CCIP:		'		'		'	'	'	'
Fair value differences	[6]	20,956		'		20,956	'	'	'
Purchase of treasury shares		-300,000		'		'	-300,000	'	'
Purchase of treasury shares, shares	[2]	'		-4,614,000		'	'	'	'
Cancellation of treasury shares		'		-854		'	349,261	-348,407	'
Share-based payments	[7]	95,895		'		95,895	'	'	'
Issuance of shares	[8]	2,357,593		3,476		2,309,250	50,611	-5,744	'
Issuance of shares, shares	[2],[8]	'		38,301,000		'	'	'	'
Dividend paid		-216,085		'		'	'	-216,085	'
Tax benefit/deficit from share-based payments		3,110		'		3,110	'	'	'
Ending Balance at Dec. 31, 2013		€ 6,922,427		€ 40,092		€ 2,912,862	-€ 364,702	€ 4,376,613	-€ 42,438	[1]
Ending Balance, shares at Dec. 31, 2013		440,852,334		440,852,000	[2]	'	'	'	'
[1]	As of December 31, 2013, accumulated OCI, net of taxes, consists of EUR 30.2 million relating to foreign currency translation loss (2012: EUR 83.5 million; 2011: EUR 75.5 million) and EUR 12.2 million relating to unrealized losses on financial instruments (2012: EUR 4.5 million losses; 2011: EUR 3.0 million gains).
[2]	As of December 31, 2013, the number of issued shares was 446,822,452. This includes the number of issued and outstanding shares of 440,852,334 and the number of treasury shares of 5,970,118. As of December 31, 2012, the number of issued shares was 419,852,467. This includes the number of issued and outstanding shares of 407,165,221 and the number of treasury shares of 12,687,246.
[3]	The difference between the fair value of the shares and the subscription price of the shares issued to the Participating Customers in the CCIP.
[4]	In 2012, as part of the capital repayment, EUR 3,728.3 million of shareholders' equity was returned to our shareholders (excluding Participating Customers in the CCIP) and the number of shares was reduced by 23 percent. See Note 26.
[5]	The difference of EUR 125.6 million between the capital repayment of EUR 3,728.3 million and the net proceeds from issuance of shares of EUR 3,853.9 million relates to the capital repayment on ASML's treasury shares which was also part of the Synthetic Share Buyback in November 2012.
[6]	EUR 21.0 million is recognized to increase equity to the fair value of the shares issued to the Participating Customers in the CCIP. The portion of the NRE funding allocable to the shares is recognized over the NRE Funding Agreements period (2013-2017).
[7]	Share-based payments include an amount of EUR 43.5 million in relation to the fair value compensation of unvested equity awards exchanged as part of acquisition of Cymer.
[8]	Issuance of shares includes 36,464,576 ordinary shares issued in relation to the acquisition of Cymer for a total fair value of EUR 2,346.7 million. The difference of EUR 1.0 million with the fair value of shares as disclosed in Note 2 is explained by 14,533 shares still to be issued to former Cymer shareholders.

Consolidated_Statements_of_Sha1

Consolidated Statements of Shareholders' Equity (Parenthetical) (EUR €)	0 Months Ended	12 Months Ended
	30-May-13	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Number of issued shares	'	446,822,452		419,852,467		'
Number of issued and outstanding shares	'	440,852,334		407,165,221		'
Number of treasury shares	'	5,970,118		12,687,246		'
Accumulated OCI, net of taxes relating to foreign currency translation loss	'	€ 30,200,000		€ 83,500,000		€ 75,500,000
Accumulated OCI, net of taxes unrealized gains (losses) on financial instruments	'	-12,200,000		-4,500,000		3,000,000
Payment for Synthetic Share Buyback	'	'		3,728,324,000	[1],[2]	'
Reduction percentage in number of shares	'	'		23.00%		'
Fair value of shares issued to participating customers	'	-20,956,000	[3]	123,416,000	[4]	'
Fair value compensation of unvested equity awards to be exchanged	43,527,000	43,527,000		'		'
Ordinary shares issued	36,479,109	'		'		'
Total fair value shares issued Cymer acquisition	'	2,346,700,000		'		'
Fair value of equity interest outstanding	'	1,000,000		'		'
Ordinary Shares Issued in Relation to Acquisition of Cymer [Member]	'	'		'		'
Ordinary shares issued	'	36,464,576		'		'
Ordinary Shares to be Issued [Member]	'	'		'		'
Ordinary shares issued	'	14,533		'		'
CCIP [Member]	'	'		'		'
Fair value of shares issued to participating customers	'	-€ 20,956,000		'		'
[1]	In 2012, as part of the capital repayment, EUR 3,728.3 million of shareholders' equity was returned to our shareholders (excluding Participating Customers in the CCIP) and the number of shares was reduced by 23 percent. See Note 26.
[2]	The difference of EUR 125.6 million between the capital repayment of EUR 3,728.3 million and the net proceeds from issuance of shares of EUR 3,853.9 million relates to the capital repayment on ASML's treasury shares which was also part of the Synthetic Share Buyback in November 2012.
[3]	EUR 21.0 million is recognized to increase equity to the fair value of the shares issued to the Participating Customers in the CCIP. The portion of the NRE funding allocable to the shares is recognized over the NRE Funding Agreements period (2013-2017).
[4]	The difference between the fair value of the shares and the subscription price of the shares issued to the Participating Customers in the CCIP.

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Cash Flows from Operating Activities	'		'		'
Net income	€ 1,015,490		€ 1,146,316		€ 1,466,960
Adjustments to reconcile net income to net cash flows from operating activities:	'		'		'
Depreciation and amortization	228,775		186,620		165,185
Impairment	13,057		3,234		12,272
Loss on disposal of property, plant and equipment	2,823	[1]	2,272	[1]	3,368	[1]
Share-based payments	52,371		18,714		12,430
Allowance for doubtful receivables	1,062	[2]	458	[2]	849
Allowance for obsolete inventory	164,852		130,911		60,300
Deferred income taxes	-22,658		-72,374		63,250
Changes in assets and liabilities:	'		'		'
Accounts receivable	-192,149		246,982		267,209
Finance receivables	9,277		-225,103		-37,301
Inventories	-518,121	[1]	-352,716	[1]	-276,243	[1]
Other assets	-32,941		19,117		-58,292
Accrued and other liabilities	-57,282		-147,691		589,217
Accounts payable	321,486		-225,083		-126,234
Current income taxes	68,131		-28,179		-72,530
Net cash provided by operating activities	1,054,173		703,478		2,070,440
Cash Flows from Investing Activities	'		'		'
Purchase of property, plant and equipment	-210,804	[1]	-171,878	[1]	-300,898	[1]
Purchase of intangible assets	-4,000		-7,658		'
Purchase of available for sale securities	-904,856		-1,379,997		'
Maturity of available for sale securities	1,195,031		449,992		'
Acquisition of subsidiaries (net of cash acquired)	-443,712	[3]	-10,292		'
Net cash used in investing activities	-368,341		-1,119,833		-300,898
Cash Flows from Financing Activities	'		'		'
Dividend paid	-216,085		-188,892		-172,645
Purchase of shares	-300,000		-535,373		-700,452
Net proceeds from issuance of shares	31,822		3,907,666	[4]	34,084
Net proceeds from issuance of notes	740,445	[5]	'		'
Repurchase of notes	-368,303	[6]	'		'
Capital repayment	'		-3,728,324	[7],[8]	'
Deposits from customers	'		'		-150,000
Repayment of debt	-4,100		-2,776		-2,537
Tax benefit (deficit) from share-based payments	3,110		2,116		-11
Net cash provided by (used in) financing activities	-113,111		-545,583		-991,561
Net cash flows	572,721		-961,938		777,981
Effect of changes in exchange rates on cash	-9,623		-2,248		3,967
Net increase (decrease) in cash and cash equivalents	563,098		-964,186		781,948
Cash and cash equivalents at beginning of the year	1,767,596		2,731,782		1,949,834
Cash and cash equivalents at end of the year	2,330,694		1,767,596		2,731,782
Supplemental Disclosures of Cash Flow Information:	'		'		'
Interest paid	-50,535		-37,906		-35,919
Income taxes paid	-€ 2,278		-€ 109,504		-€ 202,312
[1]	An amount of EUR 115.9 million (2012: EUR 204.8 million, 2011: EUR 300.5 million) of the additions in property, plant and equipment relates to non-cash transfers from inventory, an amount of EUR 12.5 million (2012: EUR 9.6 million, 2011: EUR 17.7 million) relates to other non-cash movements (mainly investments not yet paid and inceptions of finance lease arrangements) and an amount of EUR 48.2 million (2012: EUR 222.9 million, 2011: EUR 145.3 million) of the disposal of property, plant and equipment relates to non-cash transfers to inventory. Since the transfers between inventory and property, plant and equipment are non-cash events, these are not reflected in these Consolidated Statements of Cash Flows. For further details see Note 12.
[2]	The addition for the year is recorded in the cost of sales.
[3]	In addition to the cash paid in relation to the acquisition of Cymer, we issued 36,464,576 shares for an amount of EUR 2,346.7 million (non-cash event) as part of the consideration paid.
[4]	The net proceeds from issuance of shares includes an amount of EUR 3,853.9 million related to the share issuances in connection to the CCIP.
[5]	Net proceeds from issuance of notes relate to the total cash proceeds of EUR 740.4 million (net of incurred transaction costs) from the offering of our EUR 750 million 3.375 percent senior notes due 2023.
[6]	Repurchase of notes relates to the net cash outflows of EUR 368.3 million for the partial repurchase of our EUR 600 million 5.75 percent senior notes due 2017 including the partial unwinding of the related interest rate swaps.
[7]	In 2012, as part of the capital repayment, EUR 3,728.3 million of shareholders' equity was returned to our shareholders (excluding Participating Customers in the CCIP) and the number of shares was reduced by 23 percent. See Note 26.
[8]	The difference of EUR 125.6 million between the capital repayment of EUR 3,728.3 million and the net proceeds from issuance of shares of EUR 3,853.9 million relates to the capital repayment on ASML's treasury shares which was also part of the Synthetic Share Buyback in November 2012.

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (EUR €)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
						Ordinary Shares Issued in Relation to Acquisition of Cymer [Member]	3.375 Percent Senior Notes Due 2023 [Member]	5.75 Percent senior notes due 2017 [Member]
Additions related to non-cash transfers from inventory	€ 115,900,000		€ 204,800,000		€ 300,500,000	'	'	'
Repurchase of notes	368,303,000	[1]	'		'	'	'	368,303,000
Amount relates to other non-cash transfers from inventory	12,500,000		9,600,000		17,700,000	'	'	'
Disposal related to non-cash transfers to inventory	48,200,000		222,900,000		145,300,000	'	'	'
Ordinary shares issued in relation to acquisition of Cymer	'		'		'	36,464,576	'	'
Total fair value shares issued Cymer acquisition	2,346,700,000		'		'	'	'	'
Shares issued under CCIP	'		3,853,900,000		'	'	'	'
Net proceeds from issuance of notes	740,445,000	[2]	'		'	'	740,445,000	'
Principal amount	600,000,000		'		'	'	750,000,000	600,000,000
Interest rate on principal amount of Eurobond	5.75%		'		'	'	3.38%	5.75%
Year of maturity	'2017		'		'	'	'2023	'2017
Capital repayment on ASML's treasury shares	'		125,600,000		'	'	'	'
Payment for Synthetic Share Buyback	'		€ 3,728,324,000	[3],[4]	'	'	'	'
[1]	Repurchase of notes relates to the net cash outflows of EUR 368.3 million for the partial repurchase of our EUR 600 million 5.75 percent senior notes due 2017 including the partial unwinding of the related interest rate swaps.
[2]	Net proceeds from issuance of notes relate to the total cash proceeds of EUR 740.4 million (net of incurred transaction costs) from the offering of our EUR 750 million 3.375 percent senior notes due 2023.
[3]	In 2012, as part of the capital repayment, EUR 3,728.3 million of shareholders' equity was returned to our shareholders (excluding Participating Customers in the CCIP) and the number of shares was reduced by 23 percent. See Note 26.
[4]	The difference of EUR 125.6 million between the capital repayment of EUR 3,728.3 million and the net proceeds from issuance of shares of EUR 3,853.9 million relates to the capital repayment on ASML's treasury shares which was also part of the Synthetic Share Buyback in November 2012.

General_Information_Summary_of

General Information / Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
General Information / Summary of Significant Accounting Policies	'
	1. General Information / Summary of Significant Accounting Policies
	ASML, with its corporate headquarters in Veldhoven, the Netherlands, is engaged in the development, production, marketing, selling and servicing of advanced semiconductor equipment systems, exclusively consisting of lithography systems. ASML’s principal operations are in the Netherlands, the United States of America and Asia.
	Our shares are listed for trading in the form of registered shares on NASDAQ and on NYSE Euronext Amsterdam. The principal trading market of our ordinary shares is NYSE Euronext Amsterdam.
	Basis of Preparation
	The accompanying Consolidated Financial Statements are stated in thousands of EUR unless indicated otherwise.
	The accompanying Consolidated Financial Statements have been prepared in conformity with US GAAP.
	On May 30, 2013 we acquired 100 percent of the issued share capital of Cymer. Comparative financial information presented in the Consolidated Financial Statements does not include Cymer, unless stated otherwise.
	Use of Estimates
	The preparation of ASML’s Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities on the balance sheet dates, and the reported amounts of sales and costs during the reported periods. Actual results could differ from those estimates.
	Principles of Consolidation
	The Consolidated Financial Statements include the Financial Statements of ASML Holding N.V. and all of its subsidiaries and the VIE of which ASML is the primary beneficiary. All intercompany profits, balances and transactions have been eliminated in the consolidation.
	Subsidiaries
	Subsidiaries are all entities over which ASML has the power to govern financial and operating policies generally accompanying a shareholding of more than half of the voting rights. As from the date that these criteria are met, the financial data of the relevant subsidiaries are included in the consolidation.
	Business Combinations
	Acquisitions of subsidiaries are included on the basis of the acquisition method. The cost of acquisition is measured based on the consideration transferred at fair value, the fair value of identifiable assets distributed and the fair value of liabilities incurred or assumed at the acquisition date (i.e. the date at which we obtain control). The excess of the costs of an acquired subsidiary over the net of the amounts assigned to identifiable assets acquired and liabilities incurred or assumed, is capitalized as goodwill. Acquisition-related costs are expensed when incurred in the period they arise or the service is received.
	Variable Interest Entities
	We assess whether we have a controlling financial interest in any VIE and, thus, whether we are the VIE’s primary beneficiary. ASML shall be deemed to have a controlling financial interest in a VIE if it has both of the following characteristics: a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. If ASML has a controlling financial interest in a VIE, it is required to consolidate the VIE.
	Foreign Currency translation
	The financial information for subsidiaries outside the euro-zone is generally measured using local currencies as the functional currency. The Financial Statements of those foreign subsidiaries are translated into euros in the preparation of ASML’s consolidated financial statements. Assets and liabilities are translated into euros at the exchange rate in effect on the respective balance sheet dates. Income and costs are translated into euros based on the average exchange rate for the corresponding period. The resulting translation adjustments are recorded directly in shareholders’ equity.
	Derivative Financial Instruments
	We principally use derivative hedging instruments for the management of foreign currency risks and interest rate risks. We measure all derivative hedging instruments based on fair values derived from market prices of the instruments. We adopt hedge accounting for hedges that are highly effective in offsetting the identified hedged risks taking into account required effectiveness criteria.
	Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently remeasured at their fair value. The method of recognizing the resulting gain or loss depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the item being hedged. We designate certain derivatives as either:
	•		A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk (fair value hedge); or
	•		A hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk (cash flow hedge).
	We document at the inception of the transaction the relationship between hedging instruments and hedged items, as well as our risk management objectives and strategy for undertaking various hedging transactions. We also document our assessment, both at hedge inception and on an ongoing basis, of whether derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items.
	Fair Value Hedge
	Changes in the fair value of a derivative financial instrument, that is designated and qualified as a fair value hedge, along with the gain or loss on the hedged asset or liability that is attributable to the hedged risk, are recorded in the Consolidated Statements of Operations.
	Hedge accounting is discontinued when we revoke the hedging relationship, the hedging instrument expires or is sold, terminated or exercised, or no longer qualifies for hedge accounting. The adjustment to the carrying amount of the hedged item arising from the hedged risk is amortized to the Consolidated Statements of Operations from that date.
	Interest rate swaps that are being used to hedge the fair value of fixed loan coupons payable are designated as fair value hedges. The change in fair value is intended to offset the change in the fair value of the underlying fixed loan coupons, which is recorded accordingly. The gain or loss relating to the ineffective portion of interest rate swaps hedging fixed loan coupons payable is recognized in the Consolidated Statements of Operations as “interest and other, net”.
	Cash Flow Hedge
	Changes in the fair value of a derivative that is designated and qualified as a cash flow hedge are recorded in OCI, net of taxes, until the underlying hedged transaction is recognized in the Consolidated Statements of Operations. In the event that the underlying hedge transaction will not occur within the specified time period, the gain or loss on the related cash flow hedge is released from OCI and included in the Consolidated Statements of Operations, unless, extenuating circumstances exist that are related to the nature of the forecasted transaction and are outside our control or influence and which cause the forecasted transaction to be probable of occurring on a date that is beyond the specified time period.
	Foreign currency hedging instruments that are being used to hedge cash flows related to forecasted sales or purchase transactions in non-functional currencies are designated as cash flow hedges. The gain or loss relating to the ineffective portion of the foreign currency hedging instruments is recognized in the Consolidated Statements of Operations in “net sales” or “cost of sales”.
	Interest rate swaps that are being used to hedge changes in the variability of future interest cash flows to certain of our operating lease obligations are designated as cash flow hedges. The changes in fair value of the derivatives are intended to offset changes in future interest cash flows of such operating lease obligations. The gain or loss relating to the ineffective portion of interest rate swaps hedging the variability of future interest cash flows is recognized in the Consolidated Statements of Operations as “interest and other, net”.
	Net Investment Hedge
	Foreign currency hedging instruments that are being used to hedge changes in the value of a net investment are designated as net investment hedges. Changes in the fair value of a derivative that is designated and qualifies as a net investment hedge are recorded in OCI, net of taxes. The gain or loss relating to the ineffective portion is recognized in the Consolidated Statements of Operations as “interest and other, net”. Gains and losses accumulated in OCI are recognized in the Consolidated Statements of Operations when the foreign operation is (partially) disposed or sold.
	Cash and Cash Equivalents
	Cash and cash equivalents consist primarily of highly liquid investments, such as bank deposits, money market funds and interest-bearing bank accounts with insignificant interest rate risk and remaining maturities of three months or less at the date of acquisition.
	Short-term Investments
	Investments with remaining maturities longer than three months and less than one year at the date of acquisition are presented as short-term investments. The short-term investments are classified as available-for-sale securities and are stated at fair value. Gains and losses, other than impairments, interest income and foreign exchange results, are recognized in OCI until the short-term investments are derecognized. Upon derecognition, the cumulative gain or loss recognized in OCI, is recognized in the Consolidated Statements of Operations.
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out method) or market value. Cost includes net prices paid for materials purchased, charges for freight and customs duties, production labor cost and factory overhead. Allowances are made for slow-moving, obsolete or unsellable inventory.
	Allowances for inventory are determined based on the expected demand which is derived from sales forecasts as well as the expected market value of the inventory.
	Intangible Assets
	Goodwill
	Goodwill represents the excess of the costs of an acquisition over the fair value of the amounts assigned to assets acquired and liabilities incurred or assumed of the acquired subsidiary at the date of acquisition. Goodwill on acquisition of subsidiaries is allocated to reporting units for the purpose of impairment testing. The allocation is made to those reporting units that are expected to benefit from the business combination in which the goodwill arose. Goodwill is tested for impairment annually at the end of the third quarter and whenever events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. Goodwill is stated at cost less accumulated impairment losses.
	Other Intangible Assets
	Other intangible assets include brands, intellectual property, developed technology, customer relationships, in-process R&D and other intangible assets. Other intangible assets are stated at cost, less accumulated amortization and any accumulated impairment losses. Amortization is calculated using the straight-line method based on the estimated useful lives of the assets. The following table presents the estimated useful lives of ASML’s finite-lived other intangible assets:
			Estimated useful life
	Category
	Brands		20 years
	Intellectual property		3 - 10 years
	Developed technology		6 - 15 years
	Customer relationships		8 - 18 years
	Other		2 - 6 years
	Infinite-lived other intangibles assets are tested for impairment annually at the end of the third quarter and whenever events or changes in circumstances indicate that the carrying amount of the infinite-lived other intangible assets may not be recoverable.
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost, less accumulated depreciation and accumulated impairment losses. Costs of assets manufactured by ASML include direct manufacturing costs, production overhead and interest costs incurred for qualifying assets during the construction period. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets. In the case of leasehold improvements, the estimated useful lives of the related assets do not exceed the remaining term of the corresponding lease.
	The following table presents the estimated useful lives of ASML’s property, plant and equipment:
			Estimated useful life
	Category
	Buildings and constructions		5 - 45 years
	Machinery and equipment		2 - 10 years
	Leasehold improvements		5 - 10 years
Furniture, fixtures and other equipment		3 - 5 years
Land is not depreciated.
Certain internal and external costs associated with the purchase and/or development of internally used software are capitalized when both the preliminary project stage is completed and management has authorized further funding for the project, which it has deemed probable to be completed and to be usable for the intended function. These costs are depreciated on a straight-line basis over the period of related benefit, which ranges primarily from three to five years.
Evaluation of Long-lived Assets for Impairment
Long-lived assets include goodwill, other intangible assets and property, plant and equipment.
Goodwill is tested for impairment annually at the end of the third quarter and whenever events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. The test is based on a two-step approach for each reporting unit (being an operating segment or one level below an operating segment) in which goodwill has been recorded. First, recoverability is tested by comparing the carrying amount of the reporting unit including goodwill with the fair value of the reporting unit. If the carrying amount of the reporting unit is higher than the fair value of the reporting unit, the second step should be performed. Goodwill impairment is measured as the excess of the carrying amount of the goodwill over its implied fair value. The implied fair value of goodwill is determined by calculating the fair value of the various assets and liabilities included in the reporting unit in the same manner as goodwill is determined in a business combination.
Other intangible assets and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of those assets may not be recoverable. Other intangible assets and property, plant and equipment are tested for impairment based on a two-step approach. First, the recoverability is tested by comparing the carrying amount of the other intangible assets and property, plant and equipment with their fair value, being the sum of the related undiscounted future cash flows. Second, if the carrying amount of the other intangible assets and property, plant and equipment is higher than this fair value the assets are considered to be impaired. The impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
In determining the fair value of a long-lived asset (other than goodwill), we make estimates about future cash flows. These estimates are based on our financial plan updated with the latest available projection of the semiconductor market conditions and our sales and cost expectations, which are consistent with the plans and estimates that we use to manage our business. We also make estimates and assumptions concerning WACC and future inflation rates. It is possible that actual results may differ from our plans, estimates and assumptions, which may require impairment of certain long-lived assets (other than goodwill). Future adverse changes in market conditions may also require impairment of certain long-lived assets (other than goodwill), which could have a material adverse effect on our financial condition and results of operations.
Provisions
Provisions for lease contract termination costs are recognized when costs will continue to be incurred under a contract for its remaining term without economic benefit to us and we cease using the rights conveyed by the contract. The provisions are measured at fair value, which for an operating lease contract is determined based on the remaining lease payments reduced by the estimated sublease payments that could be reasonably obtained.
Revenue Recognition
ASML recognizes revenue when all four revenue recognition criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; seller’s price to buyer is fixed or determinable; and collectability is reasonably assured. At ASML this policy generally results in revenue recognition from the sale of a system upon shipment. The revenue from the installation of a system is generally recognized upon completion of that installation at the customer site. Prior to shipment, systems undergo a “Factory Acceptance Test” in our clean room facilities, effectively replicating the operating conditions that will be present on the customer’s site, in order to verify whether the system will meet its standard specifications and any additional technical and performance criteria agreed with the customer, if any. A system is shipped, and revenue is recognized, only after all contractual specifications are met and customer sign-off is received or waived. In case not all specifications are met and the remaining performance obligation is not essential to the functionality of the system but is substantive rather than inconsequential or perfunctory, a portion of the sales price is deferred. Although each system’s performance is re-tested upon installation at the customer’s site, we have never failed to successfully complete installation of a system at a customer’s premises.
In connection with the introduction of new technology, such as our second- and third-generation EUV systems (NXE:3100 and NXE:3300B), we initially defer revenue recognition until acceptance of the new technology based system and completion of installation at the customer premises. As our systems are based largely on two product platforms that permit incremental, modular upgrades, the introduction of genuinely “new” technology occurs infrequently, and in the past 15 years, has occurred on only two occasions: 1999 (TWINSCAN) and 2010 (EUV).
We have no significant repurchase commitments in our general sales terms and conditions. From time to time we repurchase systems that we have manufactured and sold and, following refurbishment, we resell those systems to other customers. This repurchase decision is driven by market demand expressed by other customers and not by explicit or implicit contractual arrangements relating to the initial sale. We consider reasonable offers from any vendor, including customers, to repurchase used systems so that we can refurbish, resell, and install these systems as part of our normal business operations. Once repurchased, the repurchase price of the used system is recorded in work-in-process inventory during the period it is being refurbished, following which the refurbished system is reflected in finished products inventory until it is sold to the customer. As of December 31, 2013 and 2012, ASML had no repurchase commitments.
We offer customers discounts in the normal course of sales negotiations. These discounts are directly deducted from the gross sales price at the moment of revenue recognition. In addition, we offer volume discounts to customers. In some instances these volume discounts can be used to purchase field options (system enhancements). The related amount is recorded as a reduction in net sales at time of shipment. From time to time, we offer free or discounted products or services (award credits) to our customers as part of a volume purchase agreement. The sales transaction that gives rise to these award credits is accounted for as a multiple element sales transaction as the agreements involve the delivery of multiple products. The consideration received from the sales transaction is allocated between the award credits and the other elements of the sales transaction. The consideration allocated to the award credits is recognized as deferred revenue until award credits are delivered to the customer. The amount allocable to a delivered item is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the non-contingent amount).
Net sales are recognized excluding the taxes levied on sales (net basis).
In the event of expected losses on executory contracts, we recognize a liability for the amount that the cost of settling the contract exceeds the amount of the contract price. When we satisfy these contracts, we derecognize the related liability.
Multiple Element Arrangements
The main portion of our net sales is derived from contractual arrangements with our customers that have multiple deliverables, which mainly include the sale of our systems, installation and training services and prepaid extended and enhanced (optic) warranty contracts. As of January 1, 2011, we have adopted ASU 2009-13, “Sales Arrangements with Multiple Deliverables” which amended the guidance on arrangements with multiple deliverables in ASC 605-25. The amended standard changes the requirements for establishing separate units of accounting in a multiple element arrangement and requires the allocation of arrangement consideration to each deliverable to be based on the relative selling price.
Each element in the arrangement is accounted for as a separate unit of accounting provided the following criteria are met: the delivered products or services have value to the customer on a standalone basis; and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by us. We consider a deliverable to have stand-alone value if the product or service is sold separately by us or another vendor or could be resold by the customer. Further, our sales arrangements do not include a general right of return relative to the delivered products. Where the aforementioned criteria for a separate unit of accounting are not met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition.
The hierarchy of evidence to determine a selling price in ASC 605-25 is as follows:
•		VSOE – the price at which we sell the element in a separate stand-alone transaction;
•		TPE – evidence from us or other companies of the value of a largely interchangeable element in a transaction;
•		BESP – our best estimate of the selling price of an element in the transaction.
To determine the selling price in multiple elements arrangements, we establish VSOE of the selling price for installation, training services and prepaid extended and enhanced (optic) warranty contracts. VSOE for installation is determined based on the prices that we charge for billable labor and materials consumed in comparable services (such as relocating a system to another customer site). VSOE for prepaid extended and enhanced (optic) warranty contracts is determined on the basis of similair products we sell on a standalone basis, such as full service contracts and billable lens swaps, and which are subject to normal price negotiations. Revenue from installation and training services is recognized when the services are completed. Revenue from prepaid extended and enhanced (optic) warranty contracts is recognized over the term of the contract. When we are unable to establish the selling price using VSOE or TPE, we use BESP. The objective of using estimated selling price-based methodology is to determine the price at which we would transact a sale if the product or service were sold on a stand-alone basis. Accordingly, we determine BESP considering several internal and external factors including, but not limited to, pricing practices, gross margin objectives, market conditions, competitive environment, internal costs and geographies. We review selling prices annualy and maintain internal controls over the establishment and updates of these estimates.
Lease Arrangements
A lease is classified as a sales-type lease if any of the following lease classification criteria is met at its inception:
1	The lease transfers ownership of the property to the lessee by the end of the lease term;
2	The lease contains a bargain purchase option;
3	The lease term is equal to 75 percent or more of the estimated economic life of the leased property; and
4	The present value at the beginning of the lease term of the minimum lease payments, excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, including any profit thereon, equals or exceeds 90 percent of the excess of the fair value of the leased property to the lessor at lease inception over any related investment tax credit retained by the lessor and expected to be realized by the lessor.
In addition, revenue is recognized at commencement of the lease term. The present value of the lease payments is recognized as a finance receivable. The difference between the gross receivable and the present value of the receivable is recognized as unearned interest in the Consolidated Statements of Operations.
A lease is classified as an operating lease if the lease classification criteria (as described above) are not met. If ASML has offered its customers an operating lease arrangement, the contract consideration is recognized in the Consolidated Statements of Operations on a straight-line basis over the period of the lease.
Warranty
We provide standard warranty coverage on our systems for 12 months and on certain optic parts for 60 months, providing labor and parts necessary to repair systems and optic parts during the warranty period. The estimated warranty costs are accounted for by accruing these costs for each system upon recognition of the system sale. The estimated warranty costs are based on historical product performance and field expenses. Based upon historical service records, we calculate the charge of average service hours and parts per system to determine the estimated warranty costs. On a semi-annual basis, we assess, and update if necessary, our accounting estimates used to calculate the standard warranty reserve based on the latest actual historical warranty costs and expected future warranty costs.
The extended and enhanced (optic) warranty on our system is accounted for as a separate element of multiple element revenue recognition transactions.
Customer Co-Investment Program
In connection with the CCIP, we entered into investment agreements, Shareholders Agreements and NRE Funding Agreements and commercial agreements with Participating Customers.
The investment agreements, Shareholder Agreements, NRE Funding Agreements and commercial agreement are accounted for as a multiple-element arrangement with each of the Participating Customers. Based upon ASC 605-25 Multiple-Element Arrangements guidance, the following two separate elements are identified for each arrangement: (1) the share issuance (governed by the investment agreement and the Shareholder Agreement) and (2) the NRE funding and commercial discounts and credits (governed by the NRE Funding Agreement and the commercial agreement with Intel).
The shares issued to the Participating Customers are recorded at fair value based on quoted share prices (EUR 3,977.4 million) with the remaining aggregate arrangement consideration allocated to the NRE funding and commercial discounts and credits. The difference between the fair value of the shares and the subscription price of the shares (EUR 39.91) was recorded as a deduction from shareholders’ equity upon issuance of the shares (EUR 123.4 million). Shareholders’ equity is increased to the fair value of the shares as the portion of the NRE funding allocable to the shares is received over the NRE funding period (2013-2017). The amounts are deemed receivables from the Participating Customers in their capacity as shareholders of ASML.
A significant related party relationship exists between ASML and Intel as a result of the equity investment made by Intel as part of the CCIP. Based on the commercial discounts and credits (governed by the Commercial Agreement with Intel) and the significant related party relationship, all NRE funding will be deferred and recognized in the Consolidated Statement of Operations only when the commercial discounts and credits are earned.
In addition see also other income for further explanation on the accounting policies with respect to CCIP.
Accounting for Shipping and Handling Fees and Costs
ASML bills the customer for, and recognizes as revenue, any charges for shipping and handling costs. The related costs are recognized as cost of sales.
Cost of Sales
Cost of system sales comprise direct product costs such as materials, labor, cost of warranty, depreciation, shipping and handling costs and related overhead costs. ASML accrues for the estimated cost of the warranty on its systems, which includes the cost of labor and parts necessary to repair systems during the warranty period. The amounts recorded in the accrued warranty reserve are estimated based on actual historical expenses incurred and on estimated probable future expenses related to current sales. Actual warranty costs are charged against the accrued warranty reserve.
Costs of service sales comprise direct service costs such as materials, labor, depreciation and overhead costs.
Cost of field option sales comprise direct product costs such as materials, labor, cost of warranty, depreciation, shipping and handling costs and related overhead costs.
Other Income
The portion of the NRE funding from TSMC and Samsung not allocable to the shares issued to those Participating Customers under the CCIP is recognized in Other income when the R&D costs relating to the development of 450mm lithography equipment and EUV platforms are recognized over the NRE funding period (2013-2017).
R&D Costs and Credits
Costs relating to R&D are charged to operating expenses as incurred. ASML receives subsidies and other grants from several Dutch and international (inter-)governmental institutes. These subsidies and other government grants that cover R&D costs relating to approved projects are recorded as R&D credits in the R&D line in the Consolidated Statements of Operations in the period in which such costs occur.
Government grants are not recognized until there is reasonable assurance that ASML will comply with the conditions attaching to them and that the grants will be received.
Government grants whose primary condition is that ASML should purchase, construct or otherwise acquire non-current assets are recognized as deferred income in the Consolidated Balance Sheets and transferred to the Consolidated Statements of Operations on a systematic and rational basis over the useful lives of the related assets.
Other government grants are recognized as income over the periods necessary to match them with the costs for which they are intended to compensate, on a systematic basis. Government grants that are received as compensation for expenses or losses already incurred, or for the purpose of giving immediate financial support to ASML with no future related costs are recognized in the Consolidated Statements of Operations in the period in which they become receivable.
Borrowing Costs
Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time that the assets are substantially ready for their intended use or sale.
Share-based Payments
The cost of employee services received (compensation expenses) in exchange for awards of equity instruments are recognized based upon the grant-date fair value of stock options and shares. The grant-date fair value of stock options is estimated using a Black-Scholes option valuation model. This Black-Scholes model requires the use of assumptions, including expected share price volatility, the estimated life of each award and the estimated dividend yield. The risk-free interest rate used in the model is determined, based on an index populated with euro-denominated European government agency bond with high credit ratings and with a life equal to the expected life of the equity-settled share-based payments. The grant-date fair value of shares is determined based on the closing price of our shares listed at NYSE Euronext Amsterdam on the grant-date.
The grant-date fair value of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on our estimate of equity instruments that will eventually vest. At each balance sheet date, we revise our estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognized in the Consolidated Statements of Operations in the period in which the revision is determined, with a corresponding adjustment to shareholders’ equity.
Income Taxes
The asset and liability method is used in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the tax effect of incurred net operating losses and for tax consequences attributable to differences between the balance sheet carrying amounts of existing assets and liabilities and their respective tax bases. If it is more likely than not that the carrying amounts of deferred tax assets will not be realized, a valuation allowance is recorded to reduce the carrying amounts of those assets.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Consolidated Statements of Operations in the period that includes the enactment date.
We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes, and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.
Contingencies and Litigation
We are party to various legal proceedings generally incidental to our business, as disclosed in Note 19. In connection with these proceedings and claims, our management evaluated, based on the relevant facts and legal principles, the likelihood of an unfavorable outcome and whether the amount of the loss could be reasonably estimated. In most cases, management determined that either a loss was not probable or was not reasonably estimable. Significant subjective judgments were required in these evaluations, including judgments regarding the validity of asserted claims and the likely outcome of legal and administrative proceedings. The outcome of these proceedings, however, is subject to a number of factors beyond our control, most notably the uncertainty associated with predicting decisions by courts and administrative agencies. In addition, estimates of the potential costs associated with legal and administrative proceedings frequently cannot be subjected to any sensitivity analysis, as damage estimates or settlement offers by claimants may bear little or no relation to the eventual outcome. Finally, in any particular proceeding, we may agree to settle or to terminate a claim or proceeding in which we believe that it would ultimately prevail where we believe that doing so, when taken together with other relevant commercial considerations, is more cost-effective than engaging in an expensive and protracted litigation, the outcome of which is uncertain.
We accrue for legal costs related to litigation in our Consolidated Statements of Operations at the time when the related legal services are actually provided.
Net Income per Ordinary Share
Basic net income per ordinary share is calculated by dividing net income by the weighted average number of ordinary shares outstanding for that period. The dilutive effect is calculated using the treasury stock method. Excluded from the diluted weighted average number of shares outstanding calculation are cumulative preference shares contingently issuable to the preference share foundation, since they represent a different class of stock than the ordinary shares. See Note 26 for further discussion.
The basic and diluted net income per ordinary share has been calculated in accordance with the following schedule:
			2013	2012	2011
Year ended December 31			EUR	EUR	EUR
(in thousands, except per share data)
Net income			1,015,490	1,146,316	1,466,960
Weighted average number of shares outstanding during the year			429,770	424,096	425,618
(after deduction of treasury stock)
Basic net income per ordinary share			2.36	2.7	3.45
Weighted average number of shares:			429,770	424,096	425,618
Plus shares applicable to:
Options and conditional shares			3,676	2,890	3,435
Dilutive potential ordinary shares			3,676	2,890	3,435
Adjusted weighted average number of shares			433,446	426,986	429,053
Diluted net income per ordinary share1			2.34	2.68	3.42
1	The calculation of diluted net income per ordinary share assumes the exercise of options issued under our stock option plans and the issuance of shares under our share plans for periods in which exercises or issuances would have a dilutive effect. The calculation of diluted net income per ordinary share does not assume exercise of such options or issuance of shares when such exercises or issuance would be anti-dilutive.
Comprehensive Income
Comprehensive income consists of net income (loss) and OCI.
OCI refers to gains and losses that are not included in net income (loss), but recorded directly in shareholders’ equity. For the years ending December 31, 2013 and 2012, comprehensive income consists of net income, unrealized gains and losses on financial instruments, being available-for-sale securities and derivative financial instruments designated for hedge accounting, net of taxes, and unrealized gains and losses on foreign currency translation, net of taxes. For the year ending December 31, 2011 comprehensive income consists of net income, unrealized gains and losses on financial instruments, being derivative financial instruments designated for hedge accounting, net of taxes and unrealized gains and losses on foreign currency translation, net of taxes.
New US GAAP Accounting Pronouncements
For the below mentioned ASUs, issued in 2013, the impact on our Financial Statements needs to be assessed:
•		In February 2013, FASB issued ASU No. 2013-04 “Liabilities (Topic 405): Obligations Resulting from Joint and Several Liability Arrangements for which the Total Amount of the Obligation is Fixed at the Reporting Date”. The objective of the amendments in this Update is to provide guidance for the recognition, measurement and disclosure of obligations resulting from joint an several liability arrangements for which the total amount of the obligation within the scope of this guidance is fixed at the reporting date, except for obligations addressed within existing guidance in US GAAP. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013.
•		In March 2013, FASB issued ASU No. 2013-05 “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The objective of the amendments in this Update is to resolve the diversity in practice about whether Subtopic 810-10, “Consolidation-Overall”, or Subtopic 830-30, ““Foreign Currency Matters-Translation of Financial Statements”, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013.
•		In July 2013, FASB issued ASU No. 2013-11 “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry forward, a Similar Tax Loss, or a Tax Credit Carry forward Exists”. Topic 740, Income Taxes, does not include explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carry forward, a similar tax loss, or a tax credit carry forward exists. There is diversity in practice in the presentation of unrecognized tax benefits in those instances. Some entities present unrecognized tax benefits as a liability unless the unrecognized tax benefit is directly associated with a tax position taken in a tax year that results in, or that resulted in, the recognition of a net operating loss or tax credit carry forward has not been utilized. Other entities present unrecognized tax benefits as a reduction of a deferred tax asset for a net operating loss or tax credit carry forward in certain circumstances. The objective of the amendments in this Update is to eliminate that diversity in practice. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Business Combinations	'
	2. Business Combinations
	On May 30, 2013, we concluded the acquisition of Cymer and obtained control through acquiring 100 percent of the issued share capital of Cymer, for a consideration of EUR 3.1 billion. There are no contingent consideration arrangements.
	Prior to the acquisition, Cymer was an industry leader in developing and servicing lithography light sources used by chip manufacturers worldwide to pattern advanced semiconductor chips. Cymer has production facilities in San Diego, California, the United States of America and in Pyongtaek-city, South Korea, Asia.
	The acquisition of Cymer will support our strategic objective of delivering an economically viable EUV scanner to semiconductor manufacturers within the timeline required by our customers. In addition, there are opportunities to further enhance Cymer’s growing advanced immersion systems and related installed base products business.
	The following table summarizes the major classes of consideration transferred, and the recognized amounts of the fair value of the identifiable assets distributed and the fair value of the liabilities incurred or assumed at the acquisition date.
	(in thousands)
			May 30, 2013
			EUR1
	Cash and cash equivalents			84,129
	Short-term investments			40,055
	Accounts receivable, net			121,395
	Finance receivables, net			611
	Current tax assets			37,289
	Inventories, net			301 ,279
	Deferred tax assets			90,045
	Other assets, current and non-current			29,418
	Other intangible assets, net			751,542
	Property, plant and equipment, net			124,308
	Assets acquired			1,580,071
	Accounts payable			151,412
	Accrued and other liabilities, current and non-current			90,900
	Deferred and other tax liabilities			297,977
	Long-term debt, current and non-current			609
	Liabilities assumed			540,898
	Total net identifiable assets			1,039,173
	Consideration paid in cash for the transaction on May 30, 2013			486,325
	Fair value of shares2			2,347,663
	Fair value of equity awards cash settled			41,516
	Fair value of unvested equity awards to be exchanged			43,527
	Gain on settlement of pre-existing relationships			178,427
	Consideration transferred			3,097,458
	Goodwill on acquisition			2,058,285
	1	Amounts were converted into euro at the rate of USD/EUR 1.3043.
	2	As part of the consideration transferred, Cymer shares were converted into a right to receive 36,479,109 ASML ordinary shares. These shares were valued at USD 83.94 being the opening price on NASDAQ at May 30, 2013. As at December 31, 2013, 14,533 ASML ordinary shares are still to be issued.
	Prior to the acquisition, supply and R&D arrangements existed between Cymer and ASML. These pre-existing relationships were effectively settled as a result of the acquisition. We determined that the R&D arrangement as well as the supply arrangements (excluding EUV) were at current market terms and therefore no gain or loss was recognized. We determined that the EUV supply arrangements were favorable to ASML and therefore a gain of EUR 178.4 million was recognized in cost of sales within our Consolidated Statements of Operations. This gain was recognized separately from the business combination as it is not part of the assets acquired or liabilities assumed. The approach for quantifying the favorable component to ASML of the EUV supply arrangements is based on the assessment of the prices for such light sources if the EUV supply arrangements would have been renegotiated in May 2013. This approach is in line with (and offsets) the expected losses (for which a liability is recognized of EUR 171.2 million included in costs to be paid, see Note 13) to upgrade the first 11 EUV sources in the field, which was assumed by ASML as a result of the acquisition of Cymer.
	The majority of the goodwill arising on the acquisition of Cymer is attributable to the fact that we believe that the acquisition will help us achieving our strategic objective of delivering an economically viable EUV scanner to semiconductor manufacturers as soon as reasonably possible. We believe that combining Cymer’s expertise in EUV light sources with our expertise in lithography systems design and integration will reduce the risks related to the successful development of and accelerate the introduction of EUV technology. Without the acquisition, we do not believe that Cymer would have sufficient resources to complete the development of the EUV light source and as a result, the only way to make the EUV light source development successful without additional delay was through the acquisition of Cymer. We believe that the acquisition will allow us to more effectively partition responsibilities between Cymer, its suppliers and us with respect to EUV light source development, thereby reducing risk and increasing development speed. Also, synergies are expected from the combination. All goodwill has been allocated to the RU ASML. None of the goodwill recognized is expected to be deductible for income tax purposes.
	Cymer contributed EUR 178.7 million to net sales and a loss of EUR 138.5 million to net income (including a charge of EUR 85.5 million related to the purchase price allocation adjustments) for the period between the date of acquisition and December 31, 2013.
	In 2013, we incurred EUR 7.8 million transaction costs relating to the acquisition of Cymer. These costs are included in SG&A.
	The following unaudited pro forma summary presents estimated consolidated information of ASML as if the Cymer acquisition had occurred on January 1, 2012. These amounts have been calculated after applying our accounting policies and adjusting the results of Cymer to reflect the charges and benefits assuming the fair value adjustments had been applied from January 1, 2012 with the consequential tax effects.
	Pro Forma Year ended December 31					Unaudited
	(in millions)		Unaudited			2012
			2013			EUR
			EUR
	Total net sales			5,362			5,053
	Net income			1,031	1		965	2
	1	Pro forma net income was adjusted to exclude EUR 60 million of non-recurring costs related to the fair value adjustments to acquisition date inventory and exclude EUR 30 million of acquisition related costs incurred in 2013.
	2	Pro forma net income was adjusted to include EUR 60 million of non-recurring costs related to the fair value adjustments to acquisition date inventory and exclude EUR 15 million of acquisition related costs incurred in 2012.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3. Fair Value Measurements
	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement hierarchy prioritizes the inputs to valuation techniques used to measure fair value as follows:
	•		Level 1: Valuations based on inputs such as quoted prices for identical assets or liabilities in active markets that the entity has the ability to access.
	•		Level 2: Valuations based on inputs other than level 1 inputs such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
	•		Level 3: Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). A financial instrument’s fair value classification is based on the lowest level of any input that is significant in the fair value measurement hierarchy.
	Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis
	Investments in money market funds (as part of our cash and cash equivalents) have fair value measurements which are all based on quoted prices for identical assets or liabilities.
	Our available-for-sale financial instruments consist of Dutch Treasury Certificates and deposits with the Dutch government. Dutch Treasury Certificates are traded in an active market and the fair value is determined based on quoted market prices for identical assets or liabilities. The fair value of deposits is determined with reference to quoted market prices for similar assets or discounted cash flow analysis.
	The principal market in which we execute our derivative contracts is the institutional market in an over-the-counter environment with a high level of price transparency. The market participants usually are large commercial banks. The valuation inputs for our derivative contracts are based on quoted prices and quoting pricing intervals from public data sources; they do not involve management judgement.
	The valuation technique used to determine the fair value of forward foreign exchange contracts (used for hedging purposes) approximates the NPV technique which is the estimated amount that a bank would receive or pay to terminate the forward foreign exchange contracts at the reporting date, taking into account current interest rates and current exchange rates.
	The valuation technique used to determine the fair value of interest rate swaps (used for hedging purposes) is the NPV technique, which is the estimated amount that a bank would receive or pay to terminate the swap agreements at the reporting date, taking into account current interest rates.
	Our Eurobonds serve as hedged items in fair value hedge relationships in which we hedge the variability of changes in the fair value of our Eurobonds due to changes in market interest rates with interest rate swaps. The fair value changes of these interest rate swaps are recorded on the Consolidated Balance Sheets under derivative financial instruments (within other current assets and other non-current assets) and the carrying amounts of the Eurobonds are adjusted for these fair value changes only. For the actual aggregate carrying amount and the fair value of our Eurobonds, see Note 15.
	The following table presents our financial assets and financial liabilities that are measured at fair value on a recurring basis:
			Level 1	Level 2	Level 3	Total
	As of December 31, 2013		EUR	EUR	EUR	EUR
	(in thousands)
	Assets
	Derivative financial instruments 1		-	71,620	-		71,620
	Money market funds 2		535,000	-	-		535,000
	Short-term investments 3		304,884	375,000	-		679,884
	Total		839,884	446,620	-		1,286,504
	Liabilities
	Long-term debt 4		-	1,021,930	-		1,021,930
	Derivative financial instruments1		-	11,652	-		11,652
	Total		-	1,033,582	-		1,033,582
	As of December 31, 2012		Level 1	Level 2	Level 3	Total
	(in thousands)		EUR	EUR	EUR	EUR
	Assets
	Derivative financial instruments1		-	151,748	-		151,748
	Money market funds 2		385,420	-	-		385,420
	Short-term investments 3		279,988	650,017	-		930,005
	Total		665,408	801,765	-		1,467,173
	Liabilities
	Long-term debt 4		-	759,490	-		759,490
	Derivative financial instruments 1		-	10,893	-		10,893
	Total		-	770,383	-		770,383
	1	Derivative financial instruments consist of forward foreign exchange contracts and interest rate swaps. See Note 4.
	2	Money market funds are part of our cash and cash equivalents.
	3	Short-term investments consist of Dutch Treasury Certificates and deposits with the Dutch government.
	4	Long-term debt mainly relates to our Eurobonds (carrying amount as at December 31, 2013: EUR 1,021.9 million (2012: EUR 710.1 million)) and excludes accrued interest. For further details see Note 15.
	There were no transfers between levels during the years ended December 31, 2013 and December 31, 2012.
	Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
	In 2013, we recognized impairment charges of EUR 13.1 million (2012: EUR 3.2 million; 2011: EUR 12.3 million) on our property, plant and equipment, mainly relating to buildings (EUR 3.6 million) and machinery and equipment (EUR 8.0 million). Valuation of these assets is classified as Level 3 in the fair value hierarchy since their fair values were determined based on unobservable inputs. The impairment charge is determined based on the difference between the assets’ estimated fair value (being EUR 16.4 million) and their carrying amount. For further information, see Note 12.
	We did not recognize any impairment charges for goodwill and other intangible assets during 2013. See Notes 10 and 11 for more information. For fair value measurements in relation to the acquisition of Cymer, we refer to Note 2.

Financial_Risk_Management

Financial Risk Management	12 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Financial Risk Management	'
	4. Financial Risk Management
	We are exposed to certain financial risks such as market risk (including foreign currency risk and interest rate risk), credit risk, liquidity risk and capital risk. The overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potentially adverse effects on our financial performance. We use derivative financial instruments to hedge certain risk exposures. None of our transactions are entered into for trading or speculative purposes. We believe that market information is the most reliable and transparent measure for our derivative financial instruments that are measured at fair value.
	Foreign Currency Risk Management
	Our sales are predominately denominated in euros. Exceptions may occur on a customer by customer basis. Our cost of sales and other costs are mainly denominated in euros, to a certain extent in U.S. dollar and Japanese Yen and to a limited extent in other currencies. Therefore, we are exposed to foreign currency exchange risk. It is our policy to hedge material transaction exposures, such as forecasted sales and purchase transactions, and material net remeasurement exposures, such as accounts receivable and payable. We hedge these exposures through the use of foreign exchange contracts.
	As of December 31, 2013, accumulated OCI includes EUR 10.7 million (net of taxes: EUR 9.5 million; 2012: EUR 5.3 million loss) representing the total anticipated loss to be charged to cost of sales, which will offset the EUR equivalent of foreign currency denominated forecasted purchase transactions. All amounts are expected to be charged over the next 12 months. As of December 31, 2013, no amount was included in accumulated OCI representing the total anticipated gain to be released to sales (2012: EUR 4.3 million gain, net of taxes). The effectiveness of all contracts for which we apply hedge accounting is monitored on a quarterly basis throughout the life of the hedges. During 2012 and 2013, no ineffective hedge relationships were recognized.
	Interest Rate Risk Management
	We have interest-bearing assets and liabilities that expose us to fluctuations in market interest rates. We use interest rate swaps to align the interest-typical terms of interest-bearing liabilities with the interest-typical terms of interest-bearing assets. There may be residual interest rate risk to the extent the asset and liability positions do not fully offset.
	As part of our hedging policy, we use interest rate swaps to hedge changes in fair value of our Eurobonds due to changes in market interest rates, thereby offsetting the variability of future interest receipts on part of our cash and cash equivalents. During 2013, these hedges were highly effective in hedging the fair value exposure to interest rate movements. The changes in fair value of the Eurobonds were included at the same time in the Consolidated Statements of Operations as the changes in the fair value of the interest rate swaps.
	Furthermore, as part of our hedging policy, we use interest rate swaps to hedge the variability of future interest cash flows relating to certain of our operating lease obligations. During 2013, these hedges were highly effective in hedging the cash flow exposure to interest rate movements.
	Financial Instruments
	We use foreign exchange contracts to manage our foreign currency risk and interest rate swaps to manage our interest rate risk. The following table summarizes the notional amounts and estimated fair values of our derivative financial instruments:
											2012
			2013
	As of December 31		Notional				Fair Value				Notional		Fair Value
	(in thousands)		amount				EUR				amount		EUR
			EUR								EUR
	Forward foreign exchange contracts1			986,986				8,583				262,146		16,805
	Interest rate swaps2			1,013,053				51,385				624,900		124,050
	1	Relates to forward contracts assigned as a hedge to forecasted sales and purchase transactions and to monetary assets and liabilities, mainly in U.S. dollar and Japanese Yen.
	2	Relates to interest rate swaps assigned as a hedge to interest bearing assets and liabilities, mainly related to our Eurobonds; the fair value of the interest rate swaps includes accrued interest.
	The following table summarizes our derivative financial instruments per category:
													2012
					2013
	As of December 31				Assets				Liabilities				Assets		Liabilities
	(in thousands)				EUR				EUR				EUR		EUR
	Interest rate swaps - cash flow hedges					-				3,598				-		4,780
	Interest rate swaps - fair value hedges					54,983				-				128,830		-
	Forward foreign exchange contracts - cash flow hedges					3				6,039				5,975		5,688
	Forward foreign exchange contracts - other hedges (no hedge accounting)					16,634				2,015				16,943		425
	Total					71,620				11,652				151,748		10,893
	Less non-current portion:
	Interest rate swaps - cash flow hedges					-				2,608				-		4,032
	Interest rate swaps - fair value hedges					30,777				-				101,651		-
	Total non-current portion					30,777				2,608				101,651		4,032
	Total current portion					40,843				9,044				50,097		6,861
	The fair value part of a hedging derivative financial instruments that has a remaining term of 12 months or less after balance sheet date is classified as current asset or liability. When the fair value part of a hedging derivative has a term of more than 12 months after balance sheet date, it is classified as non-current asset or liability. The current portion of derivative financial instruments is included in respectively other current assets and current accrued and other liabilities in the Consolidated Balance Sheets. The non-current portion of derivative financial instruments is included in, respectively, other non-current assets and non-current accrued and other liabilities in the Consolidated Balance Sheets.
	For further information regarding our derivative financial instruments, see Notes 1 and 3.
	Foreign Exchange Contracts
	The notional principal amounts of the outstanding forward foreign exchange contracts in the main currencies U.S. dollar and Japanese yen at December 31, 2013 are USD 1,144.0 million and JPY 2.2 billion (2012: USD 159.8 million and JPY 8.4 billion).
	The hedged highly probable forecasted transactions denominated in foreign currency are expected to occur at various dates during the coming 12 months. Gains and losses recognized in OCI on forward foreign exchange contracts as of December 31, 2013 will be recognized in the Consolidated Statements of Operations in the period or periods during which the hedged forecasted transactions affect the Consolidated Statements of Operations.
	In 2013, we recognized a net amount of EUR 2.3 million gain (2012: EUR 8.7 million gain; 2011: EUR 58.1 million loss) in the Consolidated Statements of Operations resulting from effective cash flow hedges for forecasted sales and purchase transactions that occurred in the year. Furthermore, we recognized a net amount of EUR 62.5 million gain in the Consolidated Statements of Operations resulting from derivative financial instruments measured at fair value through profit or loss (2012: EUR 3.0 million gain; 2011: EUR 38.3 million loss).
	Interest Rate Swaps
	The notional principal amounts of the outstanding interest rate swap contracts as of December 31, 2013 were EUR 1,013.1 million (2012: EUR 624.9 million).
	Credit Risk Management
	Financial instruments that potentially subject us to significant concentration of credit risk consist principally of cash and cash equivalents, short-term investments, derivative financial instruments used for hedging activities, accounts receivable and finance receivables.
	Cash and cash equivalents, short-term investments and derivative financial instruments contain an element of risk of the counterparties being unable to meet their obligations. Our risk management program focuses appropriately on the current environment of uncertainty in the financial markets, especially in the euro-zone. We invest our cash and cash equivalents and short-term investments in short-term deposits with high-rated financial institutions and the Dutch government, in Dutch Treasury Certificates and in AAAm-rated money market funds that invest in high-rated short-term debt securities of financial institutions and governments. To mitigate the risk that any of our counterparties in hedging transactions is unable to meet its obligations, we only enter into transactions with a limited number of major financial institutions that have good credit ratings and closely monitor the creditworthiness of our counterparties. Concentration risk is mitigated by limiting the exposure to a single counterparty.
	Our customers consist of IC manufacturers located throughout the world. We perform ongoing credit evaluations of our customers’ financial condition. We take additional measures to mitigate credit risk when considered appropriate by means of e.g. down payments, letters of credit or retention of ownership provisions in contracts. Retention of ownership enables us to recover the systems in the event a customer defaults on payment.

Cash_and_Cash_Equivalents_and_

Cash and Cash Equivalents and Short-term Investments	12 Months Ended
	Dec. 31, 2013
Cash And Cash Equivalents [Abstract]	'
Cash and Cash Equivalents and Short-term Investments	'
	5. Cash and Cash Equivalents and Short-term Investments
	Cash and cash equivalents at December 31, 2013 include deposits with high-rated financial institutions and the Dutch government of EUR 853.5 million (2012: EUR 775.6 million), investments in AAAm-rated money market funds that invest in high-rated debt securities of financial institutions and governments of EUR 535.0 million (2012: EUR 385.4 million) and interest-bearing bank accounts of EUR 942.2 million (2012: EUR 606.6 million). Our cash and cash equivalents are predominantly denominated in euros and partly in U.S. dollars.
	Cash and cash equivalents have insignificant interest rate risk and remaining maturities of three months or less at the date of acquisition. Except for an amount of EUR 4.7 million, no restrictions on usage of cash and cash equivalents exist. The carrying amount of these assets approximates their fair value.
	Short-term investments have insignificant interest rate risk and remaining maturities longer than three months but less than one year at the date of acquisition.
	Short-term investments (classified as available for sale securities) consist of the following:
		Cost basis		Unrealized		Unrealized		Recorded Basis
	As of December 31, 2013			Gains		Losses
	(in thousands)
	Dutch Treasury Certificates		304,884		-		-		304,884
	Deposits		375,000		-		-		375,000
	Total		679,884		-		-		679,884
		Cost basis		Unrealized		Unrealized		Recorded Basis
	As of December 31, 2012			Gains		Losses
	(in thousands)
	Dutch Treasury Certificates		279,988		-		-		279,988
	Deposits		650,017		-		-		650,017
	Total		930,005		-		-		930,005

Accounts_Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Accounts Receivable	'
	6. Accounts Receivable
	Accounts receivable consist of the following:
			2013		2012
	As of December 31		EUR		EUR
	(in thousands)
	Accounts receivable, gross			880,169		607,359
	Allowance for doubtful receivables			-1,848		-2,071
	Accounts receivable, net			878,321		605,288
	The increase in accounts receivable as of December 31, 2013 compared to December 31, 2012 is mainly caused by an increased number of systems shipped and recognized in sales in the last months of 2013 compared to the last months of 2012.
	The carrying amount of the accounts receivable approximates the fair value. We perform ongoing credit evaluations on our customers’ financial condition. We periodically review whether an allowance for credit losses is needed by considering factors such as historical payment experience, credit quality, aging of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.
	Movements of the allowance for doubtful receivables are as follows:
			2013		2012
	Year ended December 31		EUR		EUR
	(in thousands)
	Balance at beginning of year			-2,071		-2,582
	Addition for the year1			-1,062		-458
	Utilization of the provision			1,285		969
	Allowance for doubtful receivables			(1,848)		(2,071)
	1	The addition for the year is recorded in the cost of sales.

Finance_Receivables

Finance Receivables	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Finance Receivables	'
	7. Finance Receivables
	Finance receivables consist of the net investment in sales-type leases. The following table lists the components of the finance receivables as of December 31, 2013 and 2012:
		2013		2012
	As of December 31	EUR		EUR
	(in thousands)
	Finance receivables, gross		302,977		309,616
	Unearned interest		-6,488		-5,828
	Finance receivables, net		296,489		303,788
	Current portion of finance receivables, gross		254,227		268,617
	Current portion of unearned interest		-3,755		-3,450
	Non-current portion of finance receivables, net		46,017		38,621
	The slight decrease in finance receivables as of December 31, 2013 compared to December 31, 2012 is caused by a change in the product mix (lower number of high-end system types included at the end of 2013 compared to 2012). At December 31, 2013, the finance receivables due for payment in each of the next five years and thereafter are as follows:
		EUR
	(in thousands)
	2014		254,227
	2015		-
	2016		6,150
	2017		36,450
	2018		6,150
	Thereafter		-
	Finance receivables, gross		302,977
	We perform ongoing credit evaluations on our customers’ financial condition. We periodically review whether an allowance for credit losses is needed by considering factors such as historical payment experience, credit quality, the aging of the finance receivables balances, and current economic conditions that may affect a customer’s ability to pay. In 2013 and 2012, we did not record any expected credit losses from finance receivables. As of December 31, 2013 the finance receivables were neither past due nor impaired.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	8. Inventories
	Inventories consist of the following:
		2013		2012
	As of December 31	EUR		EUR
	(in thousands)
	Raw materials		438,853		307,315
	Work-in-process		1,549,119		1,074,042
	Finished products		666,648		742,979
	Inventories, gross		2,654,620		2,124,336
	Allowance for obsolescence and/or lower market value		-261,598		-267,366
	Inventories, net		2,393,022		1,856,970
	A summary of activity in the allowance for obsolescence and/or lower market value is as follows:
		2013		2012
	Year ended December 31	EUR		EUR
	(in thousands)
	Balance at beginning of year		-267,366		-193,513
	Addition for the year		-164,852		-130,911
	Effect of changes in exchange rates		2,532		1,009
	Utilization of the provision		168,088		56,049
	Allowance for obsolescence and/or lower market value		(261,598)		(267,366)
	In 2013, the addition for the year is recorded in cost of sales for an amount of EUR 155.4 million and R&D costs for an amount of EUR 9.5 million (2012: cost of sales EUR 125.2 million and R&D costs for an amount of EUR 5.7 million). The 2013 addition for the year mainly relates to inventory items which were ceased to be used due to technological developments and design changes which resulted in obsolescence of certain parts.
	Utilization of the provision mainly relates to the sale and scrapping of obsolete inventories. In 2013 ASML made no profit on the sale of inventories that had been previously written down (2012: EUR 2.3 million).

Other_Assets

Other Assets	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Assets	'
	9. Other Assets
	Other current assets consist of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Advance payments to Zeiss			99,415		70,257
	Prepaid expenses			100,077		64,708
	Derivative financial instruments			40,843		50,097
	VAT			67,381		25,215
	Other receivables			28,705		35,728
	Other current assets			336,421		246,005
	Zeiss is our sole supplier of main optical systems (including lenses) and, from time to time, receives non-interest bearing advance payments from us that supports Zeiss’ work-in-process, thereby securing lens and optical module deliveries to us. Amounts owed under these advance payments are settled through future lens or EUV optical module deliveries.
	Prepaid expenses include prepaid income taxes on intercompany profit, not realized by the ASML group of EUR 45.4 million as of December 31, 2013 (2012: EUR 29.8 million).
	Derivative financial instruments consist of forward foreign exchange contracts and the current part of the aggregate fair value of interest rate swaps, see Note 4.
	Other non-current assets consist of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Advance payments to Zeiss			224,123		183,025
	Derivative financial instruments			30,777		101,651
	Compensation plan assets1			20,174		12,080
	Prepaid expenses			10,950		4,462
	Subordinated loan granted to lessor in respect of Veldhoven headquarters2			5,445		5,445
	Other			7,090		4,875
	Other non-current assets			298,559		311,538
	1	For further details on compensation plan assets see Note 18.
	2	For further details on the loan granted to lessor in respect of Veldhoven headquarters see Note 12.
	The non-current part of non-interest bearing advance payments to Zeiss mainly relates to payments made to support Zeiss’ investments in ASML’s EUV program, which are settled through future EUV optical module deliveries.
	Derivative financial instruments consist of the non-current part of the fair value of interest rate swaps, see Note 4.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	10. Goodwill
	Changes in goodwill are summarized as follows:
	Year ended December 31	2013		2012
	(in thousands)	EUR		EUR
	Cost
	Balance, January 1		149,168		146,044
	Acquisition through business combinations		2,058,285		6,038
	Effect of changes in exchange rates		-118,864		-2,914
	Goodwill		2,088,589		149,168
	Goodwill increased due to the acquisition of Cymer. For more information with respect to business combinations, see Note 2.
	Goodwill is tested for impairment annually at the end of the third quarter and whenever events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable.
	Due to the acquisition of Cymer we have re-evaluated our RU structure in 2013. As a result, all goodwill recognized in relation to the acquisition of Cymer is allocated to the RU ASML. The fair value of the RU ASML is based on ASML’s market capitalization.
	Based on the recoverability testing during the annual goodwill impairment test, we believe that the fair value of the RU ASML substantially exceeds its carrying value, therefore goodwill was not impaired as of December 31, 2013 and December 31, 2012.

Other_Intangible_Assets

Other Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Other Intangible Assets	'
	11. Other Intangible Assets
	Other intangible assets consist of both finite-lived intangible assets and indefinite-lived intangible assets. The main part of the other intangible assets was acquired as part of the acquisitions of Brion and Cymer. For more information with respect to business combinations, see Note 2.
	Finite-lived other intangible assets consist of the following:
	(in thousands)	Brands		Intellectual		Developed		Customer		Other		Total
		EUR		property		technology		relationships		EUR		EUR
				EUR		EUR		EUR
	Cost
	Balance, January 1, 2012		-		47,250		49,031		8,733		2,231		107,245
	Additions		-		7,658		-		-		-		7,658
	Balance, December 31, 2012		-		54,908		49,031		8,733		2,231		114,903
	Acquisitions through business combinations		13,280		-		427,797		162,980		-		604,057
	Additions		-		4,000		-		-		-		4,000
	Effect of changes in exchange rates		-726		-		-23,380		-8,907		-		-33,013
	Balance, December 31, 2013		12,554		58,908		453,448		162,806		2,231		689,947
	Accumulated amortization
	Balance, January 1, 2012		-		47,228		44,271		5,277		2,103		98,879
	Amortization		-		800		4,080		1,092		109		6,081
	Balance, December 31, 2012		-		48,028		48,351		6,369		2,212		104,960
	Amortization		382		2,135		18,694		6,332		19		27,562
	Effect of changes in exchange rates		-13		-		-596		-174		-		-783
	Balance, December 31, 2013		369		50,163		66,449		12,527		2,231		131,739
	Carrying amount
	December 31, 2012		-		6,880		680		2,364		19		9,943
	December 31, 2013		12,185		8,745		386,999		150,279		-		558,208
	The weighted-average amortization period for the total finite-lived other intangible assets acquired, as a result of the acquisition of Cymer, is 15.2 years.
	The weighted-average amortization period for the finite-lived other intangible assets acquired, as a result of the acquisition of Cymer, by major intangible asset class is as follows:
	(in years)	Brands		Developed technology		Customer relationships
	Weighted-average amortization period		20		14		17.9
	Acquired finite-lived other intangible assets are amortized on a straight-line basis not taking into account any residual value.
	Intellectual property relates to licenses and patents purchased from third parties. During 2013, we acquired intellectual property from third parties for an amount of EUR 4.0 million (2012: EUR 7.7 million).
	Indefinite-lived other intangible assets consist of the following:
	(in thousands)	In-process
		R&D
		EUR
	Cost
	Balance, January 1, 2012		-
	Additions		-
	Balance, December 31, 2012		-
	Acquisitions through business combinations		147,485
	Additions		-
	Effect of changes in exchange rates		-8,059
	Carrying amount, December 31, 2013		139,426
	All acquired infinite-lived other intangible assets are allocated to the RU ASML.
	Brands, Developed technology, Customer relationships, In-process R&D and Other were obtained from the acquisitions of Cymer (2013) and Brion (2007).
	During 2013, we recorded amortization charges of EUR 27.6 million (2012: EUR 6.1 million; 2011: EUR 5.3 million) which were recorded in cost of sales for EUR 27.0 million (2012: EUR 6.0 million; 2011: EUR 5.3 million) and in R&D costs for EUR 0.6 million (2012:EUR 0.1 million and 2011: nil).
	During 2013, 2012 and 2011, we did not record any impairment charges for other intangible assets.
	As at December 31, 2013, the estimated amortization expenses for other intangible assets, for the next five years and thereafter, are as follows:
	(in thousands)	EUR
	2014		42,227
	2015		41,317
	2016		52,753
	2017		51,958
	2018		50,619
	Thereafter		458,760
	Amortization expenses		697,634

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	12. Property, Plant and Equipment
	Property, plant and equipment consist of the following:
	(in thousands)	Land,		Machinery		Leasehold		Furniture,		Total
		buildings and		and		improvements		fixtures and		EUR
		constructions		equipment		EUR		other
		EUR		EUR				equipment
								EUR
	Cost
	Balance, January 1, 2012		742,141		764,023		206,660		344,979		2,057,803
	Additions		106,234		248,429		8,883		22,749		386,295
	Disposals		-347		-317,022		-300		-30,894		-348,563
	Effect of changes in exchange rates		-995		-4,671		-391		-59		-6,116
	Balance, December 31, 2012		847,033		690,759		214,852		336,775		2,089,419
	Acquisitions through business combinations		71,040		48,965		1,057		3,246		124,308
	Additions		123,646		171,895		11,543		32,168		339,252
	Disposals		-14		-90,244		-336		-1,925		-92,519
	Effect of changes in exchange rates		-6,605		-17,490		-1,464		-1,783		-27,342
	Balance, December 31, 2013		1,035,100		803,885		225,652		368,481		2,433,118
	Accumulated depreciation and impairment
	Balance, January 1, 2012		155,877		401,800		145,775		300,741		1,004,193
	Depreciation		31,598		110,571		13,416		23,668		179,253
	Impairment charges		649		906		-		1,679		3,234
	Disposals		-347		-92,205		-248		-30,575		-123,375
	Effect of changes in exchange rates		-505		-3,090		-165		-49		-3,809
	Balance, December 31, 2012		187,272		417,982		158,778		295,464		1,059,496
	Depreciation		47,791		114,677		12,415		22,170		197,053
	Impairment charges		3,619		7,997		1,352		89		13,057
	Disposals		-5		-42,625		-266		-1,282		-44,178
	Effect of changes in exchange rates		-1,116		-8,068		-422		-544		-10,150
	Balance, December 31, 2013		237,561		489,963		171,857		315,897		1,215,278
	Carrying amount
	December 31, 2012		659,761		272,777		56,074		41,311		1,029,923
	December 31, 2013		797,539		313,922		53,795		52,584		1,217,840
	Property, plant and equipment include amounts recorded as a result of the acquisition of Cymer. For more information with respect to business combinations, we refer to Note 2.
	As of December 31, 2013, the carrying amount includes assets under construction for land, buildings and constructions of EUR 49.3 million (2012: EUR 5.5 million), machinery and equipment of EUR 35.9 million (2012: EUR 21.8 million), leasehold improvements of EUR 1.0 million (2012: EUR 1.0 million) and furniture, fixtures and other equipment of EUR 13.9 million (2012: EUR 9.3 million). As of December 31, 2013, the carrying amount of land amounts to EUR 79.2 million (2012: EUR 60.7 million).
	The majority of the additions and disposals in 2013 and 2012 relate to machinery and equipment (including operating leases to customers, prototypes, evaluation and training systems). These systems are similar to those that ASML sells in its ordinary course of business. The systems are capitalized under property, plant and equipment because they are held for own use, for operating lease and for evaluation purposes. These systems are recorded at cost and depreciated over their expected useful life taking into consideration their residual value. From the time that these assets are no longer held for use but intended for sale in the ordinary course of business, they are reclassified from property, plant and equipment to inventory at the lower of their carrying value or fair market value. Since the transfers between inventory and property, plant and equipment are non-cash events, these are not reflected in the Consolidated Statements of Cash Flows. An amount of EUR 115.9 million (2012: EUR 204.8 million) of the additions relates to non-cash transfers from inventory and an amount of EUR 12.5 million (2012: EUR 9.6 million) relates to other non-cash movements (mainly capital expenditures not yet paid as at December 31, 2013). An amount of EUR 48.2 million (2012: EUR 222.9 million) of the disposals relates to non-cash transfers to inventory. When sold, the proceeds and cost of these systems are recorded as net sales and cost of sales, respectively, identical to the treatment of other sales transactions. The cost of sales for these systems includes the inventory value and the additional costs of refurbishing (materials and labor).
	The impairment charges recorded in 2013 mainly related to buildings (EUR 3.6 million) and machinery and equipment (EUR 8.0 million). We recorded impairment charges in buildings relating to the rebuild of cleanroom cabins and in machinery and equipment relating to proto types. The total impairment charges were determined based on the difference between the assets’ estimated fair value (being EUR 16.4 million) and their carrying amount.
	The impairment charges recorded in 2012 mainly related to furniture, fixture and other equipment (EUR 1.7 million). We recorded impairment charges with respect to software which ceased to be used. The total impairment charges were determined based on the difference between the assets’ estimated fair value (being EUR 0.1 million) and their carrying amount.
	The impairment charges recorded in 2011 mainly related to machinery and equipment and furniture, fixture and other equipment (EUR 9.5 million). We recorded impairment charges with respect to technical equipment and software which ceased to be used. The total impairment charges were determined based on the difference between the assets’ estimated fair value (being EUR 1.9 million) and their carrying amount.
	As of December 31, 2013, the carrying amount of machinery and equipment includes an amount of EUR 36.7 million with respect to evaluation and operating lease systems (2012: EUR 82.2 million).
	During 2013, we recorded impairment charges of EUR 13.1 million (2012: EUR 3.2 million; 2011: EUR 12.3 million) of which we recorded EUR 6.3 million (2012: EUR 1.0 million; 2011: EUR 6.2 million) in cost of sales, EUR 6.7 million (2012: EUR 0.5 million; 2011: EUR 3.5 million) in R&D costs and EUR 0.1 million (2012: EUR 1.7 million; 2011: EUR 2.6 million) in SG&A costs.
	During 2013, we recorded depreciation charges of EUR 197.1 million (2012: EUR 179.3 million; 2011: EUR 158.0 million) of which we recorded EUR 144.1 million (2012: EUR 147.7 million; 2011: EUR 117.7 million) in cost of sales, EUR 35.0 million (2012 EUR 15.3 million; 2011: EUR 24.9 million) in R&D costs and EUR 18.0 million (2012: EUR 16.3 million; 2011: EUR 15.4 million) in SG&A costs.
	Variable Interest Entity
	The carrying amount of land, buildings and constructions includes an amount of EUR 30.9 million (2012: EUR 32.4 million) relating to our headquarters in Veldhoven, the Netherlands, which is owned by Koppelenweg II B.V., a “VIE”.
	As of 2003, we are leasing the Veldhoven headquarters for a period of 15 years (starting in 2003) from an entity (“lessor”) that was incorporated by the VIE Shareholders. The lessor’s shareholders’ equity amounts to EUR 1.9 million and has not changed since 2003.
	The VIE shareholders each granted a loan of EUR 11.6 million and a fourth bank granted a loan of EUR 12.3 million (EUR 47.1 million in total) to the parent of the lessor. ASML provided the parent of the lessor with a subordinated loan of EUR 5.4 million and has a purchase option that is exercisable either at the end of the lease in 2018, at a price of EUR 24.5 million, or during the lease at a price equal to the book value of the assets. The total assets of the lessor entity amounted to EUR 54.5 million at inception of the lease. The entity is determined to be a VIE because the equity investors do not have sufficient equity at risk for the legal entity to finance its activities without sufficient additional subordinated support.
	The primary purpose for which the VIE was created was to provide ASML with use of the building for 15 years, where ASML does not retain substantially all the risks and rewards from changes in value of the building. The main activities of the entity are to rent, re-market and ultimately sell the building that is owned by the VIE. The economic performance of the VIE is most significantly impacted by the ability of the lessee (ASML) to exercise the purchase option at any time during the lease term, and thus we could potentially benefit from increases in the fair value of the building.
	While the debt holders have an interest, and may absorb losses, and the equity holders have an interest and may receive benefits, they do not have the power to direct activities that most significantly impact the entity’s economic performance and therefore, cannot be the primary beneficiary. Through the pre-determined price of the call option ASML has the power over the VIE, therefore only ASML meets both the power and losses/benefit criterion and consolidates the VIE.

Accrued_and_Other_Liabilities

Accrued and Other Liabilities	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Accrued and Other Liabilities	'
	13. Accrued and Other Liabilities
	Accrued and other liabilities consist of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Deferred revenue			939,358		739,136
	Costs to be paid			440,010		278,066
	Down payments from customers			821,959		1,033,768
	Personnel related items			247,246		200,670
	Derivative financial instruments			11,652		10,893
	Standard warranty reserve			27,475		21,626
	Other			12,324		1,352
	Accrued and other liabilities			2,500,024		2,285,511
	Less: non-current portion of accrued and other liabilities1			283,142		405,141
	Current portion of accrued and other liabilities			2,216,882		1,880,370
	1	The main part of the non-current portion of accrued and other liabilities relates to down payments received from customers regarding future shipments of EUV systems and deferrals with respect to services.
	The increase in accrued and other liabilities mainly relates to the increase in deferred revenue and costs to be paid, partly offset by the decrease in down payments from customers.
	Deferred revenue as of December 31, 2013 mainly consists of award credits regarding free or discounted products or services as part of volume purchase agreements amounting to EUR 660.1 million (2012: EUR 581.5 million) and prepaid extended and enhanced (optic) warranty contracts amounting to EUR 261.2 million (2012: EUR 242.2 million). In addition, the deferred revenue also includes deferrals with respect to our first third-generation EUV system, NXE:3300B.
	Costs to be paid include an amount of EUR 171.2 million relating to the expected losses to upgrade the first 11 EUV sources in the field, which was assumed by ASML as a result of the acquisition of Cymer. In addition, costs to be paid include accrued cost for unbilled services provided by suppliers including contracted labor, outsourced services and consultancy.
	We receive down payments from customers prior to shipment for systems included in ASML’s current product portfolio or systems currently under development.
	Personnel related items mainly consist of accrued management bonuses, accrued profit sharing, accrued vacation days, accrued vacation allowance, accrued wage tax, social securities and accrued pension premiums.
	Derivative financial instruments consist of the fair value of foreign currency contracts and the aggregate fair value of interest rate swaps which includes accrued interest, see Note 4.
	Changes in standard warranty reserve for the years 2013 and 2012 are as follows:
	(in thousands)		2013		2012
			EUR		EUR
	Balance, January 1			21,626		43,273
	Acquisitions through business combinations			2,978		-
	Additions for the year			37,124		35,735
	Utilization of the reserve			(19,924)		(33,746)
	Release of the reserve			-13,076		-22,733
	Effect of exchange rates			-1,253		-903
	Standard warranty reserve			27,475		21,626
	The release of the reserve is due to a change in accounting estimate based on lower than expected historical warranty expenses as a result of an improved learning-curve concerning our systems. The release has been included in cost of sales.

Provisions

Provisions	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Provisions	'
	14. Provisions
	The movement in the provision for lease contract termination costs is as follows:
	(in thousands)	2013		2012
		EUR		EUR
	Balance, January 1		10,254		12,338
	Utilization of the provision		-2,790		-2,545
	Release of the provision		-1,011		-
	Unwinding of discount		391		628
	Effect of exchange rates		3		-167
	Provision for lease contract termination costs		6,847		10,254
	Less: current portion of provision for lease contract termination costs		2,227		2,280
	Non-current portion of provision for lease contract termination costs		4,620		7,974
	The provision for lease contract termination costs relates to an operating lease contract for a building for which no economic benefits are expected. The provision for lease contract termination costs is expected to be fully utilized by 2017.

Longterm_Debt

Long-term Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-term Debt	'
	15. Long-term Debt
	Long-term debt consists of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	EUR 600 million 5.75 percent senior notes due 2017, carrying amount			270,339		710,095
	EUR 750 million 3.375 percent senior notes due 2023, carrying amount			751,591		-
	Loan headquarter building1			30,936		32,366
	Other			21,704		17,029
	Long-term debt			1,074,570		759,490
	Less: current portion of long-term debt			4,385		3,610
	Non-current portion of long-term debt			1,070,185		755,880
	1	This loan relates to our VIE, see Note 12.
	Our obligations to make principal repayments under our Eurobonds and other borrowing arrangements excluding interest expense as of December 31, 2013, for the next five years and thereafter, are as follows:
	(in thousands)		EUR
	2014			4,385
	2015			4,252
	2016			4,211
	2017			242,361
	2018			27,997
	Thereafter			757,467
	Long-term debt			1,040,673
	Less: current portion of long-term debt			4,385
	Non-current portion of long-term debt			1,036,288
	Eurobonds
	The following table summarizes the carrying amount of our outstanding Eurobonds, including the fair value of interest rate swaps used to hedge the change in the fair value of the Eurobonds:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Amortized cost amount			981,291		600,000
	Fair value interest rate swaps1			40,639		110,095
	Carrying amount			1,021,930		710,095
	1	The fair value of the interest rate swaps excludes accrued interest.
	In June 2007, we completed an offering of our EUR 600 million 5.75 percent senior notes due 2017, with interest payable annually on June 13. The notes are redeemable at the option of ASML, in whole or in part, at any time by paying a make whole premium, and unless previously redeemed, will be redeemed at 100 percent of their principal amount on June 13, 2017. In September 2013, we repurchased a nominal amount of EUR 361.8 million of these notes in a tender offer for a cash amount of EUR 423.0 million including accrued interest.
	In September 2013, we completed an offering of our EUR 750 million 3.375 percent senior notes due 2023, with interest payable annually on September 19. The notes are redeemable at the option of ASML, in whole or in part, at any time by paying a make whole premium, and unless previously redeemed, will be redeemed at 100 percent of their principal amount on September 19, 2023.
	The Eurobonds serve as hedged items in fair value hedge relationships in which we hedge the variability of changes in the fair value of our Eurobonds due to changes in market interest rates with interest rate swaps. The fair value changes of these interest rate swaps are recorded on the Consolidated Balance Sheets under derivative financial instruments (within other current assets and other non-current assets) and the carrying amount of the Eurobonds is adjusted for these fair value changes only. Following the repurchase of part of our EUR 600 million 5.75 percent senior notes due 2017, the corresponding part of the interest rate swaps has been terminated, simultaneously.
	The following table summarizes amongst others the estimated fair value of the Eurobonds:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Principal amount			988,153		600,000
	Carrying amount			1,021,930		710,095
	Fair value1			1,028,238		700,644
	1	Source: Bloomberg Finance LP
	The fair value of our Eurobonds is estimated based on quoted market prices as of December 31, 2013. Due to changes in market interest rates and credit spreads since the issue of our Eurobonds which carry a fixed coupon interest rate, the fair value deviates from the principal amount.

Lines_of_Credit

Lines of Credit	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Lines of Credit	'
	16. Lines of Credit
	Our available credit facilities amount to EUR 700.0 million as of December 31, 2013 and EUR 500.0 million as of December 31, 2012. No amounts were outstanding under these credit facilities at the end of 2013 and 2012.
	The amount at December 31, 2013 consists of one EUR 700 million committed revolving credit facility from a group of banks that will mature in 2018. This credit facility replaced our EUR 500 million committed revolving credit facility that was due to expire in May 2015 and that we, in line with our financing policy, cancelled in March 2013. The new credit facility contains a similar restrictive covenant as the credit facility it replaced and that requires us to maintain a minimum long-term committed capital to net total assets ratio of 40.0 percent calculated in accordance with contractually agreed definitions. Long-term committed capital contains, among others, shareholders’ equity and debt maturing at least one year after the maturity date of the credit facility, while net total assets mainly comprises of total assets minus cash, cash equivalents and certain short-term investments. Furthermore, adjustments are made for e.g. intangibles and operating leases. As of December 31, 2013 this ratio was 89.6 percent. Therefore, we are in compliance with the covenant at the end of 2013. Outstanding amounts under this credit facility will bear interest at EURIBOR or LIBOR plus a margin that depends on our liquidity position.
	The amount at December 31, 2012, consisted of one EUR 500 million committed revolving credit facility from a group of banks that we cancelled in March 2013. The credit facility contained a restrictive covenant that required us to maintain a minimum committed capital to net total assets ratio of 40.0 percent calculated in accordance with contractually agreed definitions. As of December 31, 2012, this ratio was 85.8 percent. Therefore, we were in compliance with the covenant at the end of 2012.

Commitments_Contingencies_and_

Commitments, Contingencies and Guarantees	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments, Contingencies and Guarantees	'
	17. Commitments, Contingencies and Guarantees
	We have various contractual obligations, some of which are required to be recorded as liabilities in our Financial Statements, including long- and short-term debt. Other contractual obligations, namely operating lease commitments, purchase obligations and guarantees, are generally not required to be recognized as liabilities on our Consolidated Balance Sheets but are required to be disclosed.
	Our contractual obligations as of December 31, 2013 can be summarized as follows:
	Payments due by period		Total		1 year		2 year		3 year		4 year		5 year		After
	(in thousands)		EUR		EUR		EUR		EUR		EUR		EUR		5 years
															EUR
	Long-Term Debt Obligations, including interest expense1			1,341,380		45,079		44,952		44,907		275,640		54,155		876,647
	Operating Lease Obligations			74,946		30,293		21,543		14,081		4,803		2,539		1,687
	Purchase Obligations			2,012,913		1,894,455		85,548		16,223		13,772		2,382		533
	Unrecognized Tax Benefits,			74,069		580		945		7,680		26,105		785		37,974
	including interest expense
	Total Contractual Obligations			3,503,308		1,970,407		152,988		82,891		320,320		59,861		916,841
	1	See Note 15 for the amounts excluding interest expenses.
	Long-term debt obligations mainly relate to interest payments and the principal amount of our Eurobonds. See Note 15.
	Operating lease obligations include leases of equipment and facilities. Lease payments recognized as an expense were EUR 42.0 million, EUR 41.6 million and EUR 40.6 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Several operating leases for our buildings contain purchase options, exercisable at the end of the lease, and in some cases, during the term of the lease. The amounts to be paid if ASML would exercise these purchase options at the end of the lease as of December 31, 2013 can be summarized as follows:
	Purchase options		Total		1 year		2 year		3 year		4 year		5 year		After
	due by period		EUR		EUR		EUR		EUR		EUR		EUR		5 years
	(in thousands)														EUR
	Purchase options			13,983		-		-		13,983		-		-		-
	Purchase obligations include purchase commitments with suppliers in the ordinary course of business. ASML expects that it will honor these purchase obligations to fulfill future sales, in line with the timing of those future sales. The general terms and conditions of the agreements relating to the major part of our purchase commitments as of December 31, 2013 contain clauses that enables us to delay or cancel delivery of ordered goods and services up to the dates specified in the corresponding purchase contracts. These terms and conditions that we have agreed with our supply chain partners gives us additional flexibility to adapt our purchase obligations to our requirements in light of the inherent cyclicality of the semiconductor equipment industry in which we operate. We establish a provision for cancellation fees when it is probable that the liability has been incurred and the amount of cancellation fees is reasonably estimable.

Employee_Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2013
Compensation Related Costs [Abstract]	'
Employee Benefits	'
	18. Employee Benefits
	Our bonus expenses for the Board of Management (including Mr. Nickl and Mr. Meurice) and senior management were as follows:
	Year ended December 31		2013				2012				2011
	(in thousands)		EUR				EUR				EUR
	Bonus expenses			32,698				16,474				15,557
	Bonus expenses include an amount of EUR 2.1 million (2012: EUR 1.8 million; 2011: EUR 1.7 million) in relation to the STI cash bonus for our Board of Management, Mr. Nickl and Mr. Meurice.
	We have a performance related bonus plan for senior management, who are not members of the Board of Management. Under this plan, the bonus amount is dependent on actual performance against corporate, departmental and personal targets. Within ASML the bonus for members of senior management can range between 0.0 percent and 40.0 percent, or 0.0 percent and 70.0 percent, of their annual salaries, depending upon their seniority. The performance targets are set for each half year. The bonus over the first half of 2013 was paid in the second half of 2013. The bonus over the second half of 2013 is accrued for in the Consolidated Balance Sheets as of December 31, 2013 and is expected to be paid in the first quarter of 2014. As a result of the acquisition of Cymer, we assumed all existing bonus plans eligible to Cymer employees. Within Cymer bonuses can range between 0.0 percent and 150.0 percent, or 0.0 percent and 200.0 percent of the relevant employee’s annual salary, depending upon such employee’s seniority and respective division. The performance targets are set for a whole year. The bonus over 2013 is accrued for in the Consolidated Balance Sheets as of December 31, 2013 and is expected to be paid in the first quarter of 2014.
	Our bonus costs under these plans were as follows:
	Year ended December 31		2013				2012				2011
	(in thousands)		EUR				EUR				EUR
	Bonus expenses			30,631				14,588				13,131
	The increase in bonus costs in 2013 compared to 2012 is mainly attributable to the acquisition of Cymer.
	Profit-sharing Plan
	We have a profit-sharing plan covering all European and US non-sales employees who are not members of the Board of Management or senior management. Under the plan, eligible employees receive an annual profit-sharing, based on a percentage of net income relative to sales ranging from 0.0 to 20.0 percent of their annual salary. The profit sharing for the years 2013, 2012 and 2011 was 14.0 percent or EUR 55.9 million, 18.0 percent or EUR 64.5 million and 20.0 percent or EUR 64.0 million, respectively. Our profit is also one of the criteria for the individual variable pay programs for employees in Asia and employees eligible to the sales reward plan which amount to EUR 25.8 million for 2013 (including EUR 2.3 million for the sales reward plan), EUR 24.4 million for 2012 and EUR 23.2 million for 2011.
	Share-based Compensation
	We have adopted various share (option) plans for our employees. Each year, the Board of Management determines, by category of our personnel, the total available number of stock options and maximum number of shares that can be granted in that year. The determination is subject to the approval of our Supervisory Board. For members of the Board of Management, we have separate share-based payment plans, for details on service and vesting conditions see below. Our current share-based payment plans do not provide cash settlement of options and shares.
	The total gross amount of recognized compensation expenses associated with share-based payments (including share-based payments to the Board of Management) was EUR 52.4 million in 2013, EUR 18.7 million in 2012 and EUR 12.4 million in 2011. Compensation expenses in 2013 included EUR 25.2 million relating to incurred post-acquisition expenses for share-based compensation awards exchanged as part of the acquisition of Cymer, see Note 2. Details concerning the share (option) plans which have been adopted by ASML as part of the Cymer acquisition are included in the tables below. The tax benefit recognized related to the recognized share-based compensation costs amounts to EUR 10.7 million in 2013, EUR 0.9 million in 2012 and EUR 0.5 million in 2011.
	Total compensation costs related to non-vested awards to be recognized in future periods amount to EUR 78.9 million as per December 31, 2013 (2012: EUR 30.4 million; 2011: EUR 23.3 million). The weighted average period over which these costs are expected to be recognized is calculated at 1.6 years (2012: 2.0 years; 2011: 1.9 years).
	Option Plans
	Options granted under our stock option plans have fixed exercise prices equal to the closing price of our shares listed at NYSE Euronext Amsterdam or our shares listed at NASDAQ on the applicable grant-dates. Granted stock options generally vest over a three-year period with any unexercised stock options expiring ten years after the grant-date.
	We have five different stock option plans:
	•		Employee plan
	•		Option purchase plan
	•		Brion stock option plan
	•		Cymer stock option plan
	•		Senior management plan (already vested)
	The Option purchase plan has no service and vesting conditions. The other plans typically have a three to four year service condition. The fair value of the stock options is determined using a Black-Scholes option valuation model.
	The Black-Scholes option valuation of our stock options is based on the following assumptions:
			2013				2012				2011
	Year ended December 31
	Weighted average share price (in EUR)			62				40.3				28
	Volatility (in percentage)			27				25.6				37.8
	Expected life (in years)			5.6				5				4.8
	Risk free interest rate			0.8				2.1				2.9
	Expected dividend yield (in EUR)			2				1.45				1.25
	Forfeiture rate1			-				-				-
	1	As of year end for each of the three years ended December 31, forfeitures are estimated to be nil.
	When establishing the expected life assumption we annually take into account the contractual terms of the stock options as well as historical employee exercise behavior.
	Other details with respect to stock options are set out in the following table:
															USD-denominated
			EUR-denominated
	Year ended December 31		2013				2012				2011				2013				2012				2011
	Weighted average fair value of stock options granted			14.22				8.97				8.28				21.74				11.87				10.42
	Weighted average share price at the exercise date of stock options			59.53				40.45				29.39				77.25				50.88				41.94
	Aggregate intrinsic value of stock options exercised (in thousands)			15,924				71,331				30,204				11,086				12,684				11,323
	Aggregate remaining contractual term of currently exercisable options (years)			3.09				3.59				2.08				3.12				3.17				1.8
	Aggregate intrinsic value of exercisable stock options (in thousands)			37,441				34,438				39,384				22,781				21,882				20,492
	Aggregate intrinsic value of outstanding stock options (in thousands)			38,718				35,671				45,141				25,369				22,433				20,791
	The number and weighted average exercise prices of stock options as of December 31, 2013, and changes during the year then ended are presented below:
											USD-denominated
			EUR-denominated
			Number				Weighted average				Number				Weighted average
			of options				exercise price				of options				exercise price
							per ordinary								per ordinary
							share (EUR)								share (USD)
	Outstanding, January 1, 2013			1,128,162				16.38				494,836				19.06
	Granted			28,308				58.35				101,400	1			60.86
	Exercised			-358,581				15.12				-178,374				14.86
	Forfeited			-4,234				20.27				-7,311				23.81
	Expired			-11,353				10.11				-3,916				11.33
	Outstanding, December 31, 2013			782,302				18.55				406,635				31.31
	Exercisable, December 31, 2013			731,452				16.85				325,026				23.61
	1	USD-denominated grants include 79,153 options with a weighted average exercise price of USD 53.07 which have been assumed by ASML as part of the acquisition of Cymer.
Details with respect to the stock options outstanding are set out in the following table:
												USD-denominated
EUR-denominated
Range of				Number of				Weighted				Range of				Number of				Weighted
exercise				outstanding				average				exercise				outstanding				average
prices (EUR)				options at				remaining				prices (USD)				options at				remaining
				December 31, 2013				contractual life								December 31, 2013				contractual life
								of outstanding												of outstanding
								options (years)												options (years)
	0 -10				-				-				0 - 10				20,560				1.97
	15-Oct				380,681				2.36				10 - 15				133,117				0.9
	15 - 20				185,086				3.11				15 - 20				4,311				4.8
	20 - 25				141,192				4.05				20 - 25				80,019				3.92
	25 - 40				24,843				7.76				25 - 40				93,456				5.72
	40 - 50				25,256				8.8				40 - 50				1,468				7.7
	50 - 60				6,156				9.17				50 - 60				9,540				8.71
	60 - 70				19,088				9.76				60 - 70				1,383				9.07
	70 - 80				-				-				70 - 80				43,993				9.14
	80 - 90				-				-				80 - 90				18,788				9.78
	Total				782,302				3.46				Total				406,635				4.23
In 2013, 2012 and 2011, only repurchased shares were used to satisfy the option rights upon exercise. For more information with respect to repurchased shares we refer to Note 27.
Share Plans
Shares granted under our share plans include a three to four year service period and for some plans performance conditions. The fair value of shares is determined based on the closing trading price of our shares listed at NYSE Euronext Amsterdam on the grant date.
We have eight different share plans:
•		Employee plan
•		Cymer employee plan
•		Share purchase plan
•		New hire performance share plan
•		Brion performance share plan
•		Cymer performance share plan
•		Senior management performance share plan
•		Board of management performance share plan
The Share purchase plan has no service and vesting conditions. The employee plans only have service conditions. The other plans have service conditions which are similar and have vesting conditions which are based on performance.
Details with respect to shares are set out in the following table:
														USD-denominated
		EUR-denominated
Year ended December 31		2013				2012				2011				2013				2012				2011
Total fair value at vesting date of shares vested during the year (in thousands)			38,280				16,179				9,155				51,798				5,392				1,956
Weighted average fair value of shares granted			55.83				36.15				28.09				83.58				47.71				39
A summary of the status of conditionally outstanding shares as of December 31, 2013, and changes during the year ended December 31, 2013, is presented below:
										USD-denominated
		EUR-denominated
		Number of				Weighted				Number of				Weighted
		shares				average				shares				average
						fair value at grant								fair value at grant
						date (EUR)								date (USD)
Conditional shares outstanding at January 1, 2013			1,693,610				29.92				249,094				40.71
Granted			548,786				55.83				1,852,320	1			83.58
Vested/Issued			-635,753				26.94				-628,802				76.12
Forfeited			-62,311				33.4				-92,292				78.94
Conditional shares outstanding at December 31, 2013			1,544,332				40.21				1,380,320				79.55
1	USD-denominated grants include 1,634,990 shares with a weighted average fair value of USD 83.94 which have been assumed by ASML as part of the acquisition of Cymer.
Other Plans
Employee Purchase Plan
Every quarter, we offer our worldwide payroll employees the opportunity to buy our shares or our stock options against fair value out of their net salary. The fair value for shares is determined based on the closing price of our shares listed at NYSE Euronext Amsterdam on the grant-date. The fair value of the stock options is determined using a Black-Scholes option valuation model. For the assumptions on which the Black-Scholes option valuation model is used, see the disclosure above under the caption “Option Plans”. The maximum net amount for which employees can participate in the plan amounts to 10.0 percent of gross base salary. When employees retain the shares and/or stock options for a minimum of 12 months, we will pay out a 20.0 percent cash bonus on the net invested amount.
Deferred Compensation Plans
In July 2002, we adopted a non-qualified deferred compensation plan for our United States employees that allows a select group of management or highly compensated employees to defer a portion of their salary, bonus, and commissions. The plan allows us to credit additional amounts to the participants’ account balances. The participants divide their funds among the investments available in the plan. Participants elect to receive their funds in future periods after the earlier of their employment termination or their withdrawal election, at least three years after deferral. There were minor expenses relating to this plan in 2013, 2012 and 2011. Cymer has a similar non-qualified deferred compensation plan for a selected group of management level employees in the United States in which the employee may elect to defer receipt of current compensation from us in order to provide retirement and other benefits on behalf of such employee backed by Cymer owned life insurance policies.
As of December 31, 2013, and 2012, our liability under deferred compensation plans was EUR 23.5 million and EUR 11.8 million, respectively.
Pension Plans
We maintain various pension plans covering substantially all of our employees. Our employees in the Netherlands, 5,525 FTEs, participate in a multi-employer union plan (PME) determined in accordance with the collective bargaining agreements effective for the industry in which we operate. This collective bargaining agreement has no expiration date. This multi-employer union plan covers approximately 1,296 companies and approximately 146,000 contributing members. Our contribution to the multi-employer union plan is less than 5.0 percent of the total contribution to the plan as per the annual report for the year ended December 31, 2012. The plan monitors its risks on a global basis, not by company or employee, and is subject to regulation by Dutch governmental authorities. By law (the Dutch Pension Act), a multi-employer union plan must be monitored against specific criteria, including the coverage ratio of the plan’s assets to its obligations. This coverage ratio must exceed 104.3 percent for the total plan. Every company participating in a Dutch multi-employer union plan contributes a premium calculated as a percentage of its total pensionable salaries, with each company subject to the same percentage contribution rate. The premium can fluctuate yearly based on the coverage ratio of the multi-employer union plan. The pension rights of each employee are based upon the employee’s average salary during employment.
In 2009, because of a low coverage ratio, PME prepared and executed a so-called “Recovery Plan” which was approved by De Nederlandsche Bank. Under the terms of the recovery plan, which terminated at the end of 2013, a minimal coverage percentage of 104.3 percent was required. The coverage percentage of the multi-employer union plan increased to 103.4 percent as of December 31, 2013 (December 31, 2012: 93.9 percent), which is below the requirements as set out in the recovery plan. However we have no obligation whatsoever to pay off any deficits the pension fund may incur, nor have we any claim to any potential surpluses. The coverage percentage is calculated by dividing the funds capital by the total sum of pension liabilities and is based on actual market interest. In 2014 the pension premium percentage will increase from 24.0 to 24.1.
Our net periodic pension cost for this multi-employer union plan for any period is the amount of the required contribution for that period.
We also participate in several defined contribution pension plans, with our expenses for these plans equaling the contributions made in the relevant period.
Our pension and retirement expenses for all employees for the three years ended December 31, 2013, 2012 and 2011 were:
		2013				2012				2011
Year ended December 31		EUR				EUR				EUR
(in thousands)
Pension plan based on multi-employer union plan			40,476				34,525				31,819
Pension plans based on defined contribution			19,799				15,773				14,128
Pension and retirement expenses			60,275				50,298				45,947

Legal_Contingencies

Legal Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Legal Contingencies	'
	19. Legal Contingencies
	ASML is party to various legal proceedings generally incidental to our business. ASML also faces exposures from other actual or potential claims and legal proceedings. In addition, ASML’s customers may be subject to claims of infringement from third parties alleging that the ASML equipment used by those customers in the manufacture of semiconductor products, and/or the methods relating to use of the ASML equipment, infringes one or more patents issued to those third parties. If these claims were successful, ASML could be required to indemnify such customers for some or all of the losses incurred or damages assessed against them as a result of that infringement.
	We accrue for legal costs related to litigation in our Consolidated Statements of Operations at the time when the related legal services are actually provided to ASML. In 2013, EUR 3.2 million estimated losses were recorded as a charge to our Consolidated Statements of Operations (2012 and 2011: no estimated losses were recorded).
	From late 2001 through 2004, ASML was party to a series of civil litigations and administrative proceedings in which Nikon alleged ASML’s infringement of Nikon patents relating to lithography. ASML in turn filed claims against Nikon. Pursuant to agreements executed on December 10, 2004, ASML and Nikon agreed to settle all pending worldwide patent litigation between the companies. The settlement included an exchange of releases, a patent Cross-License agreement related to lithography equipment used to manufacture semiconductor devices and payments to Nikon by ASML. Beginning on January 1, 2015, the parties may bring suit for infringement of patents subject to the Nikon Cross-License Agreement, including any infringement that occurred during the Cross-License Transition Period. Damages resulting from claims for patent infringement occurring during the Cross-License Transition Period are limited to three percent of the net sales price of products found to infringe valid and enforceable patents.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	20. Income Taxes
	The components of the provision for income taxes are as follows:
			2013		2012		2011
	Year ended December 31		EUR		EUR		EUR
	(in thousands)
	Current tax			-52,753		-79,255		-129,127
	Deferred tax			44,766		74,993		-52,548
	Provision for income taxes			-7,987		-4,262		-181,675
	The Dutch statutory tax rate was 25.0 percent in 2013, 2012 and 2011. Tax amounts in other jurisdictions are calculated at the rates prevailing in the relevant jurisdictions.
	The reconciliation of the provision for income taxes is as follows:
			2013		%		2012		%		2011		%
	Year ended December 31		EUR				EUR				EUR
	(in thousands)
	Income before income taxes			1,023,477		100		1,150,578		100		1,648,635		100
	Income tax provision based on ASML’s domestic rate			-255,869		25		-287,644		25		-412,159		25
	Effects of tax rates in foreign jurisdictions			23,459		-2.3		9,786		-0.9		20,663		-1.3
	Adjustments in respect of tax exempt income			29,430		-2.9		23,532		-2		19,134		-1.2
	Adjustments in respect of tax incentives			120,751		-11.7		143,160		-12.4		180,096		-10.9
	Adjustments in respect of prior years’ current taxes			5,155		-0.5		18,275		-1.6		9,097		-0.6
	Adjustments in respect of prior years’ deferred taxes			16,164		-1.6		-		-		-		-
	Movements in the liability for unrecognized tax benefits			-7,588		0.7		95,465		-8.3		6,634		-0.4
	Adjustment in respect of non-taxable pre-existing relationship			67,730		-6.6		-		-		-		-
	Other credits and non-taxable items			-7,219		0.7		-6,836		0.6		-5,140		0.4
	Provision for income taxes			-7,987		0.8		-4,262		0.4		-181,675		11
	Income Tax Provision Based on ASML’s Domestic Rate
	The provision for income taxes based on ASML’s domestic rate is based on the Dutch statutory income tax rate. It reflects the provision for income taxes that would have been applicable assuming that all of our income is taxable against the Dutch statutory tax rate and there were no permanent differences between taxable base and financial results and no Dutch tax incentives are applied.
	Effects of Tax Rates in Foreign Jurisdictions
	A portion of ASML’s results are realized in countries other than the Netherlands where different tax rates are applicable. The increase of the effects of tax rates in foreign jurisdictions compared to 2012 is mainly explained by a shift in the mix of taxable income across tax jurisdictions as a result of the acquisition of Cymer as per May 30, 2013.
	Adjustments in Respect of Tax Exempt Income
	In certain jurisdictions part of the income generated is tax exempted.
	Adjustments in Respect of Tax Incentives
	Adjustments in respect of tax incentives relate to reduced tax rates in several jurisdictions, mainly consisting of the Dutch “Innovation Box” and the RDA. The Innovation box is a facility under Dutch corporate tax law pursuant to which income associated with R&D is partially exempted from taxation. The RDA is a tax incentive in which an additional tax depreciation is allowed for tangible assets utilized for research and development purposes.
	Adjustments in Respect of Prior Years’ Current Taxes
	In 2012, we recognized a tax benefit of EUR 18.3 million or 1.6 percent of income before taxes mainly attributable to the application of tax exemptions for prior years, which had a favorable effect on the effective tax rate for 2012.
	Adjustments in Respect of Prior Years’ Deferred Taxes
	In 2013, we recognized a tax benefit of EUR 16.2 million as result of a partly release of a valuation allowance for NID credits or NID stock to the extend we expect future taxable profits to realize these NID credits before expiration of those credits.
	Movements in the Liability for Unrecognized Tax Benefits
	In 2012, the effective tax rate was impacted by a tax benefit of EUR 95.5 million or 8.3 percent of income before income taxes mainly as a result of the successful conclusion of tax audits in different jurisdictions (EUR 92.5 million) whereas the movement in the liability for unrecognized tax benefits in 2013 is considered to be limited.
	Adjustments in Respect of Non-Taxable Pre-Existing Relationships
	In 2013 the effective tax rate was impacted by the settlement gain recognized as a result of the effectively settled pre-existing relationships related to the acquisition of Cymer (see Note 2) as this gain does not represent a taxable item for income tax purposes.
	Other Credits and Non-taxable Items
	Other credits and non-taxable items reflect the impact on statutory rates of permanent non-taxable items such as non-deductible taxes, non-deductible interest expense, and non-deductible meals and entertainment expenses, as well as the impact of (the reversal of) various tax credits on our provision for income taxes.
	Income Taxes Recognized Directly in Shareholders’ Equity
	Income taxes recognized directly in shareholders’ equity (including OCI) are as follows:
			2013		2012		2011
	Income tax recognized in shareholders’ equity		EUR		EUR		EUR
	(in thousands)
	Current tax
	Derivative financial instruments1			-759		-1,066		6,257
	Tax (benefit) deficit from share-based payments			-3,110		-2,116		11
	Total income tax recognized in shareholders’ equity			-3,869		-3,182		6,268
	1	Recognized directly in OCI.
	Liability for Unrecognized Tax Benefits and Deferred Taxes
	The total deferred tax position and liability for unrecognized tax benefits recorded on the Consolidated Balance Sheets are as follows:
			2013		2012
	As of December 31		EUR		EUR
	(in thousands)
	Liability for unrecognized tax benefits			-74,069		-59,967
	Deferred tax position			-30,176		114,527
	Total			-104,245		54,560
	Liability for Unrecognized Tax Benefits
	The calculation of our liability for unrecognized tax benefits involves uncertainties in the application of complex tax laws. Our estimate for the potential outcome of any uncertain tax issue is highly judgmental. We believe that we have adequately provided for uncertain tax positions. However, settlement of these uncertain tax positions in a manner inconsistent with our expectations could have a material impact on our Consolidated Financial Statements.
	Consistent with the provisions of ASC 740, as of December 31, 2013, ASML has a liability for unrecognized tax benefits of EUR 74.1 million (2012: EUR 60.0 million) which is classified as non-current deferred and other tax liabilities. The total liability for unrecognized tax benefits, if reversed, would have a favorable effect on our effective tax rate.
Expected interest and penalties related to income tax liabilities have been accrued for and are included in the liability for unrecognized tax benefits and in the provision for income taxes. The balance of accrued interest and penalties recorded in the Consolidated Balance Sheets as per December 31, 2013 amounted to EUR 22.9 million (2012: EUR 21.4 million). Accrued interest and penalties recorded in the Consolidated Statement of Operations of 2013 amounted to a tax charge of EUR 4.1 million (2012: tax benefit of EUR 3.1 million; 2011: tax benefit of EUR 9.3 million).
A reconciliation of the beginning and ending balance of the liability for unrecognized tax benefits is as follows:
		2013		2012
As of December 31		EUR		EUR
(in thousands)
Balance, January 1			59,967		155,432
Gross increases – tax positions in prior period			6,045		4,297
Gross decreases – tax positions in prior period			-2,025		-92,521
Gross increases – tax positions in current period			6,796		3,255
Increase resulting from acquisition			6,514		-
Settlements			-2,964		-
Lapse of statute of limitations			-264		-10,496
Total liability for unrecognized tax benefits			74,069		59,967
For 2012, the gross decreases in tax positions in prior period mainly relates to the release of tax positions after successful conclusion of tax audits in different jurisdictions (EUR 92.5 million).
We believe our allowances for tax contingencies are appropriate. We estimate that the total liability for unrecognized tax benefits will decrease by EUR 0.6 million within the next 12 months. The estimated changes to the liability for unrecognized tax benefits within the next 12 months are mainly due to expected settlements with tax authorities.
We are subject to tax audits in certain of our major tax jurisdictions, for years from and including 2011 onwards in Hong Kong, and for years from and including 2001 onwards in the United States. In the course of such audits, local tax authorities may challenge the positions taken by us.
Deferred Tax Position
The changes in deferred income tax assets and liabilities consist of the following elements:
		2013		2012
Changes in deferred tax assets and liabilities		EUR		EUR
(in thousands)
Balance, January 1			114,527		137,946
Acquisitions through business combinations			-201,381		-
Consolidated Statements of Operations			53,084		-20,242
Effect of changes in exchange rates			3,594		-3,177
Balance, December 31			-30,176		114,527
The deferred tax position is classified in the consolidated balance sheets as follows:
		2013		2012
As of December 31		EUR		EUR
(in thousands)
Deferred tax assets – current			124,431		103,695
Deferred tax assets – non-current			139,513		39,443
Total deferred tax assets			263,944		143,138
Deferred tax liabilities – current			-3,494		-271
Deferred tax liabilities – non-current			-290,626		-28,340
Total deferred tax liabilities			-294,120		-28,611
Total			-30,176		114,527
The composition of total deferred tax assets and liabilities in the Financial Statements is as follows:
		January 1,		Acquisitions		Consolidated				December 31,
Deferred tax assets composition		2013		through		Statements of		Effect of		2013
of temporary		EUR		business		Operations		changes		EUR
differences				combinations		EUR		in exchange
(in thousands)				EUR				rates
								EUR
Capitalized R&D expenditures			27,403		-		5,882		-1,155		32,130
Inventories			28,167		10,258		9,269		-1,033		46,661
Deferred revenue			20,572		41,679		-43,035		-2,807		16,409
Provisions			21,528		7,148		17,960		-1,176		45,460
Installation and warranty reserve			7,151		-		-174		-275		6,702
Tax effect carry-forward losses			5,557		754		61,551		-580		67,282
Fixed assets			7,798		4,140		325		-478		11,785
Restructuring and impairment			4,336		-		-791		-184		3,361
Alternative minimum tax credits1			5,227		-		1,349		-234		6,342
Share-based payments			1,433		9,365		5,939		-586		16,151
Other temporary differences			13,966		16,701		-14,487		-4,519		11,661
Total2			143,138		90,045		43,788		-13,027		263,944
1	Alternative minimum tax credits relate to prepaid US taxes which are credited against future taxable profits after the carry-forward losses used.
2	Valuation allowances recognized in relation to deferred tax assets as at December 31, 2013 amounted to EUR 25.0 million (2012: EUR 30.5 million)
		January 1,		Acquisitions		Consolidated				December 31,
Deferred tax liabilities composition		2013		through		Statements of		Effect of		2013
of temporary		EUR		business		Operations		changes		EUR
differences				combinations		EUR		in exchange
(in thousands)				EUR				rates
								EUR
Intangible fixed assets			-		-286,337		8,730		15,702		-261,905
Fixed assets			-25,890		-4,786		12,517		567		-17,592
Borrowing costs			-1,958		-		135		-		-1,823
Other temporary differences			-763		-303		-12,086		352		-12,800
Total			-28,611		-291,426		9,296		16,621		-294,120
		January 1,		Consolidated				December 31,
Deferred tax assets composition		2012		Statements of		Effect of		2012
of temporary		EUR		Operations		changes		EUR
differences				EUR		in exchange
(in thousands)						rates
						EUR
Capitalized R&D expenditures			34,374		-6,465		-506		27,403
Inventories			35,820		-7,351		-302		28,167
Deferred revenue			23,892		-3,083		-237		20,572
Provisions			14,515		7,296		-283		21,528
Installation and warranty reserve			8,772		-1,508		-113		7,151
Tax effect carry-forward losses			7,735		-2,219		41		5,557
Fixed assets			6,495		1,454		-151		7,798
Restructuring and impairment			5,146		-733		-77		4,336
Alternative minimum tax credits1			5,028		229		-30		5,227
Share-based payments			950		516		-33		1,433
Other temporary differences			16,728		-1,138		-1,624		13,966
Total			159,455		-13,002		-3,315		143,138
1   Alternative minimum tax credits relate to prepaid US taxes which are credited against future taxable profits after the carry-forward losses used.
		January 1,		Consolidated				December 31,
Deferred tax liabilities composition		2012		Statements of		Effect of		2012
of temporary		EUR		Operations		changes		EUR
differences				EUR		in exchange
(in thousands)						rates
						EUR
Fixed assets			-19,108		-6,965		183		-25,890
Borrowing costs			-1,554		-404		-		-1,958
Other temporary differences			-847		129		-45		-763
Total			-21,509		-7,240		138		-28,611
Tax Effect Carry-forward Losses
Deferred tax assets from carry-forward losses result predominantly from net operating loss carry-forwards incurred in the United States and NID stock in Belgium.
Net operating losses qualifying as tax losses under United States federal tax laws were incurred during 2013. Net operating losses qualifying as tax losses under United States federal tax laws incurred by United States group companies can in general be offset against future profits realized in the 20 years following the year in which the losses are incurred.
Net operating losses qualified as tax losses under United States state tax laws incurred by United States group companies can in general be offset against future profits realized in the 5 to 20 years following the year in which the losses are incurred. The period of net operating loss carry forward for United States state tax purposes depends on the state in which the tax loss arose. Our ability to use United States state tax loss carry forwards in existence at December 31, 2013, is subject to varying state statutes (providing for periods of between 5 and 20 years) and valuation allowances have been set up for state carry forward losses that are not expected to be realized before they expire. The total amount of losses carried forward under United States federal tax laws as of December 31, 2013, is EUR 67.5 million tax basis or EUR 23.6 million tax effect. The total amount of losses carried forward under United States state tax laws as of December 31, 2013, is EUR 254.3 million tax basis or EUR 7.9 million tax effect.
NID stock in Belgium can generally be offset against future profits realized in the 7 years following the year in which the NID Stock occurs. The total amount of NID stock is EUR 47.6 million taxable base and EUR 16.2 million tax effect.

Segment_Disclosure

Segment Disclosure	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Disclosure	'
	21. Segment Disclosure
	ASML has one reportable segment, for the development, production, marketing, sale and servicing of advanced semiconductor equipment systems exclusively consisting of lithography related systems. In prior years our CEO was identified as CODM. As a result of ASML’s change in leadership as announced on April 17, 2013, our CEO and CTO have been jointly identified as the CODM. Both the CEO and CTO review the operating results to make decisions about allocating resources and assessing performance. The change in leadership did not result in a change in reportable segments compared to 2012.
	Management reporting includes net system sales figures of new and used systems and includes sales per technology. Net system sales for new and used systems were as follows:
		2013		2012		2011
	Year ended December 31	EUR		EUR		EUR
	(in thousands)
	New systems		3,890,154		3,620,260		4,780,720
	Used systems		102,975		181,372		103,193
	Net system sales		3,993,129		3,801,632		4,883,913
	The increase in net system sales of EUR 191.5 million, or 5.0 percent, to EUR 3,993.1 million in 2013 from EUR 3,801.6 million in 2012 is mainly caused by an increased ASP which more than offsets the lower amount of systems sold.
	Net system sales per technology was as follows:
	Year ended December 31	Net system sales		Net system sales
	(in thousands)	in units		in EUR
	2013
	EUV		1		60,100
	ArFi		77		3,120,719
	ArF dry		2		38,019
	KrF		64		720,053
	l-line		13		54,238
	Total		157		3,993,129
	2012
	EUV		1		43,700
	ArFi		72		2,715,221
	ArF dry		4		81,428
	KrF		78		908,244
	l-line		15		53,039
	Total		170		3,801,632
	2011
	EUV		3		119,300
	ArFi		101		3,549,122
	ArF dry		11		228,909
	KrF		87		926,572
	l-line		20		60,010
	Total		222		4,883,913
	For geographical reporting, net sales are attributed to the geographic location in which the customers’ facilities are located. Long-lived assets are attributed to the geographic location in which these assets are located.
	We have re-evaluated the risk and uncertainties associated with our geographic areas. This resulted in a definition change of “Long-lived assets” included in the geographical reporting disclosure. As of December 31, 2013 Long-lived assets only consist of Property, Plant and Equipment. We have adjusted our prior period amounts for comparability reasons. None of these changes impact our previously reported consolidated total net sales, gross profit, income from operations, net income or earnings per share.
	Net sales and long-lived assets (consisting of property, plant and equipment) by geographic region were as follows:
	Year ended December 31	Net sales		Long-lived
	(in thousands)	EUR		assets
				EUR
	2013
	Japan		201,664		3,340
	Korea		1,286,509		16,155
	Singapore		139,313		1,109
	Taiwan		2,221,426		48,427
	Rest of Asia		478,234		3,742
	Netherlands		11,525		969,192
	Rest of Europe		187,030		2,600
	United States		719,625		173,275
	Total		5,245,326		1,217,840
	2012
	Japan		292,309		19,585
	Korea		1,276,304		17,664
	Singapore		98,554		968
	Taiwan		1,479,768		50,372
	Rest of Asia		197,262		2,073
	Netherlands		-		869,736
	Rest of Europe		256,192		1,571
	United States		1,131,166		67,954
	Total		4,731,555		1,029,923
	2011
	Japan		405,595		69,001
	Korea		1,318,777		16,250
Singapore		436,308		1,167
Taiwan		1,146,601		46,418
Rest of Asia		450,796		1,496
Netherlands		-		851,612
Rest of Europe		505,129		1,198
United States		1,387,829		66,468
Total		5,651,035		1,053,610
In 2013, net sales to the largest customer accounted for EUR 2,058.6 million, or 39.2 percent, of net sales (2012: EUR 1,236.1 million, or 26.1 percent, of net sales; 2011: EUR 1,311.7 million, or 23.2 percent, of net sales). Our three largest customers (based on net sales) accounted for EUR 861.4 million, or 73.3 percent, of accounts receivable and finance receivables at December 31, 2013, compared with EUR 535.1 million, or 58.9 percent, at December 31, 2012.
Substantially all of our sales were export sales in 2013, 2012 and 2011.

Selected_Operating_Expenses_an

Selected Operating Expenses and Additional Information	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Selected Operating Expenses and Additional Information	'
	22. Selected Operating Expenses and Additional Information
	Personnel expenses for all payroll employees were:
	Year ended December 31	2013		2012		2011
	(in thousands)	EUR		EUR		EUR
	Wages and salaries		835,563		711,039		648,869
	Social security expenses		69,839		58,180		52,550
	Pension and retirement expenses		60,275		50,298		45,947
	Share-based payments		52,371		18,714		12,430
	Personnel expenses		1,018,048		838,231		759,796
	The average number of payroll employees in FTEs during 2013, 2012 and 2011 was 9,540, 8,140 and 7,627, respectively.
	The total number of payroll and temporary employees in FTEs per sector was:
		2013		2012		2011
	As of December 31
	Customer Support		2,949		2,538		2,478
	SG&A		1,098		869		723
	Industrial Engineering		785		637		420
	Manufacturing & Logistics		3,658		2,856		2,852
	R&D		4,735		3,736		3,417
	Total employees (in FTEs)		13,225		10,636		9,890
	Less: Temporary employees (in FTEs)		2,865		2,139		1,935
	Payroll employees (in FTEs)		10,360		8,497		7,955
	The average number of payroll employees in FTEs in our operations in the Netherlands during 2013, 2012 and 2011 was 5,112, 4,620 and 4,313, respectively.

Research_and_Development_Costs

Research and Development Costs	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Research and Development Costs	'
	23. Research and Development Costs
	R&D costs (net of credits and excluding contributions under the NRE funding agreements from Participating Customers of the CCIP) increased by EUR 292.9 million, or 49.7 percent, to EUR 882.0 million in 2013 from EUR 589.1 million in 2012. R&D spending mainly increased due the additional investments in EUV source development as a result of the acquisition of Cymer and further investments in our other strategic programs (Immersion and holistic lithography).
	R&D costs (net of credits) in 2012 (EUR 589.1 million) were in line with 2011 (EUR 590.3 million). R&D spending remained stable and mainly related to our strategic programs, in particular EUV, immersion and holistic lithography.
	R&D costs include credits for an amount of EUR 16.0 million, EUR 17.9 million and EUR 25.1 million in 2013, 2012 and 2011 respectively. R&D credits relate to worldwide (inter-)governmental funding for certain strategic development programs. The decrease in R&D credits is the result of a change in government programs from subsidy payments to fiscal incentives. These incentives lead to tax deductions in mainly Dutch and United States tax jurisdictions.

Interest_and_Other_Net

Interest and Other, Net	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Interest and Other, Net	'
	24. Interest and Other, Net
	Interest and other income of EUR 9.2 million (2012: EUR 16.6 million and 2011: EUR 41.2 million) mainly relates to interest income on deposits, short-term investments, money market funds, bank accounts and on finance receivables.
	Interest and other expense of EUR 33.6 million (2012: EUR 22.8 million and 2011: EUR 33.8 million) mainly consists of net interest expense on our Eurobonds and related interest rate swaps, interest on lease obligations and amortized financing costs of in total EUR 16.2 million (2012: EUR 10.8 million and 2011: EUR 14.2 million), and EUR 8.9 million loss on the partial extinguishment of our EUR 600 million 5.75 percent senior notes due 2017 (2012 and 2011: EUR nil million).
	Interest on cash pools is reported on a gross basis in the Consolidated Statements of Operations under both interest income and interest expense. From an economic and legal perspective, the interest on cash pools of EUR 1.9 million (2012: EUR 4.2 million and 2011: EUR 6.8 million) recorded in interest income nets off against the same amount recorded in interest expense.

Vulnerability_Due_to_Certain_C

Vulnerability Due to Certain Concentrations	12 Months Ended
	Dec. 31, 2013
Risks And Uncertainties [Abstract]	'
Vulnerability Due to Certain Concentrations	'
	25. Vulnerability Due to Certain Concentrations
	ASML relies on outside vendors to manufacture the components and subassemblies used in its systems, each of which is obtained from a sole supplier or a limited number of suppliers. ASML’s reliance on a limited group of suppliers involves several risks, including a potential inability to obtain an adequate supply of required components and reduced control over pricing and timely delivery of these subassemblies and components. In particular, from time to time, the number of systems we are able to produce may be limited by the production capacity of Zeiss. Zeiss is currently our sole supplier of lenses, collectors, and other critical optical components and is capable of producing these items only in limited numbers and only through the use of its manufacturing and testing facility in Oberkochen and Wetzlar, Germany. During 2013, ASML’s production was not limited by the deliveries from Zeiss.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Shareholders' Equity	'
	26. Shareholders’ Equity
	Share Capital
	ASML’s authorized share capital amounts to EUR 126,000,000 and is divided into:
	•	700,000,000 Cumulative Preference Shares with a nominal value of EUR 0.09 each;
	•	699,999,000 Ordinary Shares with a nominal value of EUR 0.09 each; and
	•	9,000 Ordinary Shares B with a nominal value of EUR 0.01 each.
	Per December 31, 2013, 446,822,452 ordinary shares with a nominal value of EUR 0.09 each were issued and fully paid in, of which 5,970,118 ordinary shares are held by us in treasury. No ordinary shares B and no cumulative preference shares are issued.
	Our Board of Management has the power to issue ordinary shares and cumulative preference shares insofar as the Board of Management has been authorized to do so by the General Meeting of Shareholders (either by means of a resolution or by an amendment to our Articles of Association). The Board of Management requires approval of the Supervisory Board for such an issue. The authorization by the General Meeting can only be granted for a certain period not exceeding five years and may be extended for no longer than five years on each occasion. In case the General Meeting of Shareholders has not authorized the Board of Management to issue shares, the General Meeting of Shareholders shall have the power to issue shares upon the proposal of the Board of Management, provided that the Supervisory Board has approved such proposal.
	Shares Issued as a Result of the Acquisition of Cymer
	ASML and Cymer completed the merger pursuant to which ASML acquired Cymer on May 30, 2013. As a result of the merger, each share of Cymer common stock outstanding immediately prior to the completion of the merger was converted into the right to receive USD 20.00 in cash plus 1.1502 ASML ordinary shares. As per December 31, 2013, we issued 36,464,576 ordinary shares for an aggregate amount of EUR 2,346.7 million in relation to the acquisition of Cymer.
	Synthetic Share Buyback
	At the EGM held on September 7, 2012, several changes in the Articles of Association of ASML were adopted, in connection with the Synthetic Share Buyback effectuated in connection with the CCIP. Consequently, on November 24, 2012, the Articles of Association were amended as follows. Upon the first amendment the ordinary shares to be held for the benefit of the participants to the CCIP were converted into ordinary shares M and all other ordinary shares were converted into ordinary shares A. Upon the second amendment, the par value per ordinary share A was increased from EUR 0.09 to EUR 9.24 at the expense of the share premium reserve. Upon the third amendment, the nominal value per ordinary share A was reduced to an amount of EUR 0.06, by decreasing the nominal value per ordinary share A by an amount of EUR 9.18, which resulted in a repayment of the same amount per share to holders of ordinary shares into which the ordinary shares A were converted. The fourth amendment provided for the consolidation of the ordinary shares A through the exchange of each 100 ordinary shares for 77 ordinary shares, resulting in an increase of the nominal value per ordinary share from EUR 0.06 to EUR 0.09, whereby the aggregate difference was booked at the expense of the share premium reserve. The fifth and last amendment provided for the deletion of the share class M for participants to the CCIP and the share class A for the other shareholders. The ordinary shares M and A were converted thereafter into ordinary shares without a specific letter mark attached to it.
	These amendments in substance constitute a Synthetic Share Buyback in which we effectively repurchased 93,411,216 shares at an average price of EUR 39.91 for a total amount of EUR 3,728.3 million. The difference of EUR 125.6 million between the capital repayment of EUR 3,728.3 million and the net proceeds from issuance of shares of EUR 3,853.9 million relates to the capital repayment on ASML’s treasury shares which was also part of the Synthetic Share Buyback.
	Shares Issued in Customer Co-Investment Program
	In connection with the CCIP, on September 12, 2012, we issued 62,977,877 ordinary shares to the Stichting that holds shares on behalf of Intel and 12,595,575 ordinary shares to the Stichting that holds shares on behalf of Samsung and on October 31, 2012, ASML issued 20,992,625 ordinary shares to the Stichting that holds shares on behalf of TSMC. We received an amount of EUR 3,853.9 million in relation to the shares issued under the CCIP. For further details on our CCIP see Note 28.
	Ordinary Shares
	Each ordinary share consists of 900 fractional shares. Fractional shares entitle the holder thereof to a fractional dividend but do not entitle the holder thereof to voting rights. Only those persons who hold shares directly in the share register in the Netherlands, held by us at our address at 5504 DR Veldhoven, de Run 6501, the Netherlands, or in the New York share register, held by JP Morgan Chase Bank, N.A., P.O. Box 64506, St. Paul, MN 55164-0506, United States, can hold fractional shares. Persons who hold ordinary shares through the deposit system under the Dutch Securities Bank Giro Transactions Act (Wet giraal effectenverkeer; the “Giro Act”) maintained by the Dutch central securities depository Euroclear Nederland or through the DTC cannot hold fractional shares. An ordinary share entitles the holder thereof to cast nine votes in the General Meeting of Shareholders. At our AGM held on April 24, 2013, the Board of Management was authorized from April 24, 2013 through October 24, 2014, subject to the approval of the Supervisory Board, to issue shares and/or rights thereto representing up to a maximum of 5.0 percent of our issued share capital at April 24, 2013, plus an additional 5.0 percent of our issued share capital at April 24, 2013 that may be issued in connection with mergers, acquisitions and/or (strategic) alliances.
	Holders of ASML’s ordinary shares have a preemptive right of subscription, in proportion to the aggregate nominal amount of the ordinary shares held by them, to any issuance of ordinary shares for cash, which right may be restricted or excluded. Ordinary shareholders have no pro rata preemptive right of subscription to any ordinary shares issued for consideration other than cash or ordinary shares issued to employees. If authorized for this purpose by the General Meeting of Shareholders (either by means of a resolution or by an amendment to our Articles of Association), the Board of Management has the power subject to approval of the Supervisory Board, to restrict or exclude the preemptive rights of holders of ordinary shares.
	Ordinary Shares B
	As part of the most recent changes in our Articles of Association, adopted at the EGM held on September 7, 2012, the 9,000 ordinary shares B with a nominal value of EUR 0.01 were introduced. A person who holds (a multiple of) 100 fractional shares, may exchange those fractional shares for an ordinary share B. Every holder of an ordinary share B is entitled to one-ninth (1/9) of a dividend. Each ordinary share B entitles the holder thereof to cast one vote at the General Meeting.
	Cumulative Preference Shares
	In 1998, we granted to the preference share Foundation, the Preference Share Option. This option was amended and extended in 2003 and 2007. A third amendment to the option agreement between the Foundation and ASML became effective on January 1, 2009, to clarify the procedure for the repurchase and cancellation of the preference shares when issued.
	Per the amendment of our Articles of Association on May 6, 2011, the nominal value of the cumulative preference shares was increased to EUR 0.09. The number of cumulative preference shares included in the authorized share capital was decreased to 700,000,000. This was done to simplify the Articles of Association, and to give each share the right to cast one vote in the General Meeting of Shareholders.
	The Foundation may exercise the Preference Share Option in situations where, in the opinion of the Board of Directors of the Foundation, ASML’s interests, ASML’s business or the interests of ASML’s stakeholders are at stake. This may be the case if a public bid for ASML’s shares has been announced or has been made, or the justified expectation exists that such a bid will be made without any agreement having been reached in relation to such a bid with ASML. The same may apply if one shareholder, or more shareholders acting in concert, hold a substantial percentage of ASML’s issued ordinary shares without making an offer or if, in the opinion of the Board of Directors of the Foundation, the (attempted) exercise of the voting rights by one shareholder or more shareholders, acting in concert, is materially in conflict with ASML’s interests, ASML’s business or ASML’s stakeholders.
	The objectives of the Foundation are to look after the interests of ASML and of the enterprises maintained by ASML and of the companies which are affiliated in a group with ASML, in such a way that the interests of ASML, of those enterprises and of all parties concerned are safeguarded in the best possible way, and influences in conflict with these interests which might affect the independence or the identity of ASML and those companies are deterred to the best of the Foundation’s ability, and everything related to the above or possibly conducive thereto. The Foundation seeks to realize its objects by the acquiring and holding of cumulative preference shares in the capital of ASML and by exercising the rights attached to these shares, particularly the voting rights attached to these shares.
	The preference share option gives the Foundation the right to acquire a number of cumulative preference shares as the Foundation will require, provided that the aggregate nominal value of such number of cumulative preference shares shall not exceed the aggregate nominal value of the ordinary shares that have been issued at the time of exercise of the Preference Share Option for a subscription price equal to their nominal value. Only one-fourth of the subscription price is payable at the time of initial issuance of the cumulative preference shares, with the other three-fourths of the nominal value only being payable when we call up this amount. Exercise of the preference share option could effectively dilute the voting power of the outstanding ordinary shares by one-half.
	Cancellation and repayment of the issued cumulative preference shares by ASML requires the authorization by the General Meeting of Shareholders of a proposal to do so by the Board of Management approved by the Supervisory Board. If the preference share option is exercised and as a result cumulative preference shares are issued, ASML, at the request of the Foundation, will initiate the repurchase or cancellation of all cumulative preference shares held by the Foundation. In that case ASML is obliged to effect the repurchase and cancellation respectively as soon as possible. A cancellation will have as a result a repayment of the amount paid and exemption from the obligation to pay up on the cumulative preference shares. A repurchase of the cumulative preference shares can only take place when such shares are fully paid up.
	If the Foundation will not request ASML to repurchase or cancel all cumulative preference shares held by the Foundation within 20 months after issuance of these shares, we will be obliged to convene a General Meeting of Shareholders in order to decide on a repurchase or cancellation of these shares.
	The Foundation is independent of ASML. The Board of Directors of the Foundation comprises four independent voting members from the Dutch business and academic communities. Former chairman Mr. A. Baan passed away on April 5, 2013 and was succeeded by Mr. H. Bodt. As of June 1, 2013, the members of the Board of Directors of the Foundation are: Mr. H. Bodt, Mr. M.W. den Boogert, Mr. J.M. de Jong and Mr. A.H. Lundqvist.
	Dividend Proposal
	As part of our financing policy, we aim to pay an annual dividend that will be stable or growing over time. Annually, the Board of Management will, upon prior approval from the Supervisory Board, submit a proposal to the AGM with respect to the amount of dividend to be declared with respect to the prior year. The dividend proposal in any given year will be subject to the availability of distributable profits or retained earnings and may be affected by, among other factors, the Board of Management’s views on our potential future liquidity requirements, including for investments in production capacity, the funding of our R&D programs and for acquisition opportunities that may arise from time to time; and by future changes in applicable income tax and corporate laws. Accordingly, it may be decided to propose not to pay a dividend or to pay a lower dividend with respect to any particular year in the future.
	For 2013, a proposal to declare a dividend of EUR 0.61 per ordinary share of EUR 0.09 nominal value will be submitted to the AGM to be held on April 23, 2014.

Purchases_of_Equity_Securities

Purchases of Equity Securities by the Issuer and Affiliated Purchasers	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Purchases of Equity Securities by the Issuer and Affiliated Purchasers	'
	27. Purchases of Equity Securities by the Issuer and Affiliated Purchasers
	In addition to dividend payments, we intend to return cash to our shareholders on a regular basis through share buybacks or capital repayment, subject to our actual and anticipated level of liquidity requirements, our current share price, other market conditions and other relevant factors.
	On April 24, 2013, the AGM authorized the repurchase of up to a maximum of two times 10.0 percent of our issued share capital as of the date of authorization through October 24, 2014.
	On April 17, 2013, we announced our intention to repurchase up to EUR 1.0 billion of our own shares within the 2013-2014 timeframe. During the period from April 18, 2013 up to and including December 31, 2013, we had purchased 4,614,179 of our shares for a total amount of EUR 300.0 million at an average price of EUR 65.02 per share. These shares are intended to be cancelled in 2014.
	The following table provides a summary of our repurchased shares in 2013:
	Period	Total		Average		Total number		Maximum
		number		price paid		of shares		value
		of shares		per Share		purchased as		of shares
		purchased		(EUR)		part of		that may yet
						publicly		be purchased
						announced plans		under the program
						or programs		(EUR)
	April 18 - 30, 2013		297,500		55.35		297,500		983,534,770
	May 2 - 31, 2013		389,974		61.76		687,474		959,449,401
	June 1 - 30, 2013		749,434		60.39		1,436,908		914,192,630
	July 1 - 31, 2013		321,486		65.2		1,758,394		893,232,250
	August 1 - 31, 2013		283,097		67.83		2,041,491		874,028,834
	September 1 - 30, 2013		179,146		69.06		2,220,637		861,656,533
	October 3 - 31, 2013		556,443		69.34		2,777,080		823,072,791
	November 1 - 30, 2013		962,146		66.76		3,739,226		758,841,727
	December 1 - 31, 2013		874,953		67.25		4,614,179		700,000,036
	Total		4,614,179		65.02

Customer_CoInvestment_Program

Customer Co-Investment Program	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Customer Co-Investment Program	'
	28. Customer Co-Investment Program
	Overview
	On July 9, 2012, we announced our CCIP to accelerate our development of EUV technology beyond the current generation and our development of future 450mm silicon wafer technology. The Participating Customers collectively agreed to fund EUR 1.38 billion of our research and development projects from 2013 through 2017. This program created risk sharing with some of our largest customers while the results of ASML’s development programs will be available to every semiconductor manufacturer with no restrictions. The R&D funding program in the CCIP consists of two funding projects: a 450mm technology development project and a next-generation EUV development project. ASML entered into NRE Funding Agreements with the Participating Customers.
	In addition to the funding commitments described above, the Participating Customers have invested in ordinary shares equal, in aggregate, to 23 percent of ASML’s issued share capital (calculated giving effect to our Synthetic Share Buyback in November 2012). The proceeds of the share issuance, EUR 3.85 billion, were returned to the holders of ordinary shares (excluding the Participating Customers) through a Synthetic Share Buyback executed in November 2012. For further information regarding the Synthetic Share Buyback, see Note 26.
	Description of Investment Agreements, Shareholder Agreements and NRE Funding Agreements
	In connection with the CCIP, ASML entered into an investment agreement, a shareholder agreement and NRE funding agreements with each of the Participating Customers. Intel is the largest participant in the program, with an aggregate funding commitment of EUR 829 million and an investment in 15 percent of our ordinary shares (calculated giving effect to our Synthetic Share Buyback in November 2012). A description of the investment agreement, shareholders agreement and NRE funding agreements between ASML and Intel is set out below. The agreements between ASML and the other participants – TSMC (which acquired 5 percent of our shares and made an EUR 276 million funding commitment) and Samsung (which acquired 3 percent of our shares and made an EUR 276 million funding commitment) are on substantially the same terms as those agreed with Intel. Shares were acquired by Dutch foundations (“Stichtingen”) established for each participant.
	Investment Agreements
	Pursuant to the Intel Investment Agreement, dated July 9, 2012, ASML issued to Intel Stichting ordinary shares equal to 15 percent of the issued ordinary shares with simultaneous issuance by the Intel Stichting to Intel of the corresponding depositary receipts.
	Pursuant to the TSMC Investment Agreement, dated August 5, 2012, ASML issued to TSMC Stichting ordinary shares equal to 5 percent of the issued ordinary shares with simultaneous issuance by the TSMC Stichting to TSMC of the corresponding depositary receipts.
	Pursuant to the Samsung Investment Agreement, dated August 27, 2012 ASML issued to the Samsung Stichting ordinary shares equal to 3 percent of the issued ordinary shares with simultaneous issuance by the Samsung Stichting to Samsung of the corresponding depositary receipts.
	The subscription price for the ordinary shares under the Investment Agreements was EUR 39.91 per ordinary share, which is the average of the volume weighted average price of our shares listed at NYSE Euronext Amsterdam for the twenty trading days up to and including July 6, 2012.
	Based upon the subscription price (EUR 39.91) included in the Investment Agreements, the equity participation of Intel (15 percent), TSMC (5 percent) and Samsung (3 percent) amount to EUR 2,513 million, EUR 838 million and EUR 503 million, respectively.
	Under the Intel Investment Agreements, ASML has agreed to indemnify the Participating Customers and their affiliates for certain losses and expenses related to breaches of representations, warranties, covenants and agreements in the Investment Agreements and with respect to certain legal proceedings related thereto, subject to certain limitations.
	Shareholder Agreements
	In connection with the issuance of shares pursuant to the Intel Investment Agreement, on September 12, 2012 ASML, Intel and the Intel Stichting entered into a Shareholder Agreement which governs certain matters relating to the holding of and further investment by Intel in ordinary shares of ASML, directly and indirectly through the Intel Stichting, including the matters described below.
	The Shareholder Agreements between ASML and the other program participants (TSMC and Samsung) are on substantially the same terms as those agreed with Intel.
	Voting Restrictions
	Pursuant to the Shareholder Agreement, Intel (and the Intel Stichting) will not be entitled to vote the ordinary shares that were acquired by the Intel Stichting as part of the CCIP or any other ordinary shares otherwise transferred to the Intel Stichting (under the circumstances described under “Standstill; Additional Purchases” below) prior to a Shareholder Agreement Termination Event (as defined below), except when a Suspension Event (as described below) occurs and is continuing or where the following matters are proposed at any General Meeting (the “Voting Restrictions”): (i) an issuance of ASML shares or grant of rights to subscribe for ASML shares representing 25 percent or more of the issued and outstanding share capital of ASML or the restriction or exclusion of pre-emption rights relating thereto (in each case, on an aggregate basis during the preceding 12 months) or the designation of the Board of Management as the authorized body to resolve on these matters; (ii) an authorization to repurchase 25 percent or more of ASML’s issued and outstanding share capital on an aggregate basis during the preceding 12 months; (iii) the approval of a significant change in the identity or nature of ASML or our business, including a transfer of all or substantially all business or assets of ASML and our subsidiaries to a third party, the establishment or cancellation of a long-lasting cooperation of essential importance with a third party and an acquisition or disposition of an interest in the capital or assets of a person with a value of at least one third of the assets of ASML (on a consolidated basis); (iv) an amendment to ASML’s Articles of Association that would materially affect the specific voting rights of Intel, would materially affect the identity or nature of ASML or our business, or would disproportionately (or uniquely) and adversely affect the rights or benefits attached to or derived from the ordinary shares held by Intel through the Intel Stichting as compared to the shareholders; (v) the dissolution of ASML; and (vi) any merger or demerger which would result in a material change in the identity or nature of ASML or its business.
	Standstill, Lock-up and Orderly Market Arrangements
	Standstill; Additional Purchases
	Subject to certain exceptions, pursuant to the Shareholder Agreement, Intel (or its affiliates) may not, prior to the six-year anniversary of the date of the Intel Shareholder Agreement (the “Standstill Period”), acquire more than 19.9 percent of the outstanding share capital of ASML without ASML’s prior approval (the “Standstill Restriction”). There is an exception from the Standstill Restriction in the case of a ‘suspension event’, which includes certain circumstances where a third party has acquired or made an offer to acquire at least 20 percent of ASML’s outstanding shares, and the Standstill Restriction will terminate upon the occurrence of a Shareholder Agreement Termination Event.
	The Shareholder Agreement permits Intel (and its affiliates) to acquire up to 4.99 percent of ASML’s outstanding shares (other than shares acquired through the CCIP) that may be held outside the Intel Stichting. For any additional ASML shares that Intel (or its affiliates) acquires in excess of 4.99 percent of the outstanding shares of ASML, Intel is required to deposit such shares with the Intel Stichting in exchange for Depositary Receipts. Shares held directly by Intel or its affiliates (and which not required to be deposited with the Intel Stichting) are not subject to the Voting Restrictions, or Lock-Up Restrictions (as defined below), but are subject to the Standstill Restriction.
	The Intel Stichting will continue to hold ASML shares owned by Intel (notwithstanding termination of the Standstill Period) until the earlier of (i) such time as Intel owns (directly or through the Intel Stichting) less than 2 percent of ASML’s outstanding shares (the relevant percentage is 1 percent for the other Participating Customers) (ii) the date of notification to ASML by Participating Customers that the aggregate amount of ASML’s outstanding shares owned by Intel and the other Participating Customers represents less than 5 percent of ASML’s outstanding shares and (iii) a Shareholder Agreement Termination Event (as defined below), following which time Depositary Receipts will be exchanged for the underlying ASML shares. In case Intel would acquire ASML shares within 18 months after an event described under (i) or (ii) above, any ASML shares held by Intel in excess of 4.99 percent of the outstanding shares of ASML must be transferred to (and held by) the Intel Stichting.
	Lock-up; Orderly Sell Down
	Intel may not, without prior written consent of ASML, transfer any ordinary shares or Depositary Receipts until the earliest of (i) two years and six months after the date of the Intel Shareholder Agreement, (ii) termination of the NRE Funding Agreements, and (iii) the occurrence of a Shareholder Agreement Termination Event ((i), (ii) and (iii) together, the “Lock-Up Restriction”). The Lock-Up Restriction does not apply in certain circumstances where a third party offers to acquire at least 20 percent of ASML’s shares. Intel is not permitted to transfer the ASML ordinary shares it acquired in the program in connection with an offer (before the end of the offer), or make any public statement in support of such offer, that is not recommended by the ASML Supervisory Board or Management Board, except in limited circumstances.
	In addition, Intel may not (even after the Lock-Up Period has ended), without written consent of ASML, transfer on NYSE Euronext Amsterdam, NASDAQ or another securities exchange more than (i) 4 percent of the outstanding shares of ASML during any six month period (the relevant percentage is 1.5 percent for Samsung and 2.5 percent for TSMC). There are also restrictions on Intel’s ability to transfer ASML shares to certain competitors or customers of ASML.
	Termination
	The Intel Shareholder Agreement will terminate upon the occurrence of the following events (each a “Shareholder Agreement Termination Event”) (i) certain change of control transactions were the shareholders of ASML prior to such a transaction are no longer entitled to exercise at least 50 percent of the votes in the General Meeting following such transaction, (ii) in the event of a delisting of our shares listed at NYSE Euronext Amsterdam or delisting of our shares listed at NASDAQ (except for certain voluntary delistings from NASDAQ), (iii) the winding up or liquidation of ASML, or (vi) in the event that all Depositary Receipts are exchanged for ASML shares and Intel does not acquire ASML shares in excess of 4.99 percent of the outstanding ASML shares within 18 months of such exchange (see “Standstill; Additional Purchases” above).
	NRE Funding Agreements
	On July 9, 2012, ASML and Intel entered into two NRE Funding Agreements pursuant to which Intel will support ASML’s R&D costs and project expenditures. One agreement relates to the Intel 450mm NRE Funding Agreement and the other relates to the Intel EUV NRE Funding Agreement (together the “Intel NRE Funding Agreements”). Intel has committed to provide EUR 553 million in funding under the Intel 450mm NRE Funding Agreement and EUR 276 million in funding under the Intel EUV NRE Funding Agreement, payable over the respective terms (2013-2017) of the Intel NRE Funding Agreements.
	On August 5, 2012, ASML and TSMC entered into the TSMC NRE Funding Agreement pursuant to which TSMC will support ASML’s R&D costs and project expenditures relating to the development of 450mm lithography equipment and EUV platforms. TSMC has committed to provide EUR 276 million in funding payable over the term (2013-2017) of the TSMC NRE Funding Agreement.
	On August 27, 2012, ASML and Samsung entered into the Samsung NRE Funding Agreement pursuant to which Samsung will support ASML’s R&D costs and project expenditures relating to the development of 300mm/450mm and EUV platforms. Samsung has committed to provide EUR 276 million in funding payable over the term (2013-2017) of the Samsung NRE Funding Agreement.
	Under the NRE Funding Agreements, ASML will retain sole control over the development of 450mm photo lithography equipment and EUV platforms and will own all intellectual property created by ASML in connection therewith. The NRE Funding Agreements provide that if ASML, in its reasonable discretion, determines to abandon either the 450mm or EUV development project, as a result of technical infeasibility or lack of sufficient industry demand, or if the then remaining funding exceeds the expenditure estimate for the development project (450mm or EUV) then the parties may agree on an alternative development project, and if no alternative is agreed, ASML may invoice the Participating Customers for the remaining due portion of committed funding during each year of the remaining funding period in which ASML’s actual gross R&D expenditures exceed a minimum threshold specified in the NRE Funding Agreements. The NRE Funding Agreements will terminate on December 31, 2017 or upon pre-payment by the Participating Customer of the aggregate amount of funding owed under its respective NRE Funding Agreement.
	Commercial Agreement
	On July 9, 2012, ASML and Intel entered into a Commercial Agreement, pursuant to which ASML and Intel established a contractual framework for Intel to purchase equipment related to the 450mm and EUV next-generation lithography equipment. Under this agreement, Intel has committed to purchase specified numbers of 450mm and EUV tools. The agreement sets forth pricing terms for the tools as well as milestones related to product deliveries, and provides for certain commercial discounts in the form of credits in exchange for Intel’s early purchase commitments and volume purchase commitments and for specified additional credits in the event that certain schedules are not met. In addition, subject to certain conditions, ASML has agreed to install sufficient capacity to meet Intel’s forecasted 450mm lithography equipment needs through 2022.
	For further details regarding the share issuances to the Participating Customers and the Synthetic Share Buyback effectuated in connection with our CCIP, see Note 26.
	Development 450mm silicon wafer technology
	In November 2013, following our customers’ decision, ASML decided to pause the development of 450mm lithography systems until customer demand and the timing related to such demand is clear. We believe that our 450mm development activities can be restarted if and when the industry demands the introduction of 450mm. Since 450mm requires both generic developments and wafer size-specific developments, many of our employees involved in the 450mm project are doing work that is just as relevant for future DUV and EUV platforms. The teams and people have therefore been reassigned to different projects.
	Under our CCIP, we are party to a 450mm NRE Funding Agreement with Intel for a total NRE funding commitment of EUR 553 million. We are currently in discussions with Intel to determine appropriate projects to which to apply the 450mm NRE funding.
	Under the CCIP, we are also party to EUV NRE agreements with Intel (total funding of EUR 276 million), TSMC (total funding of EUR 276 million) and Samsung (total funding of EUR 276 million), all of which funding is being used for EUV projects.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	29. Related Party Transactions
	On July 9, 2012, we announced our CCIP to accelerate our development of EUV technology beyond the current generation and our development of future 450mm silicon wafer technology. One of the Participating Customers, Intel, agreed to fund EUR 829 million for our R&D projects. In addition Intel also agreed to invest in ordinary shares equal to 15 percent of our issued share capital (calculated giving effect to our Synthetic Share Buyback in November 2012). Due to the equity investment, Intel is considered a related party of ASML as of July 9, 2012.
	The total net sales to Intel (and its affiliates) in 2013 amounted to EUR 494.7 million. The total net sales to Intel (and its affiliates) for the period from July 9, 2012 to December 31, 2012 amounted to EUR 301.7 million) whereas the outstanding balances as of December 31, 2013 amount to EUR (182.3) million (December 31, 2012: EUR 65.0 million).
	There have been no transactions during our most recent fiscal year, and there are currently no transactions, between ASML or any of its subsidiaries, and any other significant shareholder and any director or officer or any relative or spouse thereof other than ordinary course compensation arrangements. During our most recent fiscal year, there has been no, and at present there is no, outstanding indebtedness to ASML owed or owing by any director or officer of ASML or any associate thereof.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	30. Subsequent Events
	Subsequent events were evaluated up to February 11, 2014, which is the issuance date of this Annual Report 2013. There are no subsequent events to report.

General_Information_Summary_of1

General Information / Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Preparation	'
	Basis of Preparation
	The accompanying Consolidated Financial Statements are stated in thousands of EUR unless indicated otherwise.
	The accompanying Consolidated Financial Statements have been prepared in conformity with US GAAP.
	On May 30, 2013 we acquired 100 percent of the issued share capital of Cymer. Comparative financial information presented in the Consolidated Financial Statements does not include Cymer, unless stated otherwise.
Use of Estimates	'
	Use of Estimates
	The preparation of ASML’s Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities on the balance sheet dates, and the reported amounts of sales and costs during the reported periods. Actual results could differ from those estimates.
Principles of Consolidation	'
	Principles of Consolidation
	The Consolidated Financial Statements include the Financial Statements of ASML Holding N.V. and all of its subsidiaries and the VIE of which ASML is the primary beneficiary. All intercompany profits, balances and transactions have been eliminated in the consolidation.
	Subsidiaries
	Subsidiaries are all entities over which ASML has the power to govern financial and operating policies generally accompanying a shareholding of more than half of the voting rights. As from the date that these criteria are met, the financial data of the relevant subsidiaries are included in the consolidation.
	Business Combinations
	Acquisitions of subsidiaries are included on the basis of the acquisition method. The cost of acquisition is measured based on the consideration transferred at fair value, the fair value of identifiable assets distributed and the fair value of liabilities incurred or assumed at the acquisition date (i.e. the date at which we obtain control). The excess of the costs of an acquired subsidiary over the net of the amounts assigned to identifiable assets acquired and liabilities incurred or assumed, is capitalized as goodwill. Acquisition-related costs are expensed when incurred in the period they arise or the service is received.
	Variable Interest Entities
	We assess whether we have a controlling financial interest in any VIE and, thus, whether we are the VIE’s primary beneficiary. ASML shall be deemed to have a controlling financial interest in a VIE if it has both of the following characteristics: a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. If ASML has a controlling financial interest in a VIE, it is required to consolidate the VIE.
Foreign Currency translation	'
	Foreign Currency translation
	The financial information for subsidiaries outside the euro-zone is generally measured using local currencies as the functional currency. The Financial Statements of those foreign subsidiaries are translated into euros in the preparation of ASML’s consolidated financial statements. Assets and liabilities are translated into euros at the exchange rate in effect on the respective balance sheet dates. Income and costs are translated into euros based on the average exchange rate for the corresponding period. The resulting translation adjustments are recorded directly in shareholders’ equity.
Derivative Financial Instruments	'
	Derivative Financial Instruments
	We principally use derivative hedging instruments for the management of foreign currency risks and interest rate risks. We measure all derivative hedging instruments based on fair values derived from market prices of the instruments. We adopt hedge accounting for hedges that are highly effective in offsetting the identified hedged risks taking into account required effectiveness criteria.
	Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently remeasured at their fair value. The method of recognizing the resulting gain or loss depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the item being hedged. We designate certain derivatives as either:
	•		A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk (fair value hedge); or
	•		A hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk (cash flow hedge).
	We document at the inception of the transaction the relationship between hedging instruments and hedged items, as well as our risk management objectives and strategy for undertaking various hedging transactions. We also document our assessment, both at hedge inception and on an ongoing basis, of whether derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items.
	Fair Value Hedge
	Changes in the fair value of a derivative financial instrument, that is designated and qualified as a fair value hedge, along with the gain or loss on the hedged asset or liability that is attributable to the hedged risk, are recorded in the Consolidated Statements of Operations.
	Hedge accounting is discontinued when we revoke the hedging relationship, the hedging instrument expires or is sold, terminated or exercised, or no longer qualifies for hedge accounting. The adjustment to the carrying amount of the hedged item arising from the hedged risk is amortized to the Consolidated Statements of Operations from that date.
	Interest rate swaps that are being used to hedge the fair value of fixed loan coupons payable are designated as fair value hedges. The change in fair value is intended to offset the change in the fair value of the underlying fixed loan coupons, which is recorded accordingly. The gain or loss relating to the ineffective portion of interest rate swaps hedging fixed loan coupons payable is recognized in the Consolidated Statements of Operations as “interest and other, net”.
	Cash Flow Hedge
	Changes in the fair value of a derivative that is designated and qualified as a cash flow hedge are recorded in OCI, net of taxes, until the underlying hedged transaction is recognized in the Consolidated Statements of Operations. In the event that the underlying hedge transaction will not occur within the specified time period, the gain or loss on the related cash flow hedge is released from OCI and included in the Consolidated Statements of Operations, unless, extenuating circumstances exist that are related to the nature of the forecasted transaction and are outside our control or influence and which cause the forecasted transaction to be probable of occurring on a date that is beyond the specified time period.
	Foreign currency hedging instruments that are being used to hedge cash flows related to forecasted sales or purchase transactions in non-functional currencies are designated as cash flow hedges. The gain or loss relating to the ineffective portion of the foreign currency hedging instruments is recognized in the Consolidated Statements of Operations in “net sales” or “cost of sales”.
	Interest rate swaps that are being used to hedge changes in the variability of future interest cash flows to certain of our operating lease obligations are designated as cash flow hedges. The changes in fair value of the derivatives are intended to offset changes in future interest cash flows of such operating lease obligations. The gain or loss relating to the ineffective portion of interest rate swaps hedging the variability of future interest cash flows is recognized in the Consolidated Statements of Operations as “interest and other, net”.
	Net Investment Hedge
	Foreign currency hedging instruments that are being used to hedge changes in the value of a net investment are designated as net investment hedges. Changes in the fair value of a derivative that is designated and qualifies as a net investment hedge are recorded in OCI, net of taxes. The gain or loss relating to the ineffective portion is recognized in the Consolidated Statements of Operations as “interest and other, net”. Gains and losses accumulated in OCI are recognized in the Consolidated Statements of Operations when the foreign operation is (partially) disposed or sold.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents consist primarily of highly liquid investments, such as bank deposits, money market funds and interest-bearing bank accounts with insignificant interest rate risk and remaining maturities of three months or less at the date of acquisition.
Short-term Investments	'
	Short-term Investments
	Investments with remaining maturities longer than three months and less than one year at the date of acquisition are presented as short-term investments. The short-term investments are classified as available-for-sale securities and are stated at fair value. Gains and losses, other than impairments, interest income and foreign exchange results, are recognized in OCI until the short-term investments are derecognized. Upon derecognition, the cumulative gain or loss recognized in OCI, is recognized in the Consolidated Statements of Operations.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out method) or market value. Cost includes net prices paid for materials purchased, charges for freight and customs duties, production labor cost and factory overhead. Allowances are made for slow-moving, obsolete or unsellable inventory.
	Allowances for inventory are determined based on the expected demand which is derived from sales forecasts as well as the expected market value of the inventory.
Intangible Assets	'
	Intangible Assets
	Goodwill
	Goodwill represents the excess of the costs of an acquisition over the fair value of the amounts assigned to assets acquired and liabilities incurred or assumed of the acquired subsidiary at the date of acquisition. Goodwill on acquisition of subsidiaries is allocated to reporting units for the purpose of impairment testing. The allocation is made to those reporting units that are expected to benefit from the business combination in which the goodwill arose. Goodwill is tested for impairment annually at the end of the third quarter and whenever events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. Goodwill is stated at cost less accumulated impairment losses.
	Other Intangible Assets
	Other intangible assets include brands, intellectual property, developed technology, customer relationships, in-process R&D and other intangible assets. Other intangible assets are stated at cost, less accumulated amortization and any accumulated impairment losses. Amortization is calculated using the straight-line method based on the estimated useful lives of the assets. The following table presents the estimated useful lives of ASML’s finite-lived other intangible assets:
			Estimated useful life
	Category
	Brands		20 years
	Intellectual property		3 - 10 years
	Developed technology		6 - 15 years
	Customer relationships		8 - 18 years
	Other		2 - 6 years
	Infinite-lived other intangibles assets are tested for impairment annually at the end of the third quarter and whenever events or changes in circumstances indicate that the carrying amount of the infinite-lived other intangible assets may not be recoverable.
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost, less accumulated depreciation and accumulated impairment losses. Costs of assets manufactured by ASML include direct manufacturing costs, production overhead and interest costs incurred for qualifying assets during the construction period. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets. In the case of leasehold improvements, the estimated useful lives of the related assets do not exceed the remaining term of the corresponding lease.
	The following table presents the estimated useful lives of ASML’s property, plant and equipment:
			Estimated useful life
	Category
	Buildings and constructions		5 - 45 years
	Machinery and equipment		2 - 10 years
	Leasehold improvements		5 - 10 years
	Furniture, fixtures and other equipment		3 - 5 years
	Land is not depreciated.
	Certain internal and external costs associated with the purchase and/or development of internally used software are capitalized when both the preliminary project stage is completed and management has authorized further funding for the project, which it has deemed probable to be completed and to be usable for the intended function. These costs are depreciated on a straight-line basis over the period of related benefit, which ranges primarily from three to five years.
Evaluation of Long-lived Assets for Impairment	'
	Evaluation of Long-lived Assets for Impairment
	Long-lived assets include goodwill, other intangible assets and property, plant and equipment.
	Goodwill is tested for impairment annually at the end of the third quarter and whenever events or changes in circumstances indicate that the carrying amount of the goodwill may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. The test is based on a two-step approach for each reporting unit (being an operating segment or one level below an operating segment) in which goodwill has been recorded. First, recoverability is tested by comparing the carrying amount of the reporting unit including goodwill with the fair value of the reporting unit. If the carrying amount of the reporting unit is higher than the fair value of the reporting unit, the second step should be performed. Goodwill impairment is measured as the excess of the carrying amount of the goodwill over its implied fair value. The implied fair value of goodwill is determined by calculating the fair value of the various assets and liabilities included in the reporting unit in the same manner as goodwill is determined in a business combination.
	Other intangible assets and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of those assets may not be recoverable. Other intangible assets and property, plant and equipment are tested for impairment based on a two-step approach. First, the recoverability is tested by comparing the carrying amount of the other intangible assets and property, plant and equipment with their fair value, being the sum of the related undiscounted future cash flows. Second, if the carrying amount of the other intangible assets and property, plant and equipment is higher than this fair value the assets are considered to be impaired. The impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
	In determining the fair value of a long-lived asset (other than goodwill), we make estimates about future cash flows. These estimates are based on our financial plan updated with the latest available projection of the semiconductor market conditions and our sales and cost expectations, which are consistent with the plans and estimates that we use to manage our business. We also make estimates and assumptions concerning WACC and future inflation rates. It is possible that actual results may differ from our plans, estimates and assumptions, which may require impairment of certain long-lived assets (other than goodwill). Future adverse changes in market conditions may also require impairment of certain long-lived assets (other than goodwill), which could have a material adverse effect on our financial condition and results of operations.
Provisions	'
	Provisions
	Provisions for lease contract termination costs are recognized when costs will continue to be incurred under a contract for its remaining term without economic benefit to us and we cease using the rights conveyed by the contract. The provisions are measured at fair value, which for an operating lease contract is determined based on the remaining lease payments reduced by the estimated sublease payments that could be reasonably obtained.
Revenue Recognition	'
	Revenue Recognition
	ASML recognizes revenue when all four revenue recognition criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; seller’s price to buyer is fixed or determinable; and collectability is reasonably assured. At ASML this policy generally results in revenue recognition from the sale of a system upon shipment. The revenue from the installation of a system is generally recognized upon completion of that installation at the customer site. Prior to shipment, systems undergo a “Factory Acceptance Test” in our clean room facilities, effectively replicating the operating conditions that will be present on the customer’s site, in order to verify whether the system will meet its standard specifications and any additional technical and performance criteria agreed with the customer, if any. A system is shipped, and revenue is recognized, only after all contractual specifications are met and customer sign-off is received or waived. In case not all specifications are met and the remaining performance obligation is not essential to the functionality of the system but is substantive rather than inconsequential or perfunctory, a portion of the sales price is deferred. Although each system’s performance is re-tested upon installation at the customer’s site, we have never failed to successfully complete installation of a system at a customer’s premises.
	In connection with the introduction of new technology, such as our second- and third-generation EUV systems (NXE:3100 and NXE:3300B), we initially defer revenue recognition until acceptance of the new technology based system and completion of installation at the customer premises. As our systems are based largely on two product platforms that permit incremental, modular upgrades, the introduction of genuinely “new” technology occurs infrequently, and in the past 15 years, has occurred on only two occasions: 1999 (TWINSCAN) and 2010 (EUV).
	We have no significant repurchase commitments in our general sales terms and conditions. From time to time we repurchase systems that we have manufactured and sold and, following refurbishment, we resell those systems to other customers. This repurchase decision is driven by market demand expressed by other customers and not by explicit or implicit contractual arrangements relating to the initial sale. We consider reasonable offers from any vendor, including customers, to repurchase used systems so that we can refurbish, resell, and install these systems as part of our normal business operations. Once repurchased, the repurchase price of the used system is recorded in work-in-process inventory during the period it is being refurbished, following which the refurbished system is reflected in finished products inventory until it is sold to the customer. As of December 31, 2013 and 2012, ASML had no repurchase commitments.
	We offer customers discounts in the normal course of sales negotiations. These discounts are directly deducted from the gross sales price at the moment of revenue recognition. In addition, we offer volume discounts to customers. In some instances these volume discounts can be used to purchase field options (system enhancements). The related amount is recorded as a reduction in net sales at time of shipment. From time to time, we offer free or discounted products or services (award credits) to our customers as part of a volume purchase agreement. The sales transaction that gives rise to these award credits is accounted for as a multiple element sales transaction as the agreements involve the delivery of multiple products. The consideration received from the sales transaction is allocated between the award credits and the other elements of the sales transaction. The consideration allocated to the award credits is recognized as deferred revenue until award credits are delivered to the customer. The amount allocable to a delivered item is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the non-contingent amount).
	Net sales are recognized excluding the taxes levied on sales (net basis).
	In the event of expected losses on executory contracts, we recognize a liability for the amount that the cost of settling the contract exceeds the amount of the contract price. When we satisfy these contracts, we derecognize the related liability.
	Multiple Element Arrangements
	The main portion of our net sales is derived from contractual arrangements with our customers that have multiple deliverables, which mainly include the sale of our systems, installation and training services and prepaid extended and enhanced (optic) warranty contracts. As of January 1, 2011, we have adopted ASU 2009-13, “Sales Arrangements with Multiple Deliverables” which amended the guidance on arrangements with multiple deliverables in ASC 605-25. The amended standard changes the requirements for establishing separate units of accounting in a multiple element arrangement and requires the allocation of arrangement consideration to each deliverable to be based on the relative selling price.
	Each element in the arrangement is accounted for as a separate unit of accounting provided the following criteria are met: the delivered products or services have value to the customer on a standalone basis; and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by us. We consider a deliverable to have stand-alone value if the product or service is sold separately by us or another vendor or could be resold by the customer. Further, our sales arrangements do not include a general right of return relative to the delivered products. Where the aforementioned criteria for a separate unit of accounting are not met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition.
	The hierarchy of evidence to determine a selling price in ASC 605-25 is as follows:
	•		VSOE – the price at which we sell the element in a separate stand-alone transaction;
	•		TPE – evidence from us or other companies of the value of a largely interchangeable element in a transaction;
	•		BESP – our best estimate of the selling price of an element in the transaction.
	To determine the selling price in multiple elements arrangements, we establish VSOE of the selling price for installation, training services and prepaid extended and enhanced (optic) warranty contracts. VSOE for installation is determined based on the prices that we charge for billable labor and materials consumed in comparable services (such as relocating a system to another customer site). VSOE for prepaid extended and enhanced (optic) warranty contracts is determined on the basis of similair products we sell on a standalone basis, such as full service contracts and billable lens swaps, and which are subject to normal price negotiations. Revenue from installation and training services is recognized when the services are completed. Revenue from prepaid extended and enhanced (optic) warranty contracts is recognized over the term of the contract. When we are unable to establish the selling price using VSOE or TPE, we use BESP. The objective of using estimated selling price-based methodology is to determine the price at which we would transact a sale if the product or service were sold on a stand-alone basis. Accordingly, we determine BESP considering several internal and external factors including, but not limited to, pricing practices, gross margin objectives, market conditions, competitive environment, internal costs and geographies. We review selling prices annualy and maintain internal controls over the establishment and updates of these estimates.
Lease Arrangements	'
	Lease Arrangements
	A lease is classified as a sales-type lease if any of the following lease classification criteria is met at its inception:
	1	The lease transfers ownership of the property to the lessee by the end of the lease term;
	2	The lease contains a bargain purchase option;
	3	The lease term is equal to 75 percent or more of the estimated economic life of the leased property; and
	4	The present value at the beginning of the lease term of the minimum lease payments, excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, including any profit thereon, equals or exceeds 90 percent of the excess of the fair value of the leased property to the lessor at lease inception over any related investment tax credit retained by the lessor and expected to be realized by the lessor.
	In addition, revenue is recognized at commencement of the lease term. The present value of the lease payments is recognized as a finance receivable. The difference between the gross receivable and the present value of the receivable is recognized as unearned interest in the Consolidated Statements of Operations.
	A lease is classified as an operating lease if the lease classification criteria (as described above) are not met. If ASML has offered its customers an operating lease arrangement, the contract consideration is recognized in the Consolidated Statements of Operations on a straight-line basis over the period of the lease.
Warranty	'
	Warranty
	We provide standard warranty coverage on our systems for 12 months and on certain optic parts for 60 months, providing labor and parts necessary to repair systems and optic parts during the warranty period. The estimated warranty costs are accounted for by accruing these costs for each system upon recognition of the system sale. The estimated warranty costs are based on historical product performance and field expenses. Based upon historical service records, we calculate the charge of average service hours and parts per system to determine the estimated warranty costs. On a semi-annual basis, we assess, and update if necessary, our accounting estimates used to calculate the standard warranty reserve based on the latest actual historical warranty costs and expected future warranty costs.
	The extended and enhanced (optic) warranty on our system is accounted for as a separate element of multiple element revenue recognition transactions.
Customer Co-Investment Program	'
	Customer Co-Investment Program
	In connection with the CCIP, we entered into investment agreements, Shareholders Agreements and NRE Funding Agreements and commercial agreements with Participating Customers.
	The investment agreements, Shareholder Agreements, NRE Funding Agreements and commercial agreement are accounted for as a multiple-element arrangement with each of the Participating Customers. Based upon ASC 605-25 Multiple-Element Arrangements guidance, the following two separate elements are identified for each arrangement: (1) the share issuance (governed by the investment agreement and the Shareholder Agreement) and (2) the NRE funding and commercial discounts and credits (governed by the NRE Funding Agreement and the commercial agreement with Intel).
	The shares issued to the Participating Customers are recorded at fair value based on quoted share prices (EUR 3,977.4 million) with the remaining aggregate arrangement consideration allocated to the NRE funding and commercial discounts and credits. The difference between the fair value of the shares and the subscription price of the shares (EUR 39.91) was recorded as a deduction from shareholders’ equity upon issuance of the shares (EUR 123.4 million). Shareholders’ equity is increased to the fair value of the shares as the portion of the NRE funding allocable to the shares is received over the NRE funding period (2013-2017). The amounts are deemed receivables from the Participating Customers in their capacity as shareholders of ASML.
	A significant related party relationship exists between ASML and Intel as a result of the equity investment made by Intel as part of the CCIP. Based on the commercial discounts and credits (governed by the Commercial Agreement with Intel) and the significant related party relationship, all NRE funding will be deferred and recognized in the Consolidated Statement of Operations only when the commercial discounts and credits are earned.
	In addition see also other income for further explanation on the accounting policies with respect to CCIP.
Accounting for Shipping and Handling Fees and Costs	'
	Accounting for Shipping and Handling Fees and Costs
	ASML bills the customer for, and recognizes as revenue, any charges for shipping and handling costs. The related costs are recognized as cost of sales.
Cost of Sales	'
	Cost of Sales
	Cost of system sales comprise direct product costs such as materials, labor, cost of warranty, depreciation, shipping and handling costs and related overhead costs. ASML accrues for the estimated cost of the warranty on its systems, which includes the cost of labor and parts necessary to repair systems during the warranty period. The amounts recorded in the accrued warranty reserve are estimated based on actual historical expenses incurred and on estimated probable future expenses related to current sales. Actual warranty costs are charged against the accrued warranty reserve.
	Costs of service sales comprise direct service costs such as materials, labor, depreciation and overhead costs.
	Cost of field option sales comprise direct product costs such as materials, labor, cost of warranty, depreciation, shipping and handling costs and related overhead costs.
Other Income	'
	Other Income
	The portion of the NRE funding from TSMC and Samsung not allocable to the shares issued to those Participating Customers under the CCIP is recognized in Other income when the R&D costs relating to the development of 450mm lithography equipment and EUV platforms are recognized over the NRE funding period (2013-2017).
R&D Costs and Credits	'
	R&D Costs and Credits
	Costs relating to R&D are charged to operating expenses as incurred. ASML receives subsidies and other grants from several Dutch and international (inter-)governmental institutes. These subsidies and other government grants that cover R&D costs relating to approved projects are recorded as R&D credits in the R&D line in the Consolidated Statements of Operations in the period in which such costs occur.
	Government grants are not recognized until there is reasonable assurance that ASML will comply with the conditions attaching to them and that the grants will be received.
	Government grants whose primary condition is that ASML should purchase, construct or otherwise acquire non-current assets are recognized as deferred income in the Consolidated Balance Sheets and transferred to the Consolidated Statements of Operations on a systematic and rational basis over the useful lives of the related assets.
	Other government grants are recognized as income over the periods necessary to match them with the costs for which they are intended to compensate, on a systematic basis. Government grants that are received as compensation for expenses or losses already incurred, or for the purpose of giving immediate financial support to ASML with no future related costs are recognized in the Consolidated Statements of Operations in the period in which they become receivable.
Borrowing Costs	'
	Borrowing Costs
	Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time that the assets are substantially ready for their intended use or sale.
Share-based Payments	'
	Share-based Payments
	The cost of employee services received (compensation expenses) in exchange for awards of equity instruments are recognized based upon the grant-date fair value of stock options and shares. The grant-date fair value of stock options is estimated using a Black-Scholes option valuation model. This Black-Scholes model requires the use of assumptions, including expected share price volatility, the estimated life of each award and the estimated dividend yield. The risk-free interest rate used in the model is determined, based on an index populated with euro-denominated European government agency bond with high credit ratings and with a life equal to the expected life of the equity-settled share-based payments. The grant-date fair value of shares is determined based on the closing price of our shares listed at NYSE Euronext Amsterdam on the grant-date.
	The grant-date fair value of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on our estimate of equity instruments that will eventually vest. At each balance sheet date, we revise our estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognized in the Consolidated Statements of Operations in the period in which the revision is determined, with a corresponding adjustment to shareholders’ equity.
Income Taxes	'
	Income Taxes
	The asset and liability method is used in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the tax effect of incurred net operating losses and for tax consequences attributable to differences between the balance sheet carrying amounts of existing assets and liabilities and their respective tax bases. If it is more likely than not that the carrying amounts of deferred tax assets will not be realized, a valuation allowance is recorded to reduce the carrying amounts of those assets.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Consolidated Statements of Operations in the period that includes the enactment date.
	We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes, and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.
Contingencies and Litigation	'
	Contingencies and Litigation
	We are party to various legal proceedings generally incidental to our business, as disclosed in Note 19. In connection with these proceedings and claims, our management evaluated, based on the relevant facts and legal principles, the likelihood of an unfavorable outcome and whether the amount of the loss could be reasonably estimated. In most cases, management determined that either a loss was not probable or was not reasonably estimable. Significant subjective judgments were required in these evaluations, including judgments regarding the validity of asserted claims and the likely outcome of legal and administrative proceedings. The outcome of these proceedings, however, is subject to a number of factors beyond our control, most notably the uncertainty associated with predicting decisions by courts and administrative agencies. In addition, estimates of the potential costs associated with legal and administrative proceedings frequently cannot be subjected to any sensitivity analysis, as damage estimates or settlement offers by claimants may bear little or no relation to the eventual outcome. Finally, in any particular proceeding, we may agree to settle or to terminate a claim or proceeding in which we believe that it would ultimately prevail where we believe that doing so, when taken together with other relevant commercial considerations, is more cost-effective than engaging in an expensive and protracted litigation, the outcome of which is uncertain.
	We accrue for legal costs related to litigation in our Consolidated Statements of Operations at the time when the related legal services are actually provided.
Net Income per Ordinary Share	'
	Net Income per Ordinary Share
	Basic net income per ordinary share is calculated by dividing net income by the weighted average number of ordinary shares outstanding for that period. The dilutive effect is calculated using the treasury stock method. Excluded from the diluted weighted average number of shares outstanding calculation are cumulative preference shares contingently issuable to the preference share foundation, since they represent a different class of stock than the ordinary shares. See Note 26 for further discussion.
	The basic and diluted net income per ordinary share has been calculated in accordance with the following schedule:
				2013	2012	2011
	Year ended December 31			EUR	EUR	EUR
	(in thousands, except per share data)
	Net income			1,015,490	1,146,316	1,466,960
	Weighted average number of shares outstanding during the year			429,770	424,096	425,618
	(after deduction of treasury stock)
	Basic net income per ordinary share			2.36	2.7	3.45
	Weighted average number of shares:			429,770	424,096	425,618
	Plus shares applicable to:
	Options and conditional shares			3,676	2,890	3,435
	Dilutive potential ordinary shares			3,676	2,890	3,435
	Adjusted weighted average number of shares			433,446	426,986	429,053
	Diluted net income per ordinary share1			2.34	2.68	3.42
	1	The calculation of diluted net income per ordinary share assumes the exercise of options issued under our stock option plans and the issuance of shares under our share plans for periods in which exercises or issuances would have a dilutive effect. The calculation of diluted net income per ordinary share does not assume exercise of such options or issuance of shares when such exercises or issuance would be anti-dilutive.
Comprehensive income	'
	Comprehensive Income
	Comprehensive income consists of net income (loss) and OCI.
	OCI refers to gains and losses that are not included in net income (loss), but recorded directly in shareholders’ equity. For the years ending December 31, 2013 and 2012, comprehensive income consists of net income, unrealized gains and losses on financial instruments, being available-for-sale securities and derivative financial instruments designated for hedge accounting, net of taxes, and unrealized gains and losses on foreign currency translation, net of taxes. For the year ending December 31, 2011 comprehensive income consists of net income, unrealized gains and losses on financial instruments, being derivative financial instruments designated for hedge accounting, net of taxes and unrealized gains and losses on foreign currency translation, net of taxes.
New US GAAP Accounting Pronouncements	'
	New US GAAP Accounting Pronouncements
	For the below mentioned ASUs, issued in 2013, the impact on our Financial Statements needs to be assessed:
	•		In February 2013, FASB issued ASU No. 2013-04 “Liabilities (Topic 405): Obligations Resulting from Joint and Several Liability Arrangements for which the Total Amount of the Obligation is Fixed at the Reporting Date”. The objective of the amendments in this Update is to provide guidance for the recognition, measurement and disclosure of obligations resulting from joint an several liability arrangements for which the total amount of the obligation within the scope of this guidance is fixed at the reporting date, except for obligations addressed within existing guidance in US GAAP. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013.
	•		In March 2013, FASB issued ASU No. 2013-05 “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The objective of the amendments in this Update is to resolve the diversity in practice about whether Subtopic 810-10, “Consolidation-Overall”, or Subtopic 830-30, ““Foreign Currency Matters-Translation of Financial Statements”, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013.
	•		In July 2013, FASB issued ASU No. 2013-11 “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry forward, a Similar Tax Loss, or a Tax Credit Carry forward Exists”. Topic 740, Income Taxes, does not include explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carry forward, a similar tax loss, or a tax credit carry forward exists. There is diversity in practice in the presentation of unrecognized tax benefits in those instances. Some entities present unrecognized tax benefits as a liability unless the unrecognized tax benefit is directly associated with a tax position taken in a tax year that results in, or that resulted in, the recognition of a net operating loss or tax credit carry forward has not been utilized. Other entities present unrecognized tax benefits as a reduction of a deferred tax asset for a net operating loss or tax credit carry forward in certain circumstances. The objective of the amendments in this Update is to eliminate that diversity in practice. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013.

General_Information_Summary_of2

General Information / Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Estimated Useful Lives of Finite-Lived Other Intangible Assets	'
	The following table presents the estimated useful lives of ASML’s finite-lived other intangible assets:
			Estimated useful life
	Category
	Brands		20 years
	Intellectual property		3 - 10 years
	Developed technology		6 - 15 years
	Customer relationships		8 - 18 years
	Other		2 - 6 years
Property, Plant and Equipment	'
	The following table presents the estimated useful lives of ASML’s property, plant and equipment:
			Estimated useful life
	Category
	Buildings and constructions		5 - 45 years
	Machinery and equipment		2 - 10 years
	Leasehold improvements		5 - 10 years
	Furniture, fixtures and other equipment		3 - 5 years
Net Income Per Ordinary Share	'
	The basic and diluted net income per ordinary share has been calculated in accordance with the following schedule:
				2013	2012	2011
	Year ended December 31			EUR	EUR	EUR
	(in thousands, except per share data)
	Net income			1,015,490	1,146,316	1,466,960
	Weighted average number of shares outstanding during the year			429,770	424,096	425,618
	(after deduction of treasury stock)
	Basic net income per ordinary share			2.36	2.7	3.45
	Weighted average number of shares:			429,770	424,096	425,618
	Plus shares applicable to:
	Options and conditional shares			3,676	2,890	3,435
	Dilutive potential ordinary shares			3,676	2,890	3,435
	Adjusted weighted average number of shares			433,446	426,986	429,053
	Diluted net income per ordinary share1			2.34	2.68	3.42
	1	The calculation of diluted net income per ordinary share assumes the exercise of options issued under our stock option plans and the issuance of shares under our share plans for periods in which exercises or issuances would have a dilutive effect. The calculation of diluted net income per ordinary share does not assume exercise of such options or issuance of shares when such exercises or issuance would be anti-dilutive.

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Summarizes Major Classes of Consideration Transferred, and Recognized Amounts of Fair Value of Identifiable Assets Distributed and Fair Value of Liabilities Incurred or Assumed at Acquisition Date	'
	The following table summarizes the major classes of consideration transferred, and the recognized amounts of the fair value of the identifiable assets distributed and the fair value of the liabilities incurred or assumed at the acquisition date.
	(in thousands)
			May 30, 2013
			EUR1
	Cash and cash equivalents			84,129
	Short-term investments			40,055
	Accounts receivable, net			121,395
	Finance receivables, net			611
	Current tax assets			37,289
	Inventories, net			301 ,279
	Deferred tax assets			90,045
	Other assets, current and non-current			29,418
	Other intangible assets, net			751,542
	Property, plant and equipment, net			124,308
	Assets acquired			1,580,071
	Accounts payable			151,412
	Accrued and other liabilities, current and non-current			90,900
	Deferred and other tax liabilities			297,977
	Long-term debt, current and non-current			609
	Liabilities assumed			540,898
	Total net identifiable assets			1,039,173
	Consideration paid in cash for the transaction on May 30, 2013			486,325
	Fair value of shares2			2,347,663
	Fair value of equity awards cash settled			41,516
	Fair value of unvested equity awards to be exchanged			43,527
	Gain on settlement of pre-existing relationships			178,427
	Consideration transferred			3,097,458
	Goodwill on acquisition			2,058,285
	1	Amounts were converted into euro at the rate of USD/EUR 1.3043.
	2	As part of the consideration transferred, Cymer shares were converted into a right to receive 36,479,109 ASML ordinary shares. These shares were valued at USD 83.94 being the opening price on NASDAQ at May 30, 2013. As at December 31, 2013, 14,533 ASML ordinary shares are still to be issued.
Summary of Estimated Consolidated Pro Forma Information	'
	The following unaudited pro forma summary presents estimated consolidated information of ASML as if the Cymer acquisition had occurred on January 1, 2012. These amounts have been calculated after applying our accounting policies and adjusting the results of Cymer to reflect the charges and benefits assuming the fair value adjustments had been applied from January 1, 2012 with the consequential tax effects.
	Pro Forma Year ended December 31					Unaudited
	(in millions)		Unaudited			2012
			2013			EUR
			EUR
	Total net sales			5,362			5,053
	Net income			1,031	1		965	2
	1	Pro forma net income was adjusted to exclude EUR 60 million of non-recurring costs related to the fair value adjustments to acquisition date inventory and exclude EUR 30 million of acquisition related costs incurred in 2013.
	2	Pro forma net income was adjusted to include EUR 60 million of non-recurring costs related to the fair value adjustments to acquisition date inventory and exclude EUR 15 million of acquisition related costs incurred in 2012.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis	'
	The following table presents our financial assets and financial liabilities that are measured at fair value on a recurring basis:
			Level 1	Level 2	Level 3	Total
	As of December 31, 2013		EUR	EUR	EUR	EUR
	(in thousands)
	Assets
	Derivative financial instruments 1		-	71,620	-		71,620
	Money market funds 2		535,000	-	-		535,000
	Short-term investments 3		304,884	375,000	-		679,884
	Total		839,884	446,620	-		1,286,504
	Liabilities
	Long-term debt 4		-	1,021,930	-		1,021,930
	Derivative financial instruments1		-	11,652	-		11,652
	Total		-	1,033,582	-		1,033,582
	As of December 31, 2012		Level 1	Level 2	Level 3	Total
	(in thousands)		EUR	EUR	EUR	EUR
	Assets
	Derivative financial instruments1		-	151,748	-		151,748
	Money market funds 2		385,420	-	-		385,420
	Short-term investments 3		279,988	650,017	-		930,005
	Total		665,408	801,765	-		1,467,173
	Liabilities
	Long-term debt 4		-	759,490	-		759,490
	Derivative financial instruments 1		-	10,893	-		10,893
	Total		-	770,383	-		770,383
	1	Derivative financial instruments consist of forward foreign exchange contracts and interest rate swaps. See Note 4.
	2	Money market funds are part of our cash and cash equivalents.
	3	Short-term investments consist of Dutch Treasury Certificates and deposits with the Dutch government.
	4	Long-term debt mainly relates to our Eurobonds (carrying amount as at December 31, 2013: EUR 1,021.9 million (2012: EUR 710.1 million)) and excludes accrued interest. For further details see Note 15.

Financial_Risk_Management_Tabl

Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Summary of Notional Amounts and Estimated Fair Values of Financial Instruments	'
	The following table summarizes the notional amounts and estimated fair values of our derivative financial instruments:
											2012
			2013
	As of December 31		Notional				Fair Value				Notional		Fair Value
	(in thousands)		amount				EUR				amount		EUR
			EUR								EUR
	Forward foreign exchange contracts1			986,986				8,583				262,146		16,805
	Interest rate swaps2			1,013,053				51,385				624,900		124,050
	1	Relates to forward contracts assigned as a hedge to forecasted sales and purchase transactions and to monetary assets and liabilities, mainly in U.S. dollar and Japanese Yen.
	2	Relates to interest rate swaps assigned as a hedge to interest bearing assets and liabilities, mainly related to our Eurobonds; the fair value of the interest rate swaps includes accrued interest.
Derivative Financial Instruments Per Category	'
	The following table summarizes our derivative financial instruments per category:
													2012
					2013
	As of December 31				Assets				Liabilities				Assets		Liabilities
	(in thousands)				EUR				EUR				EUR		EUR
	Interest rate swaps - cash flow hedges					-				3,598				-		4,780
	Interest rate swaps - fair value hedges					54,983				-				128,830		-
	Forward foreign exchange contracts - cash flow hedges					3				6,039				5,975		5,688
	Forward foreign exchange contracts - other hedges (no hedge accounting)					16,634				2,015				16,943		425
	Total					71,620				11,652				151,748		10,893
	Less non-current portion:
	Interest rate swaps - cash flow hedges					-				2,608				-		4,032
	Interest rate swaps - fair value hedges					30,777				-				101,651		-
	Total non-current portion					30,777				2,608				101,651		4,032
	Total current portion					40,843				9,044				50,097		6,861

Cash_and_Cash_Equivalents_and_1

Cash and Cash Equivalents and Short-term Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Cash And Cash Equivalents [Abstract]	'
Short-term Investments	'
	Short-term investments (classified as available for sale securities) consist of the following:
		Cost basis		Unrealized		Unrealized		Recorded Basis
	As of December 31, 2013			Gains		Losses
	(in thousands)
	Dutch Treasury Certificates		304,884		-		-		304,884
	Deposits		375,000		-		-		375,000
	Total		679,884		-		-		679,884
		Cost basis		Unrealized		Unrealized		Recorded Basis
	As of December 31, 2012			Gains		Losses
	(in thousands)
	Dutch Treasury Certificates		279,988		-		-		279,988
	Deposits		650,017		-		-		650,017
	Total		930,005		-		-		930,005

Accounts_Receivable_Tables

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Accounts Receivable	'
	Accounts receivable consist of the following:
			2013		2012
	As of December 31		EUR		EUR
	(in thousands)
	Accounts receivable, gross			880,169		607,359
	Allowance for doubtful receivables			-1,848		-2,071
	Accounts receivable, net			878,321		605,288
Allowance for Doubtful Receivables	'
	Movements of the allowance for doubtful receivables are as follows:
			2013		2012
	Year ended December 31		EUR		EUR
	(in thousands)
	Balance at beginning of year			-2,071		-2,582
	Addition for the year1			-1,062		-458
	Utilization of the provision			1,285		969
	Allowance for doubtful receivables			(1,848)		(2,071)
	1	The addition for the year is recorded in the cost of sales.

Finance_Receivables_Tables

Finance Receivables (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Components of Finance Receivables	'
	The following table lists the components of the finance receivables as of December 31, 2013 and 2012:
		2013		2012
	As of December 31	EUR		EUR
	(in thousands)
	Finance receivables, gross		302,977		309,616
	Unearned interest		-6,488		-5,828
	Finance receivables, net		296,489		303,788
	Current portion of finance receivables, gross		254,227		268,617
	Current portion of unearned interest		-3,755		-3,450
	Non-current portion of finance receivables, net		46,017		38,621
Finance Receivables Due for Payment	'
	At December 31, 2013, the finance receivables due for payment in each of the next five years and thereafter are as follows:
		EUR
	(in thousands)
	2014		254,227
	2015		-
	2016		6,150
	2017		36,450
	2018		6,150
	Thereafter		-
	Finance receivables, gross		302,977

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories consist of the following:
		2013		2012
	As of December 31	EUR		EUR
	(in thousands)
	Raw materials		438,853		307,315
	Work-in-process		1,549,119		1,074,042
	Finished products		666,648		742,979
	Inventories, gross		2,654,620		2,124,336
	Allowance for obsolescence and/or lower market value		-261,598		-267,366
	Inventories, net		2,393,022		1,856,970
Allowance for Obsolescence and/or Lower Market Values	'
	A summary of activity in the allowance for obsolescence and/or lower market value is as follows:
		2013		2012
	Year ended December 31	EUR		EUR
	(in thousands)
	Balance at beginning of year		-267,366		-193,513
	Addition for the year		-164,852		-130,911
	Effect of changes in exchange rates		2,532		1,009
	Utilization of the provision		168,088		56,049
	Allowance for obsolescence and/or lower market value		(261,598)		(267,366)

Other_Assets_Tables

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Current Assets	'
	Other current assets consist of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Advance payments to Zeiss			99,415		70,257
	Prepaid expenses			100,077		64,708
	Derivative financial instruments			40,843		50,097
	VAT			67,381		25,215
	Other receivables			28,705		35,728
	Other current assets			336,421		246,005
Other Non-current Assets	'
	Other non-current assets consist of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Advance payments to Zeiss			224,123		183,025
	Derivative financial instruments			30,777		101,651
	Compensation plan assets1			20,174		12,080
	Prepaid expenses			10,950		4,462
	Subordinated loan granted to lessor in respect of Veldhoven headquarters2			5,445		5,445
	Other			7,090		4,875
	Other non-current assets			298,559		311,538
	1	For further details on compensation plan assets see Note 18.
	2	For further details on the loan granted to lessor in respect of Veldhoven headquarters see Note 12.

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	Changes in goodwill are summarized as follows:
	Year ended December 31	2013		2012
	(in thousands)	EUR		EUR
	Cost
	Balance, January 1		149,168		146,044
	Acquisition through business combinations		2,058,285		6,038
	Effect of changes in exchange rates		-118,864		-2,914
	Goodwill		2,088,589		149,168

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Finite-Lived Other Intangible Assets	'
	Finite-lived other intangible assets consist of the following:
	(in thousands)	Brands		Intellectual		Developed		Customer		Other		Total
		EUR		property		technology		relationships		EUR		EUR
				EUR		EUR		EUR
	Cost
	Balance, January 1, 2012		-		47,250		49,031		8,733		2,231		107,245
	Additions		-		7,658		-		-		-		7,658
	Balance, December 31, 2012		-		54,908		49,031		8,733		2,231		114,903
	Acquisitions through business combinations		13,280		-		427,797		162,980		-		604,057
	Additions		-		4,000		-		-		-		4,000
	Effect of changes in exchange rates		-726		-		-23,380		-8,907		-		-33,013
	Balance, December 31, 2013		12,554		58,908		453,448		162,806		2,231		689,947
	Accumulated amortization
	Balance, January 1, 2012		-		47,228		44,271		5,277		2,103		98,879
	Amortization		-		800		4,080		1,092		109		6,081
	Balance, December 31, 2012		-		48,028		48,351		6,369		2,212		104,960
	Amortization		382		2,135		18,694		6,332		19		27,562
	Effect of changes in exchange rates		-13		-		-596		-174		-		-783
	Balance, December 31, 2013		369		50,163		66,449		12,527		2,231		131,739
	Carrying amount
	December 31, 2012		-		6,880		680		2,364		19		9,943
	December 31, 2013		12,185		8,745		386,999		150,279		-		558,208
Weighted-Average Amortization Period for Finite-Lived Other Intangible Assets Acquired	'
	The weighted-average amortization period for the finite-lived other intangible assets acquired, as a result of the acquisition of Cymer, by major intangible asset class is as follows:
	(in years)	Brands		Developed technology		Customer relationships
	Weighted-average amortization period		20		14		17.9
Indefinite-Lived Other Intangible Assets	'
	Indefinite-lived other intangible assets consist of the following:
	(in thousands)	In-process
		R&D
		EUR
	Cost
	Balance, January 1, 2012		-
	Additions		-
	Balance, December 31, 2012		-
	Acquisitions through business combinations		147,485
	Additions		-
	Effect of changes in exchange rates		-8,059
	Carrying amount, December 31, 2013		139,426
Future Amortization Expenses	'
	As at December 31, 2013, the estimated amortization expenses for other intangible assets, for the next five years and thereafter, are as follows:
	(in thousands)	EUR
	2014		42,227
	2015		41,317
	2016		52,753
	2017		51,958
	2018		50,619
	Thereafter		458,760
	Amortization expenses		697,634

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property, plant and equipment consist of the following:
	(in thousands)	Land,		Machinery		Leasehold		Furniture,		Total
		buildings and		and		improvements		fixtures and		EUR
		constructions		equipment		EUR		other
		EUR		EUR				equipment
								EUR
	Cost
	Balance, January 1, 2012		742,141		764,023		206,660		344,979		2,057,803
	Additions		106,234		248,429		8,883		22,749		386,295
	Disposals		-347		-317,022		-300		-30,894		-348,563
	Effect of changes in exchange rates		-995		-4,671		-391		-59		-6,116
	Balance, December 31, 2012		847,033		690,759		214,852		336,775		2,089,419
	Acquisitions through business combinations		71,040		48,965		1,057		3,246		124,308
	Additions		123,646		171,895		11,543		32,168		339,252
	Disposals		-14		-90,244		-336		-1,925		-92,519
	Effect of changes in exchange rates		-6,605		-17,490		-1,464		-1,783		-27,342
	Balance, December 31, 2013		1,035,100		803,885		225,652		368,481		2,433,118
	Accumulated depreciation and impairment
	Balance, January 1, 2012		155,877		401,800		145,775		300,741		1,004,193
	Depreciation		31,598		110,571		13,416		23,668		179,253
	Impairment charges		649		906		-		1,679		3,234
	Disposals		-347		-92,205		-248		-30,575		-123,375
	Effect of changes in exchange rates		-505		-3,090		-165		-49		-3,809
	Balance, December 31, 2012		187,272		417,982		158,778		295,464		1,059,496
	Depreciation		47,791		114,677		12,415		22,170		197,053
	Impairment charges		3,619		7,997		1,352		89		13,057
	Disposals		-5		-42,625		-266		-1,282		-44,178
	Effect of changes in exchange rates		-1,116		-8,068		-422		-544		-10,150
	Balance, December 31, 2013		237,561		489,963		171,857		315,897		1,215,278
	Carrying amount
	December 31, 2012		659,761		272,777		56,074		41,311		1,029,923
	December 31, 2013		797,539		313,922		53,795		52,584		1,217,840

Accrued_and_Other_Liabilities_

Accrued and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Accrued and Other Liabilities	'
	Accrued and other liabilities consist of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Deferred revenue			939,358		739,136
	Costs to be paid			440,010		278,066
	Down payments from customers			821,959		1,033,768
	Personnel related items			247,246		200,670
	Derivative financial instruments			11,652		10,893
	Standard warranty reserve			27,475		21,626
	Other			12,324		1,352
	Accrued and other liabilities			2,500,024		2,285,511
	Less: non-current portion of accrued and other liabilities1			283,142		405,141
	Current portion of accrued and other liabilities			2,216,882		1,880,370
	1	The main part of the non-current portion of accrued and other liabilities relates to down payments received from customers regarding future shipments of EUV systems and deferrals with respect to services.
Changes in Standard Warranty Reserve	'
	Changes in standard warranty reserve for the years 2013 and 2012 are as follows:
	(in thousands)		2013		2012
			EUR		EUR
	Balance, January 1			21,626		43,273
	Acquisitions through business combinations			2,978		-
	Additions for the year			37,124		35,735
	Utilization of the reserve			(19,924)		(33,746)
	Release of the reserve			-13,076		-22,733
	Effect of exchange rates			-1,253		-903
	Standard warranty reserve			27,475		21,626

Provisions_Tables

Provisions (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Movement in Provision for Lease Contract Termination Costs	'
	The movement in the provision for lease contract termination costs is as follows:
	(in thousands)	2013		2012
		EUR		EUR
	Balance, January 1		10,254		12,338
	Utilization of the provision		-2,790		-2,545
	Release of the provision		-1,011		-
	Unwinding of discount		391		628
	Effect of exchange rates		3		-167
	Provision for lease contract termination costs		6,847		10,254
	Less: current portion of provision for lease contract termination costs		2,227		2,280
	Non-current portion of provision for lease contract termination costs		4,620		7,974

Longterm_Debt_Tables

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-term Debt	'
	Long-term debt consists of the following:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	EUR 600 million 5.75 percent senior notes due 2017, carrying amount			270,339		710,095
	EUR 750 million 3.375 percent senior notes due 2023, carrying amount			751,591		-
	Loan headquarter building1			30,936		32,366
	Other			21,704		17,029
	Long-term debt			1,074,570		759,490
	Less: current portion of long-term debt			4,385		3,610
	Non-current portion of long-term debt			1,070,185		755,880
	1	This loan relates to our VIE, see Note 12.
Principal Repayments and Other Borrowing Arrangements	'
	Our obligations to make principal repayments under our Eurobonds and other borrowing arrangements excluding interest expense as of December 31, 2013, for the next five years and thereafter, are as follows:
	(in thousands)		EUR
	2014			4,385
	2015			4,252
	2016			4,211
	2017			242,361
	2018			27,997
	Thereafter			757,467
	Long-term debt			1,040,673
	Less: current portion of long-term debt			4,385
	Non-current portion of long-term debt			1,036,288
Summary of Fair Value of Outstanding Eurobonds	'
	The following table summarizes the carrying amount of our outstanding Eurobonds, including the fair value of interest rate swaps used to hedge the change in the fair value of the Eurobonds:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Amortized cost amount			981,291		600,000
	Fair value interest rate swaps1			40,639		110,095
	Carrying amount			1,021,930		710,095
	1	The fair value of the interest rate swaps excludes accrued interest.
Estimated Fair Value of Eurobonds	'
	The following table summarizes amongst others the estimated fair value of the Eurobonds:
	As of December 31		2013		2012
	(in thousands)		EUR		EUR
	Principal amount			988,153		600,000
	Carrying amount			1,021,930		710,095
	Fair value1			1,028,238		700,644
	1	Source: Bloomberg Finance LP

Commitments_Contingencies_and_1

Commitments, Contingencies and Guarantees (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Contractual Obligations	'
	Our contractual obligations as of December 31, 2013 can be summarized as follows:
	Payments due by period		Total		1 year		2 year		3 year		4 year		5 year		After
	(in thousands)		EUR		EUR		EUR		EUR		EUR		EUR		5 years
															EUR
	Long-Term Debt Obligations, including interest expense1			1,341,380		45,079		44,952		44,907		275,640		54,155		876,647
	Operating Lease Obligations			74,946		30,293		21,543		14,081		4,803		2,539		1,687
	Purchase Obligations			2,012,913		1,894,455		85,548		16,223		13,772		2,382		533
	Unrecognized Tax Benefits,			74,069		580		945		7,680		26,105		785		37,974
	including interest expense
	Total Contractual Obligations			3,503,308		1,970,407		152,988		82,891		320,320		59,861		916,841
	1	See Note 15 for the amounts excluding interest expenses.
Purchase Options	'
	The amounts to be paid if ASML would exercise these purchase options at the end of the lease as of December 31, 2013 can be summarized as follows:
	Purchase options		Total		1 year		2 year		3 year		4 year		5 year		After
	due by period		EUR		EUR		EUR		EUR		EUR		EUR		5 years
	(in thousands)														EUR
	Purchase options			13,983		-		-		13,983		-		-

Employee_Benefits_Tables

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2013
Compensation Related Costs [Abstract]	'
Bonus Plan Expenses	'
	Our bonus expenses for the Board of Management (including Mr. Nickl and Mr. Meurice) and senior management were as follows:
	Year ended December 31		2013				2012				2011
	(in thousands)		EUR				EUR				EUR
	Bonus expenses			32,698				16,474				15,557
Bonus Costs Under Performance Related Bonus Plan	'
	Our bonus costs under these plans were as follows:
	Year ended December 31		2013				2012				2011
	(in thousands)		EUR				EUR				EUR
	Bonus expenses			30,631				14,588				13,131
Assumption of Black-Scholes Option Valuation of Fair Value of Company's Stock Options	'
	The Black-Scholes option valuation of our stock options is based on the following assumptions:
			2013				2012				2011
	Year ended December 31
	Weighted average share price (in EUR)			62				40.3				28
	Volatility (in percentage)			27				25.6				37.8
	Expected life (in years)			5.6				5				4.8
	Risk free interest rate			0.8				2.1				2.9
	Expected dividend yield (in EUR)			2				1.45				1.25
	Forfeiture rate1			-				-				-
	1	As of year end for each of the three years ended December 31, forfeitures are estimated to be nil.
Stock Options	'
	Other details with respect to stock options are set out in the following table:
															USD-denominated
			EUR-denominated
	Year ended December 31		2013				2012				2011				2013				2012				2011
	Weighted average fair value of stock options granted			14.22				8.97				8.28				21.74				11.87				10.42
	Weighted average share price at the exercise date of stock options			59.53				40.45				29.39				77.25				50.88				41.94
	Aggregate intrinsic value of stock options exercised (in thousands)			15,924				71,331				30,204				11,086				12,684				11,323
	Aggregate remaining contractual term of currently exercisable options (years)			3.09				3.59				2.08				3.12				3.17				1.8
	Aggregate intrinsic value of exercisable stock options (in thousands)			37,441				34,438				39,384				22,781				21,882				20,492
	Aggregate intrinsic value of outstanding stock options (in thousands)			38,718				35,671				45,141				25,369				22,433				20,791
Stock Option Transactions	'
	The number and weighted average exercise prices of stock options as of December 31, 2013, and changes during the year then ended are presented below:
											USD-denominated
			EUR-denominated
			Number				Weighted average				Number				Weighted average
			of options				exercise price				of options				exercise price
							per ordinary								per ordinary
							share (EUR)								share (USD)
	Outstanding, January 1, 2013			1,128,162				16.38				494,836				19.06
	Granted			28,308				58.35				101,400	1			60.86
	Exercised			-358,581				15.12				-178,374				14.86
	Forfeited			-4,234				20.27				-7,311				23.81
	Expired			-11,353				10.11				-3,916				11.33
	Outstanding, December 31, 2013			782,302				18.55				406,635				31.31
	Exercisable, December 31, 2013			731,452				16.85				325,026				23.61
	1	USD-denominated grants include 79,153 options with a weighted average exercise price of USD 53.07 which have been assumed by ASML as part of the acquisition of Cymer.
Outstanding Stock Options	'
	Details with respect to the stock options outstanding are set out in the following table:
													USD-denominated
	EUR-denominated
	Range of				Number of				Weighted				Range of				Number of				Weighted
	exercise				outstanding				average				exercise				outstanding				average
	prices (EUR)				options at				remaining				prices (USD)				options at				remaining
					December 31, 2013				contractual life								December 31, 2013				contractual life
									of outstanding												of outstanding
									options (years)												options (years)
		0 -10				-				-				0 - 10				20,560				1.97
		15-Oct				380,681				2.36				10 - 15				133,117				0.9
		15 - 20				185,086				3.11				15 - 20				4,311				4.8
		20 - 25				141,192				4.05				20 - 25				80,019				3.92
		25 - 40				24,843				7.76				25 - 40				93,456				5.72
		40 - 50				25,256				8.8				40 - 50				1,468				7.7
		50 - 60				6,156				9.17				50 - 60				9,540				8.71
		60 - 70				19,088				9.76				60 - 70				1,383				9.07
		70 - 80				-				-				70 - 80				43,993				9.14
		80 - 90				-				-				80 - 90				18,788				9.78
		Total				782,302				3.46				Total				406,635				4.23
Summary of Share Plans	'
	Details with respect to shares are set out in the following table:
															USD-denominated
			EUR-denominated
	Year ended December 31		2013				2012				2011				2013				2012				2011
	Total fair value at vesting date of shares vested during the year (in thousands)			38,280				16,179				9,155				51,798				5,392				1,956
	Weighted average fair value of shares granted			55.83				36.15				28.09				83.58				47.71				39
Employee Share Issuances	'
	A summary of the status of conditionally outstanding shares as of December 31, 2013, and changes during the year ended December 31, 2013, is presented below:
											USD-denominated
			EUR-denominated
			Number of				Weighted				Number of				Weighted
			shares				average				shares				average
							fair value at grant								fair value at grant
							date (EUR)								date (USD)
	Conditional shares outstanding at January 1, 2013			1,693,610				29.92				249,094				40.71
	Granted			548,786				55.83				1,852,320	1			83.58
	Vested/Issued			-635,753				26.94				-628,802				76.12
	Forfeited			-62,311				33.4				-92,292				78.94
	Conditional shares outstanding at December 31, 2013			1,544,332				40.21				1,380,320				79.55
	1	USD-denominated grants include 1,634,990 shares with a weighted average fair value of USD 83.94 which have been assumed by ASML as part of the acquisition of Cymer.
Pension Costs	'
	Our pension and retirement expenses for all employees for the three years ended December 31, 2013, 2012 and 2011 were:
			2013				2012				2011
	Year ended December 31		EUR				EUR				EUR
	(in thousands)
	Pension plan based on multi-employer union plan			40,476				34,525				31,819
	Pension plans based on defined contribution			19,799				15,773				14,128
	Pension and retirement expenses			60,275				50,298				45,947

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of (Provision for) Benefit from Income Taxes	'
	The components of the provision for income taxes are as follows:
			2013		2012		2011
	Year ended December 31		EUR		EUR		EUR
	(in thousands)
	Current tax			-52,753		-79,255		-129,127
	Deferred tax			44,766		74,993		-52,548
	Provision for income taxes			-7,987		-4,262		-181,675
Reconciliation Between (Provision for) Benefit from Income Taxes	'
	The reconciliation of the provision for income taxes is as follows:
			2013		%		2012		%		2011		%
	Year ended December 31		EUR				EUR				EUR
	(in thousands)
	Income before income taxes			1,023,477		100		1,150,578		100		1,648,635		100
	Income tax provision based on ASML’s domestic rate			-255,869		25		-287,644		25		-412,159		25
	Effects of tax rates in foreign jurisdictions			23,459		-2.3		9,786		-0.9		20,663		-1.3
	Adjustments in respect of tax exempt income			29,430		-2.9		23,532		-2		19,134		-1.2
	Adjustments in respect of tax incentives			120,751		-11.7		143,160		-12.4		180,096		-10.9
	Adjustments in respect of prior years’ current taxes			5,155		-0.5		18,275		-1.6		9,097		-0.6
	Adjustments in respect of prior years’ deferred taxes			16,164		-1.6		-		-		-		-
	Movements in the liability for unrecognized tax benefits			-7,588		0.7		95,465		-8.3		6,634		-0.4
	Adjustment in respect of non-taxable pre-existing relationship			67,730		-6.6		-		-		-		-
	Other credits and non-taxable items			-7,219		0.7		-6,836		0.6		-5,140		0.4
	Provision for income taxes			-7,987		0.8		-4,262		0.4		-181,675		11
Income Taxes Recognized Directly in Shareholders' Equity (Including OCI)	'
	Income taxes recognized directly in shareholders’ equity (including OCI) are as follows:
			2013		2012		2011
	Income tax recognized in shareholders’ equity		EUR		EUR		EUR
	(in thousands)
	Current tax
	Derivative financial instruments1			-759		-1,066		6,257
	Tax (benefit) deficit from share-based payments			-3,110		-2,116		11
	Total income tax recognized in shareholders’ equity			-3,869		-3,182		6,268
	1	Recognized directly in OCI.
Deferred Tax Position and Liability for Unrecognized Tax Benefits Recorded on Consolidated Balance Sheets	'
	The total deferred tax position and liability for unrecognized tax benefits recorded on the Consolidated Balance Sheets are as follows:
			2013		2012
	As of December 31		EUR		EUR
	(in thousands)
	Liability for unrecognized tax benefits			-74,069		-59,967
	Deferred tax position			-30,176		114,527
	Total			-104,245		54,560
Reconciliation of Beginning and Ending Balance of Liability for Unrecognized Tax Benefits	'
	A reconciliation of the beginning and ending balance of the liability for unrecognized tax benefits is as follows:
			2013		2012
	As of December 31		EUR		EUR
	(in thousands)
	Balance, January 1			59,967		155,432
	Gross increases – tax positions in prior period			6,045		4,297
	Gross decreases – tax positions in prior period			-2,025		-92,521
	Gross increases – tax positions in current period			6,796		3,255
	Increase resulting from acquisition			6,514		-
	Settlements			-2,964		-
	Lapse of statute of limitations			-264		-10,496
	Total liability for unrecognized tax benefits			74,069		59,967
Changes in Deferred Income Tax Assets and Liabilities	'
	The changes in deferred income tax assets and liabilities consist of the following elements:
			2013		2012
	Changes in deferred tax assets and liabilities		EUR		EUR
	(in thousands)
	Balance, January 1			114,527		137,946
	Acquisitions through business combinations			-201,381		-
	Consolidated Statements of Operations			53,084		-20,242
	Effect of changes in exchange rates			3,594		-3,177
	Balance, December 31			-30,176		114,527
Deferred Tax Position	'
	The deferred tax position is classified in the consolidated balance sheets as follows:
			2013		2012
	As of December 31		EUR		EUR
	(in thousands)
	Deferred tax assets – current			124,431		103,695
	Deferred tax assets – non-current			139,513		39,443
	Total deferred tax assets			263,944		143,138
	Deferred tax liabilities – current			-3,494		-271
	Deferred tax liabilities – non-current			-290,626		-28,340
	Total deferred tax liabilities			-294,120		-28,611
	Total			-30,176		114,527
Composition of Deferred Tax Assets and Liabilities in Financial Statements	'
	The composition of total deferred tax assets and liabilities in the Financial Statements is as follows:
			January 1,		Acquisitions		Consolidated				December 31,
	Deferred tax assets composition		2013		through		Statements of		Effect of		2013
	of temporary		EUR		business		Operations		changes		EUR
	differences				combinations		EUR		in exchange
	(in thousands)				EUR				rates
									EUR
	Capitalized R&D expenditures			27,403		-		5,882		-1,155		32,130
	Inventories			28,167		10,258		9,269		-1,033		46,661
	Deferred revenue			20,572		41,679		-43,035		-2,807		16,409
	Provisions			21,528		7,148		17,960		-1,176		45,460
	Installation and warranty reserve			7,151		-		-174		-275		6,702
	Tax effect carry-forward losses			5,557		754		61,551		-580		67,282
	Fixed assets			7,798		4,140		325		-478		11,785
	Restructuring and impairment			4,336		-		-791		-184		3,361
	Alternative minimum tax credits1			5,227		-		1,349		-234		6,342
	Share-based payments			1,433		9,365		5,939		-586		16,151
	Other temporary differences			13,966		16,701		-14,487		-4,519		11,661
	Total2			143,138		90,045		43,788		-13,027		263,944
	1	Alternative minimum tax credits relate to prepaid US taxes which are credited against future taxable profits after the carry-forward losses used.
	2	Valuation allowances recognized in relation to deferred tax assets as at December 31, 2013 amounted to EUR 25.0 million (2012: EUR 30.5 million)
			January 1,		Acquisitions		Consolidated				December 31,
	Deferred tax liabilities composition		2013		through		Statements of		Effect of		2013
	of temporary		EUR		business		Operations		changes		EUR
	differences				combinations		EUR		in exchange
	(in thousands)				EUR				rates
									EUR
	Intangible fixed assets			-		-286,337		8,730		15,702		-261,905
	Fixed assets			-25,890		-4,786		12,517		567		-17,592
	Borrowing costs			-1,958		-		135		-		-1,823
	Other temporary differences			-763		-303		-12,086		352		-12,800
	Total			-28,611		-291,426		9,296		16,621		-294,120
			January 1,		Consolidated				December 31,
	Deferred tax assets composition		2012		Statements of		Effect of		2012
	of temporary		EUR		Operations		changes		EUR
	differences				EUR		in exchange
	(in thousands)						rates
							EUR
	Capitalized R&D expenditures			34,374		-6,465		-506		27,403
	Inventories			35,820		-7,351		-302		28,167
	Deferred revenue			23,892		-3,083		-237		20,572
	Provisions			14,515		7,296		-283		21,528
	Installation and warranty reserve			8,772		-1,508		-113		7,151
	Tax effect carry-forward losses			7,735		-2,219		41		5,557
	Fixed assets			6,495		1,454		-151		7,798
	Restructuring and impairment			5,146		-733		-77		4,336
	Alternative minimum tax credits1			5,028		229		-30		5,227
	Share-based payments			950		516		-33		1,433
	Other temporary differences			16,728		-1,138		-1,624		13,966
	Total			159,455		-13,002		-3,315		143,138
	1   Alternative minimum tax credits relate to prepaid US taxes which are credited against future taxable profits after the carry-forward losses used.
			January 1,		Consolidated				December 31,
	Deferred tax liabilities composition		2012		Statements of		Effect of		2012
	of temporary		EUR		Operations		changes		EUR
	differences				EUR		in exchange
	(in thousands)						rates
							EUR
	Fixed assets			-19,108		-6,965		183		-25,890
	Borrowing costs			-1,554		-404		-		-1,958
	Other temporary differences			-847		129		-45		-763
	Total			-21,509		-7,240		138		-28,611

Segment_Disclosure_Tables

Segment Disclosure (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Net Sales for New and Used Systems	'
	Management reporting includes net system sales figures of new and used systems and includes sales per technology. Net system sales for new and used systems were as follows:
		2013		2012		2011
	Year ended December 31	EUR		EUR		EUR
	(in thousands)
	New systems		3,890,154		3,620,260		4,780,720
	Used systems		102,975		181,372		103,193
	Net system sales		3,993,129		3,801,632		4,883,913
Schedule of Net System Sales Per Technology	'
	Net system sales per technology was as follows:
	Year ended December 31	Net system sales		Net system sales
	(in thousands)	in units		in EUR
	2013
	EUV		1		60,100
	ArFi		77		3,120,719
	ArF dry		2		38,019
	KrF		64		720,053
	l-line		13		54,238
	Total		157		3,993,129
	2012
	EUV		1		43,700
	ArFi		72		2,715,221
	ArF dry		4		81,428
	KrF		78		908,244
	l-line		15		53,039
	Total		170		3,801,632
	2011
	EUV		3		119,300
	ArFi		101		3,549,122
	ArF dry		11		228,909
	KrF		87		926,572
	l-line		20		60,010
	Total		222		4,883,913
Net Sales and Long-lived Assets by Geographic Region	'
	Net sales and long-lived assets (consisting of property, plant and equipment) by geographic region were as follows:
	Year ended December 31	Net sales		Long-lived
	(in thousands)	EUR		assets
				EUR
	2013
	Japan		201,664		3,340
	Korea		1,286,509		16,155
	Singapore		139,313		1,109
	Taiwan		2,221,426		48,427
	Rest of Asia		478,234		3,742
	Netherlands		11,525		969,192
	Rest of Europe		187,030		2,600
	United States		719,625		173,275
	Total		5,245,326		1,217,840
	2012
	Japan		292,309		19,585
	Korea		1,276,304		17,664
	Singapore		98,554		968
	Taiwan		1,479,768		50,372
	Rest of Asia		197,262		2,073
	Netherlands		-		869,736
	Rest of Europe		256,192		1,571
	United States		1,131,166		67,954
	Total		4,731,555		1,029,923
	2011
	Japan		405,595		69,001
	Korea		1,318,777		16,250
	Singapore		436,308		1,167
	Taiwan		1,146,601		46,418
	Rest of Asia		450,796		1,496
	Netherlands		-		851,612
	Rest of Europe		505,129		1,198
	United States		1,387,829		66,468
	Total		5,651,035		1,053,610

Selected_Operating_Expenses_an1

Selected Operating Expenses and Additional Information (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Personnel Expenses for All Payroll Employees	'
	Personnel expenses for all payroll employees were:
	Year ended December 31	2013		2012		2011
	(in thousands)	EUR		EUR		EUR
	Wages and salaries		835,563		711,039		648,869
	Social security expenses		69,839		58,180		52,550
	Pension and retirement expenses		60,275		50,298		45,947
	Share-based payments		52,371		18,714		12,430
	Personnel expenses		1,018,048		838,231		759,796
Total Number of Payroll and Temporary Personnel Employed in FTE's Per Sector	'
	The total number of payroll and temporary employees in FTEs per sector was:
		2013		2012		2011
	As of December 31
	Customer Support		2,949		2,538		2,478
	SG&A		1,098		869		723
	Industrial Engineering		785		637		420
	Manufacturing & Logistics		3,658		2,856		2,852
	R&D		4,735		3,736		3,417
	Total employees (in FTEs)		13,225		10,636		9,890
	Less: Temporary employees (in FTEs)		2,865		2,139		1,935
	Payroll employees (in FTEs)		10,360		8,497		7,955

Purchases_of_Equity_Securities1

Purchases of Equity Securities by the Issuer and Affiliated Purchasers (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Summary of Shares Repurchased	'
	The following table provides a summary of our repurchased shares in 2013:
	Period	Total		Average		Total number		Maximum
		number		price paid		of shares		value
		of shares		per Share		purchased as		of shares
		purchased		(EUR)		part of		that may yet
						publicly		be purchased
						announced plans		under the program
						or programs		(EUR)
	April 18 - 30, 2013		297,500		55.35		297,500		983,534,770
	May 2 - 31, 2013		389,974		61.76		687,474		959,449,401
	June 1 - 30, 2013		749,434		60.39		1,436,908		914,192,630
	July 1 - 31, 2013		321,486		65.2		1,758,394		893,232,250
	August 1 - 31, 2013		283,097		67.83		2,041,491		874,028,834
	September 1 - 30, 2013		179,146		69.06		2,220,637		861,656,533
	October 3 - 31, 2013		556,443		69.34		2,777,080		823,072,791
	November 1 - 30, 2013		962,146		66.76		3,739,226		758,841,727
	December 1 - 31, 2013		874,953		67.25		4,614,179		700,000,036
	Total		4,614,179		65.02

General_Information_Summary_of3

General Information / Summary of Significant Accounting Policies - Additional Information (Detail) (EUR €)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		30-May-13	Jul. 06, 2012
Significant Accounting Policies [Line Items]	'		'		'	'
Acquisition date	30-May-13		'		'	'
Acquisition percentage	'		'		100.00%	'
Voting rights required for consolidation of subsidiaries	'More than half		'		'	'
Cash and cash equivalents maturity period	'Three months or less		'		'	'
Short-term investments maturity period	'Longer than three months and less than one year		'		'	'
Date of annual goodwill impairment test	'End of the third quarter		'		'	'
Date of Annual Infinite-lived other intangibles assets	'End of the third quarter		'		'	'
Amount of repurchase commitments	'		'		'	'
Lease term	75.00%		'		'	'
Present value of minimum lease payments	90.00%		'		'	'
Standard product warranty period in months	'12 months		'		'	'
Product warranty on certain optic parts period in months	'60 months		'		'	'
Fair value based on quoted share prices	'		3,977,368		'	'
Selling price of shares included in the customer co-investment program	'		€ 39.91		'	€ 39.91
The difference between the fair value of share and the subscription price	-20,956	[1]	123,416	[2]	'	'
Tax benefit realized upon settlement	50.00%		'		'	'
Share Premium [Member]	'		'		'	'
Significant Accounting Policies [Line Items]	'		'		'	'
Fair value based on quoted share prices	'		3,968,677		'	'
The difference between the fair value of share and the subscription price	-€ 20,956	[1]	€ 123,416	[2]	'	'
Software and Software Development Costs [Member]	'		'		'	'
Significant Accounting Policies [Line Items]	'		'		'	'
Depreciation method, description	'These costs are depreciated on a straight-line basis over the period of related benefit, which ranges primarily from three to five years.		'		'	'
Software and Software Development Costs [Member] | Minimum [Member]	'		'		'	'
Significant Accounting Policies [Line Items]	'		'		'	'
Useful life	'3 years		'		'	'
Software and Software Development Costs [Member] | Maximum [Member]	'		'		'	'
Significant Accounting Policies [Line Items]	'		'		'	'
Useful life	'5 years		'		'	'
[1]	EUR 21.0 million is recognized to increase equity to the fair value of the shares issued to the Participating Customers in the CCIP. The portion of the NRE funding allocable to the shares is recognized over the NRE Funding Agreements period (2013-2017).
[2]	The difference between the fair value of the shares and the subscription price of the shares issued to the Participating Customers in the CCIP.

General_Information_Summary_of4

General Information / Summary of Significant Accounting Policies - Estimated Useful Lives of Finite-Lived Other Intangible Assets (Detail)	12 Months Ended
	Dec. 31, 2013
Brands [Member] | Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'20 years
Intellectual property [Member] | Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'3 years
Intellectual property [Member] | Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'10 years
Developed technology [Member] | Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'6 years
Developed technology [Member] | Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'15 years
Customer relationships [Member] | Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'8 years
Customer relationships [Member] | Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'18 years
Other [Member] | Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'2 years
Other [Member] | Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful life (in years)	'6 years

General_Information_Summary_of5

General Information / Summary of Significant Accounting Policies - Property, Plant and Equipment (Detail)	12 Months Ended
	Dec. 31, 2013
Buildings and constructions [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'5 years
Buildings and constructions [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'45 years
Machinery and equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'2 years
Machinery and equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'10 years
Leasehold improvements [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'5 years
Leasehold improvements [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'10 years
Furniture, fixtures and other equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'3 years
Furniture, fixtures and other equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life (in years)	'5 years

General_Information_Summary_of6

General Information / Summary of Significant Accounting Policies - Net Income Per Ordinary Share (Detail) (EUR €)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Accounting Policies [Abstract]	'		'		'
Net income	€ 1,015,490		€ 1,146,316		€ 1,466,960
Weighted average number of shares outstanding during the year (after deduction of treasury stock)	429,770		424,096		425,618
Basic net income per ordinary share	€ 2.36		€ 2.70		€ 3.45
Plus shares applicable to:	'		'		'
Options and conditional shares	3,676		2,890		3,435
Dilutive potential ordinary shares	3,676		2,890		3,435
Adjusted weighted average number of shares	433,446	[1]	426,986	[1]	429,053	[1]
Diluted net income per ordinary share	€ 2.34	[1]	€ 2.68	[1]	€ 3.42	[1]
[1]	The calculation of diluted net income per ordinary share assumes the exercise of options issued under our stock option plans and the issuance of shares under our share plans for periods in which exercises or issuances would have a dilutive effect. The calculation of diluted net income per ordinary share does not assume exercise of such options or issuance of shares when such exercises or issuance would be anti-dilutive.

Business_Combinations_Addition

Business Combinations - Additional Information (Detail) (EUR €)	0 Months Ended	7 Months Ended	12 Months Ended
	30-May-13	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
			System
Business Acquisition [Line Items]	'	'	'	'
Acquisition date	'	'	30-May-13	'
Acquisition percentage	100.00%	'	'	'
Consideration transferred	€ 3,097,458,000	'	'	'
Contingent consideration arrangements, description	'0	'	'	'
Name of acquired entity	'Cymer	'	'Cymer	'
Description of acquired entity	'Cymer was an industry leader in developing and servicing lithography light sources used by chip manufacturers worldwide to pattern advanced semiconductor chips.	'	'	'
Business combination, reason for business combination	'The acquisition of Cymer will support our strategic objective of delivering an economically viable EUV scanner to semiconductor manufacturers within the timeline required by our customers. In addition, there are opportunities to further enhance Cymer's growing advanced immersion systems and related installed base products business.	'	'	'
Business Acquisition, Preexisting Relationship, Description	'	'	'Prior to the acquisition, supply and R&D arrangements existed between Cymer and ASML. These pre-existing relationships were effectively settled as a result of the acquisition. We determined that the R&D arrangement as well as the DUV supply arrangements were at current market terms and therefore no gain or loss was recognized. We determined that the EUV supply arrangements were favorable to ASML and therefore a gain of EUR 178.4 million was recognized in cost of sales within our Consolidated Statements of Operations. This gain was recognized separately from the business combination as it is not part of the assets acquired or liabilities assumed. The approach for quantifying the favorable component to ASML of the EUV supply arrangements is based on the assessment of the prices for such light sources if the EUV supply arrangements would have been renegotiated in May 2013.	'
Gain on settlement of pre-existing relationships	178,427,000	178,427,000	178,427,000	'
Number of EUV sources upgraded	'	'	11	'
Goodwill, expected tax deductible amount	'	0	0	'
Net sales from Acquiree	'	178,700,000	'	'
Net income loss from acquiree	'	138,500,000	'	'
Purchase price allocation adjustments	'	85,500,000	85,500,000	'
Start of pro forma period	'	'	'	1-Jan-12
Business acquisition, transaction costs	'	7,800,000	7,800,000	'
Accrued and Other Liabilities [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Cost of the liability	'	'	€ 171,200,000	'

Business_Combinations_Summariz

Business Combinations - Summarizes Major Classes of Consideration Transferred, and Recognized Amounts of Fair Value of Identifiable Assets Distributed and Fair Value of Liabilities Incurred or Assumed at Acquisition Date (Detail) (EUR €)	0 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	30-May-13	Dec. 31, 2013		Dec. 31, 2012
Business Acquisition [Line Items]	'	'		'
Cash and cash equivalents	€ 84,129	'		'
Short-term investments	40,055	'		'
Current tax assets	37,289	'		'
Inventories, net	301,279	'		'
Deferred tax assets	90,045	90,045	[1]	'
Other assets, current and non-current	29,418	'		'
Other intangible assets, net	751,542	'		'
Property, plant and equipment, net	124,308	124,308		'
Assets acquired	1,580,071	'		'
Accounts payable	151,412	'		'
Accrued and other liabilities, current and non-current	90,900	'		'
Deferred and other tax liabilities	297,977	'		'
Long-term debt, current and non-current	609	'		'
Liabilities assumed	540,898	'		'
Total net identifiable assets	1,039,173	'		'
Consideration paid in cash for the transaction on May 30, 2013	486,325	'		'
Fair value of shares	2,347,663	'		'
Fair value of equity awards cash settled	41,516	'		'
Fair value of unvested equity awards to be exchanged	43,527	43,527		'
Gain on settlement of pre-existing relationships	178,427	178,427		'
Consideration transferred	3,097,458	'		'
Goodwill on acquisition	2,058,285	2,058,285		6,038
Accounts Receivable [Member]	'	'		'
Business Acquisition [Line Items]	'	'		'
Accounts receivable, net	121,395	'		'
Financing Receivables [Member]	'	'		'
Business Acquisition [Line Items]	'	'		'
Accounts receivable, net	€ 611	'		'
[1]	Valuation allowances recognized in relation to deferred tax assets as at December 31, 2013 amounted to EUR 25.0 million (2012: EUR 30.5 million)

Business_Combinations_Summariz1

Business Combinations - Summarizes Major Classes of Consideration Transferred, and Recognized Amounts of Fair Value of Identifiable Assets Distributed and Fair Value of Liabilities Incurred or Assumed at Acquisition Date (Parenthetical) (Detail) (EUR €)	0 Months Ended	12 Months Ended
	30-May-13	Dec. 31, 2013
Business Acquisition [Line Items]	'	'
Currency conversion rate USD/EUR	1.3043	'
Right to receive ordinary shares	36,479,109	'
Ordinary Shares, opening price	€ 83.94	'
Acquisition date	'	30-May-13
Ordinary Shares to be Issued [Member]	'	'
Business Acquisition [Line Items]	'	'
Right to receive ordinary shares	'	14,533

Business_Combinations_Summary_

Business Combinations - Summary of Estimated Consolidated Pro Forma Information (Detail) (EUR €)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Combinations [Abstract]	'	'
Total net sales	€ 5,362	€ 5,053
Net income	€ 1,031	€ 965

Business_Combinations_Summary_1

Business Combinations - Summary of Estimated Consolidated Pro Forma Information (Parenthetical) (Detail) (EUR €)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition Pro Forma Information [Line Items]	'	'
Net income	€ 1,031	€ 965
Acquisition-Related Costs [Member]	'	'
Business Acquisition Pro Forma Information [Line Items]	'	'
Net income	30	15
Fair Value Adjustment to Inventory [Member]	'	'
Business Acquisition Pro Forma Information [Line Items]	'	'
Net income	€ 60	€ 60

Fair_Value_Measurements_Financ

Fair Value Measurements - Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets	'	'
Derivative financial instruments	€ 71,620	€ 151,748
Liabilities	'	'
Long-term debt	1,021,900	710,100
Derivative financial instruments	11,652	10,893
Fair Value, Measurements, Recurring [Member]	'	'
Assets	'	'
Derivative financial instruments	71,620	151,748
Money market funds	535,000	385,420
Short-term investments	679,884	930,005
Total	1,286,504	1,467,173
Liabilities	'	'
Long-term debt	1,021,930	759,490
Derivative financial instruments	11,652	10,893
Total	1,033,582	770,383
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Assets	'	'
Derivative financial instruments	'	'
Money market funds	535,000	385,420
Short-term investments	304,884	279,988
Total	839,884	665,408
Liabilities	'	'
Long-term debt	'	'
Derivative financial instruments	'	'
Total	'	'
Level 2 [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Assets	'	'
Derivative financial instruments	71,620	151,748
Money market funds	'	'
Short-term investments	375,000	650,017
Total	446,620	801,765
Liabilities	'	'
Long-term debt	1,021,930	759,490
Derivative financial instruments	11,652	10,893
Total	1,033,582	770,383
Level 3 [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Assets	'	'
Derivative financial instruments	'	'
Money market funds	'	'
Short-term investments	'	'
Total	'	'
Liabilities	'	'
Long-term debt	'	'
Derivative financial instruments	'	'
Total	'	'

Fair_Value_Measurements_Financ1

Fair Value Measurements - Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]	'	'
Carrying amount	€ 1,021.90	€ 710.10

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Transfers between levels	€ 0	€ 0	'
Impairment charges on property, plant and equipment	13,057,000	3,234,000	12,300,000
Estimated fair value of assets	16,400,000	100,000	1,900,000
Impairment of goodwill and other intangible asset	0	'	'
Buildings [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Impairment charges on property, plant and equipment	3,600,000	'	'
Machinery and equipment [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Impairment charges on property, plant and equipment	€ 7,997,000	€ 906,000	'

Financial_Risk_Management_Addi

Financial Risk Management - Additional Information (Detail)

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

EUR (€)

EUR (€)

EUR (€)

Forward Foreign Exchange Contracts [Member]

Forward Foreign Exchange Contracts [Member]

Forward Foreign Exchange Contracts [Member]

Forward Foreign Exchange Contracts [Member]

Forward Foreign Exchange Contracts [Member]

Forward Foreign Exchange Contracts [Member]

Interest Rate Swaps [Member]

Interest Rate Swaps [Member]

Cost of sales [Member]

Cost of sales [Member]

Sales [Member]

Sales [Member]

USD ($)

EUR (€)

JPY (¥)

USD ($)

EUR (€)

JPY (¥)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

Derivative Instruments, Gain (Loss) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain (loss) on financial instruments, net of taxes

-€ 7,646,000

-€ 7,547,000

€ 47,353,000

'

'

'

'

'

'

'

'

-€ 9,500,000

-€ 5,300,000

€ 0

€ 4,300,000

Total anticipated income (loss) to be released to sales/cost of sales

'

'

'

'

'

'

'

'

'

'

'

-10,700,000

'

'

'

Gain (Loss) on foreign currency cash flow hedge ineffectiveness

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative instruments release period

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Financial instruments, Notional amount

'

'

'

1,144,000,000

986,986,000

2,200,000,000

159,800,000

262,146,000

8,400,000,000

1,013,053,000

624,900,000

'

'

'

'

Gain (Loss) in Consolidated Statements of Operations resulting from effective cash flow hedge

2,300,000

8,700,000

-58,100,000

'

'

'

'

'

'

'

'

'

'

'

'

Gain (Loss) from derivative financial instruments measured at fair value

€ 62,500,000

€ 3,000,000

-€ 38,300,000

'

'

'

'

'

'

'

'

'

'

'

'

Financial_Risk_Management_Summ

Financial Risk Management - Summary of Notional Amounts and Estimated Fair Values of Financial Instruments (Detail)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	EUR (€)	EUR (€)	Forward Foreign Exchange Contracts [Member]	Forward Foreign Exchange Contracts [Member]	Forward Foreign Exchange Contracts [Member]	Forward Foreign Exchange Contracts [Member]	Forward Foreign Exchange Contracts [Member]	Forward Foreign Exchange Contracts [Member]	Interest Rate Swaps [Member]	Interest Rate Swaps [Member]
			USD ($)	EUR (€)	JPY (¥)	USD ($)	EUR (€)	JPY (¥)	EUR (€)	EUR (€)
Derivative [Line Items]	'	'	'	'	'	'	'	'	'	'
Financial instruments, Notional amount	'	'	$1,144,000	€ 986,986	¥ 2,200,000	$159,800	€ 262,146	¥ 8,400,000	€ 1,013,053	€ 624,900
Forward foreign exchange contracts, Fair Value	8,583	16,805	'	'	'	'	'	'	'	'
Interest rate swaps, Fair Value	€ 51,385	€ 124,050	'	'	'	'	'	'	'	'

Financial_Risk_Management_Deri

Financial Risk Management - Derivative Financial Instruments Per Category (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Derivative [Line Items]	'	'
Derivative Assets	€ 71,620	€ 151,748
Derivative Assets, Noncurrent	30,777	101,651
Derivative Assets, Current	40,843	50,097
Derivative Liabilities	11,652	10,893
Derivative Liabilities, Noncurrent	2,608	4,032
Derivative Liabilities, Current	9,044	6,861
Cash Flow Hedging [Member] | Interest Rate Swaps [Member]	'	'
Derivative [Line Items]	'	'
Derivative Assets	'	'
Derivative Assets, Noncurrent	'	'
Derivative Liabilities	3,598	4,780
Derivative Liabilities, Noncurrent	2,608	4,032
Cash Flow Hedging [Member] | Forward Foreign Exchange Contracts [Member]	'	'
Derivative [Line Items]	'	'
Derivative Assets	3	5,975
Derivative Liabilities	6,039	5,688
Fair Value Hedging [Member] | Interest Rate Swaps [Member]	'	'
Derivative [Line Items]	'	'
Derivative Assets	54,983	128,830
Derivative Assets, Noncurrent	30,777	101,651
Derivative Liabilities	'	'
Derivative Liabilities, Noncurrent	'	'
Other Hedges [Member] | Forward Foreign Exchange Contracts [Member]	'	'
Derivative [Line Items]	'	'
Derivative Assets	16,634	16,943
Derivative Liabilities	€ 2,015	€ 425

Cash_and_Cash_Equivalents_and_2

Cash and Cash Equivalents and Short-term Investments - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cash and cash equivalents	€ 2,330,694,000	€ 1,767,596,000	€ 2,731,782,000	€ 1,949,834,000
Cash and cash equivalents maturity period	'Three months or less	'	'	'
Restricted cash and cash equivalents	4,700,000	'	'	'
Deposits [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cash and cash equivalents	853,500,000	775,600,000	'	'
Investments in money market funds [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cash and cash equivalents	535,000,000	385,400,000	'	'
Interest-bearing bank accounts [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cash and cash equivalents	€ 942,200,000	€ 606,600,000	'	'
Minimum [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Maturity period of short-term investments	'3 Months	'	'	'
Maximum [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Maturity period of short-term investments	'1 Year	'	'	'

Cash_and_Cash_Equivalents_and_3

Cash and Cash Equivalents and Short-term Investments - Short-term Investments (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]	'	'
Cost basis	€ 679,884	€ 930,005
Unrealized Gains	'	'
Unrealized Losses	'	'
Recorded Basis	679,884	930,005
Treasury certificates at cost [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cost basis	304,884	279,988
Unrealized Gains	'	'
Unrealized Losses	'	'
Recorded Basis	304,884	279,988
Deposits [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cost basis	375,000	650,017
Unrealized Gains	'	'
Unrealized Losses	'	'
Recorded Basis	€ 375,000	€ 650,017

Accounts_Receivable_Accounts_R

Accounts Receivable - Accounts Receivable (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Receivables [Abstract]	'	'	'
Accounts receivable, gross	€ 880,169	€ 607,359	'
Allowance for doubtful receivables	-1,848	-2,071	-2,582
Accounts receivable, net	€ 878,321	€ 605,288	'

Accounts_Receivable_Allowance_

Accounts Receivable - Allowance for Doubtful Receivables (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Receivables [Abstract]	'		'		'
Allowance for doubtful receivables, Beginning Balance	-€ 2,071		-€ 2,582		'
Addition for the year	-1,062	[1]	-458	[1]	-849
Utilization of the provision	1,285		969		'
Allowance for doubtful receivables, Ending Balance	-€ 1,848		-€ 2,071		-€ 2,582
[1]	The addition for the year is recorded in the cost of sales.

Finance_Receivables_Components

Finance Receivables - Components of Finance Receivables (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Financing Receivables [Line Items]	'	'
Finance receivables, gross	€ 302,977	€ 309,616
Unearned interest	-6,488	-5,828
Finance receivables, net	296,489	303,788
Current portion of finance receivables, gross	254,227	268,617
Non-current portion of finance receivables, net	46,017	38,621
Current Portion of Unearned Interest [Member]	'	'
Financing Receivables [Line Items]	'	'
Unearned interest	-€ 3,755	-€ 3,450

Finance_Receivables_Finance_Re

Finance Receivables - Finance Receivables Due for Payment (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Receivables [Abstract]	'	'
2014	€ 254,227	'
2015	'	'
2016	6,150	'
2017	36,450	'
2018	6,150	'
Thereafter	'	'
Finance receivables, gross	€ 302,977	€ 309,616

Finance_Receivables_Additional

Finance Receivables - Additional Information (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]	'	'
Expected credit losses from finance receivables recorded	€ 0	€ 0

Inventories_Inventories_Detail

Inventories - Inventories (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'	'
Raw materials	€ 438,853	€ 307,315	'
Work-in-process	1,549,119	1,074,042	'
Finished products	666,648	742,979	'
Inventories, gross	2,654,620	2,124,336	'
Allowance for obsolescence and/or lower market value	-261,598	-267,366	-193,513
Inventories, net	€ 2,393,022	€ 1,856,970	'

Inventories_Allowance_for_Obso

Inventories - Allowance for Obsolescence and/or Lower Market Values (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Inventory Disclosure [Abstract]	'	'	'
Allowance for obsolescence and/or lower market value	-€ 267,366	-€ 193,513	'
Addition for the year	-164,852	-130,911	-60,300
Effect of changes in exchange rates	2,532	1,009	'
Utilization of the provision	168,088	56,049	'
Allowance for obsolescence and/or lower market value	-€ 261,598	-€ 267,366	-€ 193,513

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Inventory [Line Items]	'	'	'
Addition for the year	€ 164,852,000	€ 130,911,000	€ 60,300,000
Profit on sale of inventories previously written down	0	2,300,000	'
Cost of sales [Member]	'	'	'
Inventory [Line Items]	'	'	'
Addition for the year	155,400,000	125,200,000	'
Research and development costs [Member]	'	'	'
Inventory [Line Items]	'	'	'
Addition for the year	€ 9,500,000	€ 5,700,000	'

Other_Assets_Other_Current_Ass

Other Assets - Other Current Assets (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Advance payments to Zeiss	€ 99,415	€ 70,257
Prepaid expenses	100,077	64,708
Derivative financial instruments	40,843	50,097
VAT	67,381	25,215
Other receivables	28,705	35,728
Other current assets	€ 336,421	€ 246,005

Other_Assets_Additional_Inform

Other Assets - Additional Information (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Prepaid income taxes on intercompany profit, not realized	€ 45.40	€ 29.80

Other_Assets_Other_Noncurrent_

Other Assets - Other Non-current Assets (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Advance payments to Zeiss	€ 224,123	€ 183,025
Derivative financial instruments	30,777	101,651
Compensation plan assets	20,174	12,080
Prepaid expenses	10,950	4,462
Subordinated loan granted to lessor in respect of Veldhoven headquarters	5,445	5,445
Other	7,090	4,875
Other non-current assets	€ 298,559	€ 311,538

Goodwill_Goodwill_Detail

Goodwill - Goodwill (Detail) (EUR €)	0 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	30-May-13	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Goodwill, Beginning balance	'	€ 149,168	€ 146,044
Acquisition through business combinations	2,058,285	2,058,285	6,038
Effect of changes in exchange rates	'	-118,864	-2,914
Goodwill, Ending balance	'	€ 2,088,589	€ 149,168

Goodwill_Additional_Informatio

Goodwill - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Period of annual goodwill impairment test	'The end of the third quarter	'
Impairment charges of goodwill	'	'

Other_Intangible_Assets_Finite

Other Intangible Assets - Finite-Lived Other Intangible Assets (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]	'	'	'
Cost, Beginning Balance	€ 114,903	€ 107,245	'
Acquisitions through business combinations	604,057	'	'
Additions	4,000	7,658	'
Cost, Ending Balance	689,947	114,903	107,245
Accumulated amortization, Beginning Balance	104,960	98,879	'
Amortization	27,562	6,081	5,300
Accumulated amortization, Ending Balance	131,739	104,960	98,879
Carrying amount	558,208	9,943	'
Cost [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-33,013	'	'
Accumulated amortization [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-783	'	'
Brands [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Cost, Beginning Balance	'	'	'
Acquisitions through business combinations	13,280	'	'
Additions	'	'	'
Cost, Ending Balance	12,554	'	'
Accumulated amortization, Beginning Balance	'	'	'
Amortization	382	'	'
Accumulated amortization, Ending Balance	369	'	'
Carrying amount	12,185	'	'
Brands [Member] | Cost [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-726	'	'
Brands [Member] | Accumulated amortization [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-13	'	'
Intellectual property [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Cost, Beginning Balance	54,908	47,250	'
Acquisitions through business combinations	'	'	'
Additions	4,000	7,658	'
Cost, Ending Balance	58,908	54,908	'
Accumulated amortization, Beginning Balance	48,028	47,228	'
Amortization	2,135	800	'
Accumulated amortization, Ending Balance	50,163	48,028	'
Carrying amount	8,745	6,880	'
Intellectual property [Member] | Cost [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	'	'	'
Intellectual property [Member] | Accumulated amortization [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	'	'	'
Developed technology [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Cost, Beginning Balance	49,031	49,031	'
Acquisitions through business combinations	427,797	'	'
Additions	'	'	'
Cost, Ending Balance	453,448	49,031	'
Accumulated amortization, Beginning Balance	48,351	44,271	'
Amortization	18,694	4,080	'
Accumulated amortization, Ending Balance	66,449	48,351	'
Carrying amount	386,999	680	'
Developed technology [Member] | Cost [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-23,380	'	'
Developed technology [Member] | Accumulated amortization [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-596	'	'
Customer relationships [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Cost, Beginning Balance	8,733	8,733	'
Acquisitions through business combinations	162,980	'	'
Additions	'	'	'
Cost, Ending Balance	162,806	8,733	'
Accumulated amortization, Beginning Balance	6,369	5,277	'
Amortization	6,332	1,092	'
Accumulated amortization, Ending Balance	12,527	6,369	'
Carrying amount	150,279	2,364	'
Customer relationships [Member] | Cost [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-8,907	'	'
Customer relationships [Member] | Accumulated amortization [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	-174	'	'
Other [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Cost, Beginning Balance	2,231	2,231	'
Acquisitions through business combinations	'	'	'
Additions	'	'	'
Cost, Ending Balance	2,231	2,231	'
Accumulated amortization, Beginning Balance	2,212	2,103	'
Amortization	19	109	'
Accumulated amortization, Ending Balance	2,231	2,212	'
Carrying amount	0	19	'
Other [Member] | Cost [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	'	'	'
Other [Member] | Accumulated amortization [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Effect of changes in exchange rates	'	'	'

Other_Intangible_Assets_Additi

Other Intangible Assets - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]	'	'	'
Weighted-average amortization period	'15 years 2 months 12 days	'	'
Intellectual property acquired from third parties	€ 4,000,000	€ 7,658,000	'
Amortization	27,562,000	6,081,000	5,300,000
Impairment charges	0	0	0
Intellectual property [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Intellectual property acquired from third parties	4,000,000	7,658,000	'
Amortization	2,135,000	800,000	'
Cost of sales [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Amortization	27,000,000	6,000,000	5,300,000
Research and development costs [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Amortization	€ 600,000	€ 100,000	'

Other_Intangible_Assets_Weight

Other Intangible Assets - Weighted-Average Amortization Period for Finite-Lived Other Intangible Assets Acquired (Detail)	12 Months Ended
	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]	'
Weighted-average amortization period	'15 years 2 months 12 days
Brands [Member]	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Weighted-average amortization period	'20 years
Developed technology [Member]	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Weighted-average amortization period	'14 years
Customer relationships [Member]	'
Acquired Finite-Lived Intangible Assets [Line Items]	'
Weighted-average amortization period	'17 years 10 months 24 days

Other_Intangible_Assets_Indefi

Other Intangible Assets - Indefinite-Lived Other Intangible Assets (Detail) (In-process R&D [Member], EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
In-process R&D [Member]	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'
Cost, Beginning Balance	'	'
Acquisitions through business combinations	147,485	'
Additions	'	'
Effect of changes in exchange rates	-8,059	'
Cost, Ending Balance	€ 139,426	'

Other_Intangible_Assets_Future

Other Intangible Assets - Future Amortization Expenses (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Intangible Assets [Line Items]	'	'
Amortization expenses	€ 697,634	€ 9,943
2014 [Member]	'	'
Intangible Assets [Line Items]	'	'
Amortization expenses	42,227	'
2015 [Member]	'	'
Intangible Assets [Line Items]	'	'
Amortization expenses	41,317	'
2016 [Member]	'	'
Intangible Assets [Line Items]	'	'
Amortization expenses	52,753	'
2017 [Member]	'	'
Intangible Assets [Line Items]	'	'
Amortization expenses	51,958	'
2018 [Member]	'	'
Intangible Assets [Line Items]	'	'
Amortization expenses	50,619	'
Thereafter [Member]	'	'
Intangible Assets [Line Items]	'	'
Amortization expenses	€ 458,760	'

Property_Plant_and_Equipment_P

Property, Plant and Equipment - Property, Plant and Equipment (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	30-May-13
Cost	'	'	'	'
Beginning Balance	€ 2,089,419	€ 2,057,803	'	'
Acquisitions through business combinations	124,308	'	'	124,308
Additions	339,252	386,295	'	'
Disposals	-92,519	-348,563	'	'
Effect of changes in exchange rates	-27,342	-6,116	'	'
Ending Balance	2,433,118	2,089,419	2,057,803	'
Accumulated depreciation and impairment	'	'	'	'
Beginning Balance	1,059,496	1,004,193	'	'
Depreciation	197,053	179,253	158,000	'
Impairment charges	13,057	3,234	12,300	'
Disposals	-44,178	-123,375	'	'
Effect of changes in exchange rates	-10,150	-3,809	'	'
Ending Balance	1,215,278	1,059,496	1,004,193	'
Carrying amount	'	'	'	'
Carrying amount	1,217,840	1,029,923	1,053,610	'
Land, buildings and constructions [Member]	'	'	'	'
Cost	'	'	'	'
Beginning Balance	847,033	742,141	'	'
Acquisitions through business combinations	71,040	'	'	'
Additions	123,646	106,234	'	'
Disposals	-14	-347	'	'
Effect of changes in exchange rates	-6,605	-995	'	'
Ending Balance	1,035,100	847,033	'	'
Accumulated depreciation and impairment	'	'	'	'
Beginning Balance	187,272	155,877	'	'
Depreciation	47,791	31,598	'	'
Impairment charges	3,619	649	'	'
Disposals	-5	-347	'	'
Effect of changes in exchange rates	-1,116	-505	'	'
Ending Balance	237,561	187,272	'	'
Carrying amount	'	'	'	'
Carrying amount	797,539	659,761	'	'
Machinery and equipment [Member]	'	'	'	'
Cost	'	'	'	'
Beginning Balance	690,759	764,023	'	'
Acquisitions through business combinations	48,965	'	'	'
Additions	171,895	248,429	'	'
Disposals	-90,244	-317,022	'	'
Effect of changes in exchange rates	-17,490	-4,671	'	'
Ending Balance	803,885	690,759	'	'
Accumulated depreciation and impairment	'	'	'	'
Beginning Balance	417,982	401,800	'	'
Depreciation	114,677	110,571	'	'
Impairment charges	7,997	906	'	'
Disposals	-42,625	-92,205	'	'
Effect of changes in exchange rates	-8,068	-3,090	'	'
Ending Balance	489,963	417,982	'	'
Carrying amount	'	'	'	'
Carrying amount	313,922	272,777	'	'
Leasehold improvements [Member]	'	'	'	'
Cost	'	'	'	'
Beginning Balance	214,852	206,660	'	'
Acquisitions through business combinations	1,057	'	'	'
Additions	11,543	8,883	'	'
Disposals	-336	-300	'	'
Effect of changes in exchange rates	-1,464	-391	'	'
Ending Balance	225,652	214,852	'	'
Accumulated depreciation and impairment	'	'	'	'
Beginning Balance	158,778	145,775	'	'
Depreciation	12,415	13,416	'	'
Impairment charges	1,352	'	'	'
Disposals	-266	-248	'	'
Effect of changes in exchange rates	-422	-165	'	'
Ending Balance	171,857	158,778	'	'
Carrying amount	'	'	'	'
Carrying amount	53,795	56,074	'	'
Furniture, fixtures and other equipment [Member]	'	'	'	'
Cost	'	'	'	'
Beginning Balance	336,775	344,979	'	'
Acquisitions through business combinations	3,246	'	'	'
Additions	32,168	22,749	'	'
Disposals	-1,925	-30,894	'	'
Effect of changes in exchange rates	-1,783	-59	'	'
Ending Balance	368,481	336,775	'	'
Accumulated depreciation and impairment	'	'	'	'
Beginning Balance	295,464	300,741	'	'
Depreciation	22,170	23,668	'	'
Impairment charges	89	1,679	'	'
Disposals	-1,282	-30,575	'	'
Effect of changes in exchange rates	-544	-49	'	'
Ending Balance	315,897	295,464	'	'
Carrying amount	'	'	'	'
Carrying amount	€ 52,584	€ 41,311	'	'

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (EUR €)

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2003

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Variable Interest Entity [Member]

Variable Interest Entity [Member]

Variable Interest Entity [Member]

Cost of sales [Member]

Cost of sales [Member]

Cost of sales [Member]

Research and development costs [Member]

Research and development costs [Member]

Research and development costs [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Land, buildings and constructions [Member]

Land, buildings and constructions [Member]

Machinery and equipment [Member]

Machinery and equipment [Member]

Machinery and equipment [Member]

Machinery and equipment [Member]

Leasehold improvements [Member]

Leasehold improvements [Member]

Furniture, fixtures and other equipment [Member]

Furniture, fixtures and other equipment [Member]

Buildings [Member]

Machinery and Equipment Furniture, Fixtures and Other Equipment [Member]

Property Subject to Evaluation and Operating Lease [Member]

Property Subject to Evaluation and Operating Lease [Member]

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets under construction in carrying amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 49,300,000

€ 5,500,000

€ 35,900,000

€ 21,800,000

'

'

€ 1,000,000

€ 1,000,000

€ 9,300,000

€ 13,900,000

'

'

Land

79,200,000

60,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additions related to non-cash transfer from inventory

115,900,000

204,800,000

300,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other non-cash movements

12,500,000

9,600,000

17,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Disposals related to non-cash transfer to inventory

48,200,000

222,900,000

145,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges

13,057,000

3,234,000

12,300,000

'

'

'

6,300,000

1,000,000

6,200,000

6,700,000

500,000

3,500,000

100,000

1,700,000

2,600,000

3,619,000

649,000

7,997,000

906,000

'

'

1,352,000

'

1,700,000

'

3,600,000

9,500,000

Estimated fair value of assets, value used to determine amount of impairment charge

16,400,000

100,000

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Carrying amount

1,217,840,000

1,029,923,000

1,053,610,000

'

'

'

'

'

'

'

'

'

'

'

'

797,539,000

659,761,000

313,922,000

272,777,000

36,700,000

82,200,000

53,795,000

56,074,000

'

'

'

'

Depreciation

197,053,000

179,253,000

158,000,000

'

'

'

144,100,000

147,700,000

117,700,000

35,000,000

15,300,000

24,900,000

18,000,000

16,300,000

15,400,000

47,791,000

31,598,000

114,677,000

110,571,000

'

'

12,415,000

13,416,000

'

'

'

'

VIE carrying amount

'

'

'

'30.9

'32.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease period of property relating to the variable interest entity

'

'

'

'

'

'15 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lessor's shareholders equity relating to the variable interest entity

'

'

'

'

'

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loans from Shareholders relating to the variable interest entity

'

'

'

'

'

11,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan from bank relating to the variable interest entity

'

'

'

'

'

12,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total amount of granted loan relating to the variable interest entity

'

'

'

'

'

47,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subordinated loan by ASML to parent of the lessor relating to the variable interest entity

'

'

'

'

'

5,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of purchase option relating to the variable interest entity at end of lease

'

'

'

'

'

24,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total assets of the lessor relating to the variable interest entity at inception of the lease

'

'

'

'

'

€ 54,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date of purchase option relating to the variable interest entity

'

'

'

'

'

'2018

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Use of buildings relating to the variable interest entity

'

'

'

'

'

'15 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued_and_Other_Liabilities_1

Accrued and Other Liabilities - Accrued and Other Liabilities (Detail) (EUR €)	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'		'		'
Deferred revenue	€ 939,358		€ 739,136		'
Costs to be paid	440,010		278,066		'
Down payments from customers	821,959		1,033,768		'
Personnel related items	247,246		200,670		'
Derivative financial instruments	11,652		10,893		'
Standard warranty reserve	27,475		21,626		43,273
Other	12,324		1,352		'
Accrued and other liabilities	2,500,024		2,285,511		'
Less: non-current portion of accrued and other liabilities	283,142	[1]	405,141	[1]	'
Current portion of accrued and other liabilities	€ 2,216,882		€ 1,880,370		'
[1]	The main part of the non-current portion of accrued and other liabilities relates to down payments received from customers regarding future shipments of EUV systems and deferrals with respect to services.

Accrued_and_Other_Liabilities_2

Accrued and Other Liabilities - Additional Information (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	€ 939,358	€ 739,136
Costs to be paid	440,010	278,066
Award credits regarding free or discounted products or services [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	660,100	581,500
Prepaid extended and enhanced (optic) warranty contracts [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue	261,200	242,200
Related to EUV upgrade [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Costs to be paid	€ 171,200	'

Accrued_and_Other_Liabilities_3

Accrued and Other Liabilities - Changes in Standard Warranty Reserve (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Payables And Accruals [Abstract]	'	'
Balance, January 1	€ 21,626	€ 43,273
Acquisitions through business combinations	2,978	'
Additions for the year	37,124	35,735
Utilization of the reserve	-19,924	-33,746
Release of the reserve	-13,076	-22,733
Effect of exchange rates	-1,253	-903
Standard warranty reserve	€ 27,475	€ 21,626

Provisions_Movement_in_Provisi

Provisions - Movement in Provision for Lease Contract Termination Costs (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]	'	'
Less: current portion of provision for lease contract termination costs	€ 2,227	€ 2,280
Non-current portion of provision for lease contract termination costs	4,620	7,974
Lease contract termination costs [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Provision for lease contract termination costs, Beginning Balance	10,254	12,338
Utilization of the provision	-2,790	-2,545
Release of the provision	-1,011	'
Unwinding of discount	391	628
Effect of exchange rates	3	-167
Provision for lease contract termination costs, Ending Balance	6,847	10,254
Less: current portion of provision for lease contract termination costs	2,227	2,280
Non-current portion of provision for lease contract termination costs	€ 4,620	€ 7,974

Provisions_Additional_Informat

Provisions - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Operating lease contract for a building, expected economic benefits	€ 0
Lease expiration date	'2017

Longterm_Debt_Components_of_Lo

Long-term Debt - Components of Long-Term Debt (Detail) (EUR €)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Debt [Line Items]	'		'
Carrying amount	€ 1,021,900		€ 710,100
Loan headquarter building	30,936	[1]	32,366	[1]
Other	21,704		17,029
Long-term debt	1,074,570		759,490
Less: current portion of long-term debt	4,385		3,610
Non-current portion of long-term debt	1,070,185		755,880
5.75 Percent senior notes due 2017 [Member]	'		'
Debt [Line Items]	'		'
Carrying amount	270,339		710,095
3.375 Percent Senior Notes Due 2023 [Member]	'		'
Debt [Line Items]	'		'
Carrying amount	€ 751,591		'
[1]	This loan relates to our VIE, see Note 12.

Longterm_Debt_Components_of_Lo1

Long-term Debt - Components of Long-Term Debt (Parenthetical) (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2007	Dec. 31, 2013	Sep. 30, 2013
In Millions, unless otherwise specified		5.75 Percent senior notes due 2017 [Member]	5.75 Percent senior notes due 2017 [Member]	5.75 Percent senior notes due 2017 [Member]	3.375 Percent Senior Notes Due 2023 [Member]	3.375 Percent Senior Notes Due 2023 [Member]
Debt [Line Items]	'	'	'	'	'	'
Principal amount	€ 600	€ 600	€ 600	€ 600	€ 750	€ 750
Interest rate on principal amount	5.75%	5.75%	5.75%	'	3.38%	3.38%
Year of maturity	'	'2017	'2017	'	'2023	'

Longterm_Debt_Principal_Repaym

Long-term Debt - Principal Repayments and Other Borrowing Arrangements (Detail) (EUR €)	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'
2014	€ 4,385
2015	4,252
2016	4,211
2017	242,361
2018	27,997
Thereafter	757,467
Long-term debt	1,040,673
Less: current portion of long-term debt	4,385
Non-current portion of long-term debt	€ 1,036,288

Longterm_Debt_Summary_of_Carry

Long-term Debt - Summary of Carrying Amount of Outstanding Eurobonds and Fair Value of Interest Rate Swaps (Detail) (EUR €)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'		'
Carrying amount	€ 1,021,900		€ 710,100
Eurobonds [Member]	'		'
Debt Instrument [Line Items]	'		'
Carrying amount	1,021,930		710,095
Eurobonds [Member] | Amortized Costs Amount [Member]	'		'
Debt Instrument [Line Items]	'		'
Carrying amount	981,291		600,000
Eurobonds [Member] | Fair Value Adjustment Interest Rate Swaps [Member]	'		'
Debt Instrument [Line Items]	'		'
Carrying amount	€ 40,639	[1]	€ 110,095	[1]
[1]	The fair value of the interest rate swaps excludes accrued interest.

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (EUR €)	12 Months Ended					1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Jun. 30, 2007	Sep. 30, 2013	Dec. 31, 2013
		5.75 Percent senior notes due 2017 [Member]	5.75 Percent senior notes due 2017 [Member]	5.75 Percent senior notes due 2017 [Member]	5.75 Percent senior notes due 2017 [Member]	3.375 Percent Senior Notes Due 2023 [Member]	3.375 Percent Senior Notes Due 2023 [Member]
Principal amount	€ 600	€ 600	'	€ 600	€ 600	€ 750	€ 750
Interest rate on principal amount of Eurobond	5.75%	5.75%	'	5.75%	'	3.38%	3.38%
Payment date of Eurobond interest	'	'June 13	'	'	'	'September 19	'
Redemption price of notes	'	100.00%	'	'	'	100.00%	'
Due date of redemption Eurobond	'	13-Jun-17	'	'	'	19-Sep-23	'
Year of maturity	'2017	'2017	'	'	'	'2023	'2023
Repurchased of long term debt	'	'	361.8	'	'	'	'
Repurchased of long term debt including accrued interest	'	'	€ 423	'	'	'	'

Longterm_Debt_Estimated_Fair_V

Long-term Debt - Estimated Fair Value of Eurobonds (Detail) (EUR €)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'		'
Carrying amount	€ 1,021,900		€ 710,100
Eurobonds [Member]	'		'
Debt Instrument [Line Items]	'		'
Principal amount	988,153		600,000
Carrying amount	1,021,930		710,095
Fair value	€ 1,028,238	[1]	€ 700,644	[1]
[1]	Source: Bloomberg Finance LP

Lines_of_Credit_Additional_Inf

Lines of Credit - Additional Information (Detail) (EUR €)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Line of Credit Facility [Line Items]	'	'
Revolving credit facility maturity year	'2018	'
Credit facility cancellation period	'March 2013	'
Credit facility expiration period	'May 2015	'
Minimum committed capital to net total assets ratio to be maintained under new credit facility	40.00%	'
Long-term committed capital maturity year	'1 year	'
Committed capital to net assets ratio under credit facility	'This ratio was 89.6 percent. Therefore, we are in compliance with the covenant at the end of 2013.	'This ratio was 85.8 percent. Therefore, we were in compliance with the covenant at the end of 2012
New credit facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Available credit facility	700	500
Credit facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Available credit facility	700	500
Amount outstanding under credit facility	0	0
Interest rate description	'Will bear interest at EURIBOR or LIBOR plus a margin that depends on our liquidity position.	'

Commitments_Contingencies_and_2

Commitments, Contingencies and Guarantees - Contractual Obligations (Detail) (EUR €)	Dec. 31, 2013
In Thousands, unless otherwise specified
Recorded Unconditional Purchase Obligation [Line Items]	'
Contractual obligations	€ 3,503,308
1 year	1,970,407
2 year	152,988
3 year	82,891
4 year	320,320
5 year	59,861
After 5 years	916,841
Long-term Debt [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Contractual obligations	1,341,380	[1]
1 year	45,079	[1]
2 year	44,952	[1]
3 year	44,907	[1]
4 year	275,640	[1]
5 year	54,155	[1]
After 5 years	876,647	[1]
Operating Lease Obligations [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Contractual obligations	74,946
1 year	30,293
2 year	21,543
3 year	14,081
4 year	4,803
5 year	2,539
After 5 years	1,687
Purchase Obligations [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Contractual obligations	2,012,913
1 year	1,894,455
2 year	85,548
3 year	16,223
4 year	13,772
5 year	2,382
After 5 years	533
Unrecognized Tax Benefits [Member]	'
Recorded Unconditional Purchase Obligation [Line Items]	'
Contractual obligations	74,069
1 year	580
2 year	945
3 year	7,680
4 year	26,105
5 year	785
After 5 years	€ 37,974
[1]	See Note 15 for the amounts excluding interest expenses.

Commitments_Contingencies_and_3

Commitments, Contingencies and Guarantees - Additional Information (Detail) (EUR €)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments And Contingencies Disclosure [Abstract]	'	'	'
Expense on operating lease payments	€ 42	€ 41.60	€ 40.60

Commitments_Contingencies_and_4

Commitments, Contingencies and Guarantees - Purchase Options (Detail) (EUR €)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Purchase options	€ 13,983
1 year	'
2 year	'
3 year	13,983
4 year	'
5 year	'
After 5 years	'

Employee_Benefits_Bonus_Plan_E

Employee Benefits - Bonus Plan Expenses (Detail) (All Participants [Member], EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
All Participants [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Bonus expenses	€ 32,698	€ 16,474	€ 15,557

Employee_Benefits_Additional_I

Employee Benefits - Additional Information (Detail) (EUR €)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Y

Scenario, Forecast [Member]

Management [Member]

Management [Member]

Management [Member]

Minimum [Member]

Maximum [Member]

Cymer Acquisition [Member]

Employee Purchase Plan [Member]

Individual Variable Pay And Sales Reward [Member]

Individual Variable Pay And Sales Reward [Member]

Individual Variable Pay And Sales Reward [Member]

Sales Reward [Member]

Seniority Level One [Member]

Seniority Level Two [Member]

Seniority Level Three [Member]

Seniority Level Four [Member]

Employee Stock Option Plan [Member]

Profit Sharing [Member]

Profit Sharing [Member]

Profit Sharing [Member]

Employee Plan [Member]

Employee Plan [Member]

Employee Plan [Member]

Person

Cymer Acquisition [Member]

Cymer Acquisition [Member]

Companies

Plans

OptionPlan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STI (Cash)

'

'

'

'

€ 2,100,000

€ 1,800,000

€ 1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior management (excluding Board of Management) bonus, lower range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

Senior management (excluding Board of Management) bonus, higher range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

70.00%

150.00%

200.00%

'

'

'

'

'

'

'

Other labor related expenses

835,563,000

711,039,000

648,869,000

'

'

'

'

'

'

'

'

25,800,000

24,400,000

23,200,000

2,300,000

'

'

'

'

'

55,900,000

64,500,000

64,000,000

'

'

'

Profit sharing bonus, higher range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

Profit sharing bonus, lower range

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

Profit sharing percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14.00%

18.00%

20.00%

Recognized expense associated with share-based payments

52,371,000

18,714,000

12,430,000

'

'

'

'

'

'

25,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tax benefit recognized related to recognized share-based compensation costs

10,700,000

900,000

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total compensation costs related to non-vested awards to be recognized in future periods

78,900,000

30,400,000

23,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average period for non-vested awards to be recognized in future in years

'1 year 7 months

'2 years

'1 year 11 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period of granted shares options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

Expiration period of unexercised stock options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

Number of stock option plans

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Service condition, period

'

'

'

'

'

'

'

'3 years

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of share plans

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum percentage of gross base salary for which an employee can participate in stock option and share plan

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum period for retaining the shares or stock options to qualify for cash bonus (months)

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of bonus on net invested amount after minimum period for retaining the shares or stock options

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

The number of years after deferral that participants elect to receive funds in future periods after earlier of the employment termination or their withdrawal election

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's liability under deferred compensation plans

€ 23,500,000

€ 11,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Dutch payroll employees in multi-employer union plan

5,525

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of companies which are covered by Multi Employer Plan

1,296

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Contributing Members in Multi-Employer Plan

146,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contribution to the multi-employer union plan

'

'Less than 5.0 percent of the total contribution to the plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Multi employer plan, asset to obligation coverage ratio minimum

104.30%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Multi employer plan coverage ratio

103.40%

93.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pension premium percentage

24.00%

'

'

24.10%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee_Benefits_Bonus_Costs_

Employee Benefits - Bonus Costs Under Performance Related Bonus Plan (Detail) (Senior Management [Member], EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Senior Management [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Bonus expenses	€ 30,631	€ 14,588	€ 13,131

Employee_Benefits_Assumption_o

Employee Benefits - Assumption of Black-Scholes Option Valuation of Fair Value of Company's Stock Options (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Compensation Related Costs [Abstract]	'		'		'
Weighted average share price (in EUR)	€ 62		€ 40.30		€ 28
Volatility (in percentage)	27.00%		25.60%		37.80%
Expected life (in years)	'5 years 7 months		'5 years		'4 years 10 months
Risk free interest rate	0.80%		2.10%		2.90%
Expected dividend yield (in EUR)	€ 2		€ 1.45		€ 1.25
Forfeiture rate	'	[1]	'	[1]	'	[1]
[1]	As of year end for each of the three years ended December 31, forfeitures are estimated to be nil.

Employee_Benefits_Assumption_o1

Employee Benefits - Assumption of Black-Scholes Option Valuation of Fair Value of Company's Stock Options (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Compensation Related Costs [Abstract]	'		'		'
Forfeiture rate	'	[1]	'	[1]	'	[1]
[1]	As of year end for each of the three years ended December 31, forfeitures are estimated to be nil.

Employee_Benefits_Stock_Option

Employee Benefits - Stock Options (Detail)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Euro [Member]	Euro [Member]	Euro [Member]	USD [Member]	USD [Member]	USD [Member]
	EUR (€)	EUR (€)	EUR (€)	USD ($)	USD ($)	USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Weighted average fair value of stock options granted	€ 14.22	€ 8.97	€ 8.28	$21.74	$11.87	$10.42
Weighted average share price at the exercise date of stock options	€ 59.53	€ 40.45	€ 29.39	$77.25	$50.88	$41.94
Aggregate intrinsic value of stock options exercised	€ 15,924	€ 71,331	€ 30,204	$11,086	$12,684	$11,323
Aggregate remaining contractual term of currently exercisable options (years)	'3 years 1 month	'3 years 7 months	'2 years 1 month	'3 years 1 month	'3 years 2 months	'1 year 10 months
Aggregate intrinsic value of exercisable stock options	37,441	34,438	39,384	22,781	21,882	20,492
Aggregate intrinsic value of outstanding stock options	€ 38,718	€ 35,671	€ 45,141	$25,369	$22,433	$20,791

Employee_Benefits_Stock_Option1

Employee Benefits - Stock Option Transactions (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	EUR (€)	Euro [Member]	USD [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Outstanding options, Beginning Balance	'	'	1,128,162	494,836
Granted	'	'	28,308	101,400	[1]
Exercised	'	'	-358,581	-178,374
Forfeited	'	'	-4,234	-7,311
Expired	'	'	-11,353	-3,916
Outstanding options, Ending Balance	'	'	782,302	406,635
Exercisable	'	'	731,452	325,026
Outstanding, Weighted average exercise price, Beginning Balance	$19.06	€ 16.38	'	'
Granted, Weighted average exercise price	$60.86	€ 58.35	'	'
Exercised, Weighted average exercise price	$14.86	€ 15.12	'	'
Forfeited, Weighted average exercise price	$23.81	€ 20.27	'	'
Expired, Weighted average exercise price	$11.33	€ 10.11	'	'
Outstanding, Weighted average exercise price, Ending Balance	$31.31	€ 18.55	'	'
Exercisable, Weighted average exercise price	$23.61	€ 16.85	'	'
[1]	USD-denominated grants include 79,153 options with a weighted average exercise price of USD 53.07 which have been assumed by ASML as part of the acquisition of Cymer.

Employee_Benefits_Stock_Option2

Employee Benefits - Stock Option Transactions (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013		Dec. 31, 2013
	USD ($)	EUR (€)	USD [Member]		Cymer Acquisition [Member]
					USD [Member]
					USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'		'
Granted	'	'	101,400	[1]	79,153
Granted, Weighted average exercise price	$60.86	€ 58.35	'		$53.07
[1]	USD-denominated grants include 79,153 options with a weighted average exercise price of USD 53.07 which have been assumed by ASML as part of the acquisition of Cymer.

Employee_Benefits_Outstanding_

Employee Benefits - Outstanding Stock Options (Detail)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

Euro [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

USD [Member]

Price Range One [Member]

Price Range Two [Member]

Price Range Three [Member]

Price Range Four [Member]

Price Range Five [Member]

Price Range Six [Member]

Price Range Seven [Member]

Price Range Eight [Member]

Price Range Nine [Member]

Price Range Ten [Member]

Price Range One [Member]

Price Range Two [Member]

Price Range Three [Member]

Price Range Four [Member]

Price Range Five [Member]

Price Range Six [Member]

Price Range Seven [Member]

Price Range Eight [Member]

Price Range Nine [Member]

Price Range Ten [Member]

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Range of exercise prices, minimum

'

€ 0

€ 10

€ 15

€ 20

€ 25

€ 40

€ 50

€ 60

€ 70

€ 80

'

$0

$10

$15

$20

$25

$40

$50

$60

$70

$80

Range of exercise prices, maximum

'

€ 10

€ 15

€ 20

€ 25

€ 40

€ 50

€ 60

€ 70

€ 80

€ 90

'

$10

$15

$20

$25

$40

$50

$60

$70

$80

$90

Exercise Price Range, Number of Outstanding Options

782,302

'

380,681

185,086

141,192

24,843

25,256

6,156

19,088

'

'

406,635

20,560

133,117

4,311

80,019

93,456

1,468

9,540

1,383

43,993

18,788

Weighted average remaining contractual life (years)

'3 years 6 months

'

'2 years 4 months

'3 years 1 month

'4 years 1 month

'7 years 9 months

'8 years 10 months

'9 years 2 months

'9 years 9 months

'

'

'4 years 3 months

'1 year 12 months

'11 months

'4 years 10 months

'3 years 11 months

'5 years 9 months

'7 years 8 months

'8 years 9 months

'9 years 1 month

'9 years 2 months

'9 years 9 months

Employee_Benefits_Summary_of_S

Employee Benefits - Summary of Share Plans (Detail)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Euro [Member]	Euro [Member]	Euro [Member]	USD [Member]	USD [Member]	USD [Member]
	EUR (€)	EUR (€)	EUR (€)	USD ($)	USD ($)	USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Total fair value at vesting date of shares vested during the year (in thousands)	€ 38,280	€ 16,179	€ 9,155	$51,798	$5,392	$1,956
Weighted average fair value of shares granted	€ 55.83	€ 36.15	€ 28.09	$83.58	$47.71	$39

Employee_Benefits_Employee_Sha

Employee Benefits - Employee Share Issuances (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
	Euro [Member]	Euro [Member]	Euro [Member]	USD [Member]		USD [Member]	USD [Member]
	EUR (€)	EUR (€)	EUR (€)	USD ($)		USD ($)	USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'	'
Conditionally outstanding shares, Beginning balance	1,693,610	'	'	249,094		'	'
Granted	548,786	'	'	1,852,320	[1]	'	'
Vested/Issued	-635,753	'	'	-628,802		'	'
Forfeited	-62,311	'	'	-92,292		'	'
Conditionally outstanding shares, Ending balance	1,544,332	1,693,610	'	1,380,320		249,094	'
Conditionally outstanding shares, Weighted average grant date fair value, Beginning balance	€ 29.92	'	'	$40.71		'	'
Granted, Weighted average grant date fair value	€ 55.83	€ 36.15	€ 28.09	$83.58		$47.71	$39
Vested/Issued, Weighted average grant date fair value	€ 26.94	'	'	$76.12		'	'
Forfeited, Weighted average grant date fair value	€ 33.40	'	'	$78.94		'	'
Conditionally outstanding shares, Weighted average grant date fair value, Ending balance	€ 40.21	€ 29.92	'	$79.55		$40.71	'
[1]	USD-denominated grants include 1,634,990 shares with a weighted average fair value of USD 83.94 which have been assumed by ASML as part of the acquisition of Cymer.

Employee_Benefits_Employee_Sha1

Employee Benefits - Employee Share Issuances (Parenthetical) (Detail) (USD [Member], USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'
Granted	1,852,320	[1]	'	'
Granted, Weighted average grant date fair value	$83.58		$47.71	$39
Cymer Acquisition [Member]	'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'
Granted	1,634,990		'	'
Granted, Weighted average grant date fair value	$83.94		'	'
[1]	USD-denominated grants include 1,634,990 shares with a weighted average fair value of USD 83.94 which have been assumed by ASML as part of the acquisition of Cymer.

Employee_Benefits_Pension_Cost

Employee Benefits - Pension Costs (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation Related Costs [Abstract]	'	'	'
Pension plan based on multi-employer union plan	€ 40,476	€ 34,525	€ 31,819
Pension plans based on defined contribution	19,799	15,773	14,128
Pension and retirement expenses	€ 60,275	€ 50,298	€ 45,947

Legal_Contingencies_Additional

Legal Contingencies - Additional Information (Detail) (EUR €)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Litigation charges	€ 3.20
Percentage of damages related to claims for patent infringement	3.00%

Income_Taxes_Components_of_Pro

Income Taxes - Components of (Provision for) Benefit from Income Taxes (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Current tax	-€ 52,753	-€ 79,255	-€ 129,127
Deferred tax	44,766	74,993	-52,548
Provision for income taxes	-€ 7,987	-€ 4,262	-€ 181,675

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Line Items]	'	'	'
Domestic income tax rate	25.00%	25.00%	25.00%
Income tax adjustment with respect to prior year taxes	€ 5,155,000	€ 18,275,000	€ 9,097,000
Income tax adjustment with respect to prior years taxes	16,164,000	'	'
Adjustment in respect of prior years' current taxes (in percentage)	-0.50%	-1.60%	-0.60%
Tax expense (benefit) recognized, percentage	0.70%	-8.30%	-0.40%
Tax benefit (charge) recognized	-7,588,000	95,465,000	6,634,000
Tax audits in different jurisdictions	2,025,000	92,521,000	'
Liability for unrecognized tax benefits	74,069,000	59,967,000	155,432,000
The amount of loss carry forward, tax effect	67,282,000	5,557,000	7,735,000
Hong Kong [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Period subject to tax audits	'2011 onwards	'	'
United States [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Period subject to tax audits	'2001 onwards	'	'
Dutch statutory tax rate [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Domestic income tax rate	25.00%	25.00%	25.00%
Liability for Unrecognized Tax Benefits [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Liability for unrecognized tax benefits	74,100,000	60,000,000	'
Accrued interest and penalties recorded in the Consolidated Balance Sheets	22,900,000	21,400,000	'
Accrued interest and penalties recorded in the Consolidated Statements of Operations	4,100,000	-3,100,000	-9,300,000
Unrecognized tax benefits that would impact effective tax rate	600,000	'	'
Period of estimated changes to the liability for unrecognized tax benefits	'next twelve months	'	'
United States federal tax laws [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Period of offsetting net operating losses	'20 years	'	'
Total amount of loss carry forward, tax basis	67,500,000	'	'
The amount of loss carry forward, tax effect	23,600,000	'	'
United States state tax laws [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Minimum offsetting period allowed by United States	'5 years	'	'
Maximum offsetting period allowed by United States	'20 years	'	'
Total amount of loss carry forward, tax basis	254,300,000	'	'
The amount of loss carry forward, tax effect	7,900,000	'	'
Adjustments in Respect of Prior Years Current Taxes [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Income tax adjustment with respect to prior year taxes	'	18,300,000	'
Adjustment in respect of prior years' current taxes (in percentage)	'	-1.60%	'
Adjustments in Respect of Prior Years' Deferred Taxes [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Income tax adjustment with respect to prior years taxes	16,200,000	'	'
NID stock in Belgium [Member]	'	'	'
Income Tax Disclosure [Line Items]	'	'	'
Period of offsetting net operating losses	'7 years	'	'
Total amount of loss carry forward, tax basis	47,600,000	'	'
The amount of loss carry forward, tax effect	€ 16,200,000	'	'

Income_Taxes_Reconciliation_Be

Income Taxes - Reconciliation Between (Provision for) Benefit from Income Taxes (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Income before income taxes	€ 1,023,477	€ 1,150,578	€ 1,648,635
Income tax provision based on company's domestic rate	-255,869	-287,644	-412,159
Effects of tax rates in foreign jurisdictions	23,459	9,786	20,663
Adjustments in respect of tax exempt income	29,430	23,532	19,134
Adjustments in respect of tax incentives	120,751	143,160	180,096
Adjustments in respect of prior years' current taxes	5,155	18,275	9,097
Adjustments in respect of prior years' deferred taxes	16,164	'	'
Movements in the liability for unrecognized tax benefits	-7,588	95,465	6,634
Adjustment in respect of non-taxable pre-existing relationship	67,730	'	'
Other credits and non-taxable items	-7,219	-6,836	-5,140
Provision for income taxes	-€ 7,987	-€ 4,262	-€ 181,675
Income before income taxes (in percentage)	100.00%	100.00%	100.00%
Income tax (provision) benefit based on company's domestic rate (in percentage)	25.00%	25.00%	25.00%
Effects of tax rates in foreign jurisdictions (in percentage)	-2.30%	-0.90%	-1.30%
Adjustments in respect of tax exempt income (in percentage)	-2.90%	-2.00%	-1.20%
Adjustments in respect of tax incentives (in percentage)	-11.70%	-12.40%	-10.90%
Adjustments in respect of prior years' current taxes (in percentage)	-0.50%	-1.60%	-0.60%
Adjustments in respect of prior years' deferred taxes (in percentage)	-1.60%	'	'
Movements in the liability for unrecognized tax benefits (in percentage)	0.70%	-8.30%	-0.40%
Adjustment in respect of non-taxable pre-existing relationship (in percentage)	-6.60%	'	'
Other credits and non-taxable items (in percentage)	0.70%	0.60%	0.40%
Provision for income taxes (in percentage)	0.80%	0.40%	11.00%

Income_Taxes_Income_Taxes_Reco

Income Taxes - Income Taxes Recognized Directly in Shareholders' Equity (Including OCI) (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Income Tax Disclosure [Abstract]	'		'		'
Derivative financial instruments	-€ 759	[1]	-€ 1,066	[1]	€ 6,257	[1]
Tax (benefit) deficit from share-based payments	-3,110		-2,116		11
Total income tax recognized in shareholders' equity	-€ 3,869		-€ 3,182		€ 6,268
[1]	Recognized directly in OCI.

Income_Taxes_Deferred_Tax_Posi

Income Taxes - Deferred Tax Position and Liability for Unrecognized Tax Benefits Recorded on Consolidated Balance Sheets (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'	'
Liability for unrecognized tax benefits	-€ 74,069	-€ 59,967	-€ 155,432
Deferred tax position	-30,176	114,527	137,946
Total	-€ 104,245	€ 54,560	'

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Beginning and Ending Balance of Liability for Unrecognized Tax Benefits (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Beginning Balance	€ 59,967	€ 155,432
Gross increases - tax positions in prior period	6,045	4,297
Gross decreases - tax positions in prior period	-2,025	-92,521
Gross increases - tax positions in current period	6,796	3,255
Increase resulting from acquisition	6,514	'
Settlements	-2,964	'
Lapse of statute of limitations	-264	-10,496
Ending Balance	€ 74,069	€ 59,967

Income_Taxes_Changes_in_Deferr

Income Taxes - Changes in Deferred Income Tax Assets and Liabilities (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Beginning Balance	€ 114,527	€ 137,946
Acquisitions through business combinations	-201,381	'
Consolidated Statements of Operations	53,084	-20,242
Effect of changes in exchange rates	3,594	-3,177
Ending Balance	-€ 30,176	€ 114,527

Income_Taxes_Deferred_Tax_Posi1

Income Taxes - Deferred Tax Position (Detail) (EUR €)	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'		'		'
Deferred tax assets - current	€ 124,431		€ 103,695		'
Deferred tax assets - non-current	139,513		39,443		'
Total deferred tax assets	263,944	[1]	143,138	[1]	159,455
Deferred tax liabilities - current	-3,494		-271		'
Deferred tax liabilities - non-current	-290,626		-28,340		'
Total deferred tax liabilities	-294,120		-28,611		-21,509
Total	-€ 30,176		€ 114,527		€ 137,946
[1]	Valuation allowances recognized in relation to deferred tax assets as at December 31, 2013 amounted to EUR 25.0 million (2012: EUR 30.5 million)

Income_Taxes_Composition_of_De

Income Taxes - Composition of Deferred Tax Assets and Liabilities in Financial Statements (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		30-May-13	Dec. 31, 2011
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	€ 90,045	[1]	'		€ 90,045	'
Changes in deferred tax assets in Consolidated Statements of Operations	43,788	[1]	-13,002		'	'
Changes in deferred tax assets in foreign exchange	-13,027	[1]	-3,315		'	'
Capitalized R&D expenditures	32,130		27,403		'	34,374
Inventories	46,661		28,167		'	35,820
Deferred revenue	16,409		20,572		'	23,892
Provisions	45,460		21,528		'	14,515
Installation and warranty reserve	6,702		7,151		'	8,772
Tax effect carry-forward losses	67,282		5,557		'	7,735
Fixed assets	11,785		7,798		'	6,495
Restructuring and impairment	3,361		4,336		'	5,146
Alternative minimum tax credits	6,342	[2]	5,227	[2]	'	5,028	[2]
Share-based payments	16,151		1,433		'	950
Other temporary differences	11,661		13,966		'	16,728
Total deferred tax assets	263,944	[1]	143,138	[1]	'	159,455
Intangible fixed assets	-261,905		'		'	'
Fixed assets	-17,592		-25,890		'	-19,108
Borrowing costs	-1,823		-1,958		'	-1,554
Other temporary differences	-12,800		-763		'	-847
Total deferred tax liabilities	-294,120		-28,611		'	-21,509
Changes in deferred tax liability in Acquisitions through business combinations EUR	-291,426		'		'	'
Changes in deferred tax liability in Consolidated Statements of Operations	9,296		-7,240		'	'
Changes in deferred tax liability in foreign exchange	16,621		138		'	'
Capitalized R&D expenditures [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	5,882		-6,465		'	'
Changes in deferred tax assets in foreign exchange	-1,155		-506		'	'
Inventories [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	10,258		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	9,269		-7,351		'	'
Changes in deferred tax assets in foreign exchange	-1,033		-302		'	'
Deferred revenue [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	41,679		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	-43,035		-3,083		'	'
Changes in deferred tax assets in foreign exchange	-2,807		-237		'	'
Provisions [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	7,148		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	17,960		7,296		'	'
Changes in deferred tax assets in foreign exchange	-1,176		-283		'	'
Installation and warranty reserve [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	-174		-1,508		'	'
Changes in deferred tax assets in foreign exchange	-275		-113		'	'
Tax effect carry-forward losses [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	754		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	61,551		-2,219		'	'
Changes in deferred tax assets in foreign exchange	-580		41		'	'
Fixed assets [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	4,140		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	325		1,454		'	'
Changes in deferred tax assets in foreign exchange	-478		-151		'	'
Changes in deferred tax liability in Acquisitions through business combinations EUR	-4,786		'		'	'
Changes in deferred tax liability in Consolidated Statements of Operations	12,517		-6,965		'	'
Changes in deferred tax liability in foreign exchange	567		183		'	'
Restructuring and impairment [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	-791		-733		'	'
Changes in deferred tax assets in foreign exchange	-184		-77		'	'
Alternative minimum tax credits [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	1,349	[2]	229	[2]	'	'
Changes in deferred tax assets in foreign exchange	-234	[2]	-30	[2]	'	'
Share-based payments [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	9,365		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	5,939		516		'	'
Changes in deferred tax assets in foreign exchange	-586		-33		'	'
Other temporary differences [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax assets in Acquisitions through business combinations EUR	16,701		'		'	'
Changes in deferred tax assets in Consolidated Statements of Operations	-14,487		-1,138		'	'
Changes in deferred tax assets in foreign exchange	-4,519		-1,624		'	'
Changes in deferred tax liability in Acquisitions through business combinations EUR	-303		'		'	'
Changes in deferred tax liability in Consolidated Statements of Operations	-12,086		129		'	'
Changes in deferred tax liability in foreign exchange	352		-45		'	'
Intangible fixed assets [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax liability in Acquisitions through business combinations EUR	-286,337		'		'	'
Changes in deferred tax liability in Consolidated Statements of Operations	8,730		'		'	'
Changes in deferred tax liability in foreign exchange	15,702		'		'	'
Borrowing costs [Member]	'		'		'	'
Composition Of Deferred Tax Assets And Liabilities [Line Items]	'		'		'	'
Changes in deferred tax liability in Consolidated Statements of Operations	€ 135		-€ 404		'	'
[1]	Valuation allowances recognized in relation to deferred tax assets as at December 31, 2013 amounted to EUR 25.0 million (2012: EUR 30.5 million)
[2]	Alternative minimum tax credits relate to prepaid US taxes which are credited against future taxable profits after the carry-forward losses used.

Income_Taxes_Composition_of_De1

Income Taxes - Composition of Deferred Tax Assets and Liabilities in Financial Statements (Parenthetical) (Detail) (EUR €)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Valuation allowances recognized in relation to deferred tax assets	€ 25	€ 30.50

Segment_Disclosure_Additional_

Segment Disclosure - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Segment
Segment Information [Line Items]	'	'	'
Number of reportable segments	1	'	'
Increase in net system sales	€ 191,500,000	'	'
Net sales	5,245,326,000	4,731,555,000	5,651,035,000
Percentage of Increase in net system sales	5.00%	'	'
System sales [Member]	'	'	'
Segment Information [Line Items]	'	'	'
Net sales	3,993,129,000	3,801,632,000	4,883,913,000
Largest Customer [Member]	'	'	'
Segment Information [Line Items]	'	'	'
Net sales	2,058,600,000	1,236,100,000	1,311,700,000
Net sales revenue from largest customer as percentage	39.20%	26.10%	23.20%
Three Largest Customers [Member]	'	'	'
Segment Information [Line Items]	'	'	'
Accounts receivables and finance receivables of three largest customers based on net sales	€ 861,400,000	€ 535,100,000	'
Accounts receivables and finance receivables of three largest customers based on net sales	73.30%	58.90%	'

Segment_Disclosure_Net_Sales_f

Segment Disclosure - Net Sales for New and Used Systems (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Net sales	€ 5,245,326	€ 4,731,555	€ 5,651,035
System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	3,993,129	3,801,632	4,883,913
New systems [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	3,890,154	3,620,260	4,780,720
Used systems [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	€ 102,975	€ 181,372	€ 103,193

Segment_Disclosure_Net_System_

Segment Disclosure - Net System Sales Per Technology (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Net Sales in EUR	€ 5,245,326	€ 4,731,555	€ 5,651,035
System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net Sales in EUR	3,993,129	3,801,632	4,883,913
Technology [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net system Sales in unit	157	170	222
Net Sales in EUR	3,993,129	3,801,632	4,883,913
Technology [Member] | EUV [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net system Sales in unit	1	1	3
Net Sales in EUR	60,100	43,700	119,300
Technology [Member] | ArF i [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net system Sales in unit	77	72	101
Net Sales in EUR	3,120,719	2,715,221	3,549,122
Technology [Member] | ArF dry [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net system Sales in unit	2	4	11
Net Sales in EUR	38,019	81,428	228,909
Technology [Member] | KrF [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net system Sales in unit	64	78	87
Net Sales in EUR	720,053	908,244	926,572
Technology [Member] | I-line [Member] | System sales [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net system Sales in unit	13	15	20
Net Sales in EUR	€ 54,238	€ 53,039	€ 60,010

Segment_Disclosure_Net_Sales_a

Segment Disclosure - Net Sales and Long-lived Assets by Geographic Region (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Net sales	€ 5,245,326	€ 4,731,555	€ 5,651,035
Long-lived assets	1,217,840	1,029,923	1,053,610
Japan [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	201,664	292,309	405,595
Long-lived assets	3,340	19,585	69,001
Korea [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	1,286,509	1,276,304	1,318,777
Long-lived assets	16,155	17,664	16,250
Singapore [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	139,313	98,554	436,308
Long-lived assets	1,109	968	1,167
Taiwan [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	2,221,426	1,479,768	1,146,601
Long-lived assets	48,427	50,372	46,418
Rest of Asia [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	478,234	197,262	450,796
Long-lived assets	3,742	2,073	1,496
Netherlands [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	11,525	'	'
Long-lived assets	969,192	869,736	851,612
Rest of Europe [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	187,030	256,192	505,129
Long-lived assets	2,600	1,571	1,198
United States [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	719,625	1,131,166	1,387,829
Long-lived assets	€ 173,275	€ 67,954	€ 66,468

Selected_Operating_Expenses_an2

Selected Operating Expenses and Additional Information - Personnel Expenses for All Payroll Employees (Detail) (EUR €)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation Related Costs [Abstract]	'	'	'
Wages and salaries	€ 835,563	€ 711,039	€ 648,869
Social security expenses	69,839	58,180	52,550
Pension and retirement expenses	60,275	50,298	45,947
Share-based payments	52,371	18,714	12,430
Personnel expenses	€ 1,018,048	€ 838,231	€ 759,796

Selected_Operating_Expenses_an3

Selected Operating Expenses and Additional Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Employees	Employees	Employees
Payroll Personnel Employed Per Sector [Line Items]	'	'	'
Average number of payroll employees (in FTEs)	9,540	8,140	7,627
Netherlands [Member]	'	'	'
Payroll Personnel Employed Per Sector [Line Items]	'	'	'
Average number of payroll employees (in FTEs)	5,112	4,620	4,313

Selected_Operating_Expenses_an4

Selected Operating Expenses and Additional Information - Total Number of Payroll and Temporary Personnel Employed in FTE's Per Sector (Detail)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Employees	Employees	Employees
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	13,225	10,636	9,890
Customer Support [Member]	'	'	'
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	2,949	2,538	2,478
SG&A [Member]	'	'	'
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	1,098	869	723
Industrial Engineering [Member]	'	'	'
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	785	637	420
Manufacturing & Logistics [Member]	'	'	'
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	3,658	2,856	2,852
R&D [Member]	'	'	'
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	4,735	3,736	3,417
Temporary FTEs [Member]	'	'	'
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	2,865	2,139	1,935
Payroll FTEs [Member]	'	'	'
Personnel Employed Per Sector [Line Items]	'	'	'
Total employees (in FTEs)	10,360	8,497	7,955

Research_and_Development_Costs1

Research and Development Costs - Additional Information (Detail) (EUR €)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Research And Development [Abstract]	'	'	'
R&D costs net of credits and excluding contributions under the NRE funding agreements	€ 882,029,000	€ 589,182,000	€ 590,270,000
Increase in R&D costs net of credits and excluding contributions under the NRE funding agreements	292,900,000	'	'
Increase in percentage of R&D costs net of credits and excluding contributions under the NRE funding agreements	49.70%	'	'
Research and development credits as included in research and development costs	€ 16,000,000	€ 17,900,000	€ 25,100,000

Interest_and_Other_Net_Additio

Interest and Other, Net - Additional Information (Detail) (EUR €)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Banking And Thrift Interest [Abstract]	'	'	'
Interest and other income	€ 9.20	€ 16.60	€ 41.20
Interest and other expenses	33.6	22.8	33.8
Net interest expense Eurobond and Interest Rate Swaps and Lease Obligations and Amortized Financing Costs	16.2	10.8	14.2
Principal amount	600	'	'
Interest rate on principal amount of Eurobond	5.75%	'	'
Loss on partial extinguishment of debt	8.9	0	0
Year of maturity	'2017	'	'
Interest income on cash pools	€ 1.90	€ 4.20	€ 6.80

Vulnerability_Due_to_Certain_C1

Vulnerability Due to Certain Concentrations - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Risks And Uncertainties [Abstract]	'
Concentration risk, Supplier	'ASML relies on outside vendors to manufacture the components and subassemblies used in its systems, each of which is obtained from a sole supplier or a limited number of suppliers. ASMLbs reliance on a limited group of suppliers involves several risks, including a potential inability to obtain an adequate supply of required components and reduced control over pricing and timely delivery of these subassemblies and components. In particular, from time to time, the number of systems we are able to produce may be limited by the production capacity of Zeiss. Zeiss is currently our sole supplier of lenses, collectors, and other critical optical components and is capable of producing these items only in limited numbers and only through the use of its manufacturing and testing facility in Oberkochen and Wetzlar, Germany. During 2013, ASMLbs production was not limited by the deliveries from Zeiss.

Shareholders_Equity_Additional

Shareholders' Equity - Additional Information (Detail)

0 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

30-May-13

Apr. 30, 2013

Dec. 31, 2013

Nov. 30, 2013

Oct. 31, 2013

Sep. 30, 2013

Aug. 31, 2013

Jul. 31, 2013

Jun. 30, 2013

30-May-13

31-May-13

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Apr. 24, 2013

Jul. 06, 2012

Dec. 31, 2013

Sep. 12, 2012

Sep. 12, 2012

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 07, 2012

EUR (€)

USD ($)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

Cymer [Member]

Foundation Intel [Member]

Foundation Administration Office Samsung [Member]

Foundation Administration Office TSMC [Member]

Ordinary Shares Issued in Relation to Acquisition of Cymer [Member]

Synthetic Share Buyback [Member]

Ordinary Stock [Member]

Common Class B [Member]

Common Class B [Member]

Common Class B [Member]

EUR (€)

EUR (€)

EUR (€)

EUR (€)

EUR (€)

Schedule Of Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock value authorized

'

'

€ 126,000,000

'

'

'

'

'

'

'

'

€ 126,000,000

€ 126,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative Preference Shares, authorized (actual number of shares)

'

'

700,000,000

'

'

'

'

'

'

'

'

700,000,000

700,000,000

700,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative Preference Shares, nominal value

'

'

€ 0.09

'

'

'

'

'

'

'

'

€ 0.09

€ 0.09

€ 0.09

'

'

'

'

'

'

'

'

'

'

'

'

Ordinary Shares, authorized (actual number of shares)

'

'

699,999,000

'

'

'

'

'

'

'

'

699,999,000

699,999,000

699,999,000

'

'

'

'

'

'

'

'

699,999,000

9,000

9,000

9,000

Ordinary Shares, nominal value

'

'

€ 0.09

'

'

'

'

'

'

'

'

€ 0.09

€ 0.09

€ 0.09

'

'

'

'

'

'

'

'

€ 0.09

€ 0.01

€ 0.01

€ 0.01

Treasury shares

'

'

5,970,118

'

'

'

'

'

'

'

'

5,970,118

5,970,118

12,687,246

'

'

'

'

'

'

'

'

'

'

'

'

Ordinary Shares, issued (actual number of shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

446,822,452

'

'

'

Cumulative preference shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition date

'

'

'

'

'

'

'

'

'

'

'

'

30-May-13

'

'

'

'

'

'

'

'

'

'

'

'

'

Name of acquired entity

'Cymer

'

'

'

'

'

'

'

'

'

'

'

'Cymer

'

'

'

'

'

'

'

'

'

'

'

'

'

Right to receive cash

'

'

'

'

'

'

'

'

'

$20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Right to receive ordinary shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.1502

'

'

'

'

'

'

'

'

'

Business acquisition shares issued

36,479,109

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,464,576

'

'

'

'

'

Total fair value shares issued Cymer acquisition

'

'

2,346,700,000

'

'

'

'

'

'

'

'

2,346,700,000

2,346,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Nominal value

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 0.09

'

'

'

'

'

'

'

'

'

'

'

'

Nominal value upon second amendment

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 9.24

'

'

'

'

'

'

'

'

'

'

'

'

Nominal value per ordinary share upon third amendment

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 0.06

'

'

'

'

'

'

'

'

'

'

'

'

Amount of decrease in nominal value per ordinary share upon third amendment

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 9.18

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of stock shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'100 ordinary shares for 77 ordinary shares

'

'

'

'

'

'

'

'

'

'

'

'

Nominal value before second amendment

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 0.09

'

'

'

'

'

'

'

'

'

'

'

'

Total number of shares purchased

'

297,500

874,953

962,146

556,443

179,146

283,097

321,486

749,434

'

389,974

4,614,179

'

'

'

'

'

'

'

'

'

93,411,216

'

'

'

'

Selling price of shares included in the customer co-investment program

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 39.91

'

€ 39.91

'

'

'

'

'

€ 39.91

'

'

'

'

Capital repayment

'

'

'

'

'

'

'

'

'

'

'

'

'

3,728,324,000

[1],[2]

'

'

'

'

'

'

'

3,728,300,000

'

'

'

'

Difference between capital repayment and net proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

125,600,000

'

'

'

'

'

'

'

125,600,000

'

'

'

'

Shares issued under customer co-investment program

'

'

'

'

'

'

'

'

'

'

'

'

'

€ 3,853,900,000

'

'

'

'

'

'

'

€ 3,853,900,000

'

'

'

'

Ordinary shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

62,977,877

12,595,575

20,992,625

'

'

'

'

'

'

Fractional shares

'

'

'

'

'

'

'

'

'

'

'

'

'

900

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Shares Authorized for issuance as percentage of Issued Share capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

Additional maximum Shares Authorized for issuance on business acquisitions and mergers percentage of Issued Share capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

Number of fractional shares

'

'

100

'

'

'

'

'

'

'

'

100

100

100

'

'

'

'

'

'

'

'

'

'

'

'

Ordinary share holders dividend entitled description

'

'

'

'

'

'

'

'

'

'

'

'

'One-ninth

'One-ninth

'

'

'

'

'

'

'

'

'

'

'

'

Ordinary share holders voting description

'

'

'

'

'

'

'

'

'

'

'

'

'Each ordinary share B entitles the holder thereof to cast one vote at the General Meeting.

'Each ordinary share B entitles the holder thereof to cast one vote at the General Meeting.

'

'

'

'

'

'

'

'

'

'

'

'

Period in which the company to repurchase or cancel cumulative preference shares

'

'

'

'

'

'

'

'

'

'

'

'

'20 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend declared per ordinary shares of EUR

'

'

€ 0.61

'

'

'

'

'

'

'

'

€ 0.61

€ 0.61

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

In 2012, as part of the capital repayment, EUR 3,728.3 million of shareholders' equity was returned to our shareholders (excluding Participating Customers in the CCIP) and the number of shares was reduced by 23 percent. See Note 26.

[2]

The difference of EUR 125.6 million between the capital repayment of EUR 3,728.3 million and the net proceeds from issuance of shares of EUR 3,853.9 million relates to the capital repayment on ASML's treasury shares which was also part of the Synthetic Share Buyback in November 2012.

Purchases_of_Equity_Securities2

Purchases of Equity Securities by the Issuer and Affiliated Purchasers - Additional Information (Detail) (EUR €)

0 Months Ended

1 Months Ended

9 Months Ended

Apr. 30, 2013

Dec. 31, 2013

Nov. 30, 2013

Oct. 31, 2013

Sep. 30, 2013

Aug. 31, 2013

Jul. 31, 2013

Jun. 30, 2013

31-May-13

Apr. 24, 2013

Apr. 17, 2013

Dec. 31, 2013

Equity [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase program agreement, maximum percentage authorized to buy back

'

'

'

'

'

'

'

'

'

'Up to a maximum of two times 10.0 percent of our issued share capital as of the date of authorization

'

'

Maximum amount of shares intended to be repurchased

'

'

'

'

'

'

'

'

'

'

€ 1,000,000,000

'

Total number of shares purchased as a part of publicly announced plans or programs

297,500

4,614,179

3,739,226

2,777,080

2,220,637

2,041,491

1,758,394

1,436,908

687,474

'

'

4,614,179

Value of shares repurchased during the period

'

'

'

'

'

'

'

'

'

'

'

€ 300,000,000

Average price paid per share

'

'

'

'

'

'

'

'

'

'

'

€ 65.02

Purchases_of_Equity_Securities3

Purchases of Equity Securities by the Issuer and Affiliated Purchasers - Summary of Shares Repurchased (Detail) (EUR €)	0 Months Ended	1 Months Ended								9 Months Ended
	Apr. 30, 2013	Dec. 31, 2013	Nov. 30, 2013	Oct. 31, 2013	Sep. 30, 2013	Aug. 31, 2013	Jul. 31, 2013	Jun. 30, 2013	31-May-13	Dec. 31, 2013
Equity [Abstract]	'	'	'	'	'	'	'	'	'	'
Total number of shares purchased	297,500	874,953	962,146	556,443	179,146	283,097	321,486	749,434	389,974	4,614,179
Average price paid per Share	€ 55.35	€ 67.25	€ 66.76	€ 69.34	€ 69.06	€ 67.83	€ 65.20	€ 60.39	€ 61.76	€ 65.02
Total number of shares purchased as part of publicly announced plans or programs	297,500	4,614,179	3,739,226	2,777,080	2,220,637	2,041,491	1,758,394	1,436,908	687,474	4,614,179
Maximum value of shares that may yet be purchased under the program	€ 983,534,770	€ 700,000,036	€ 758,841,727	€ 823,072,791	€ 861,656,533	€ 874,028,834	€ 893,232,250	€ 914,192,630	€ 959,449,401	'

Customer_CoInvestment_Program_

Customer Co-Investment Program - Additional Information (Detail) (EUR €)

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Jul. 09, 2012

Dec. 31, 2013

Dec. 31, 2012

Jul. 06, 2012

Dec. 31, 2012

Aug. 05, 2012

Aug. 05, 2012

Dec. 31, 2013

Jul. 09, 2012

Dec. 31, 2013

Jul. 09, 2012

Dec. 31, 2013

Jul. 09, 2012

Dec. 31, 2013

Jul. 09, 2012

Aug. 05, 2012

Aug. 27, 2012

Jul. 09, 2012

Jul. 09, 2012

Jul. 09, 2012

Project

Synthetic Share Buyback [Member]

Minimum [Member]

Maximum [Member]

Participating Customers [Member]

Participating Customers [Member]

Intel [Member]

Intel [Member]

TSMC [Member]

TSMC [Member]

Samsung [Member]

Samsung [Member]

TSMC EUV NRE Funding Agreement [Member]

Samsung EUV NRE Funding Agreement [Member]

Foundation Administration Office MAKTSJAB [Member]

Intel 450 MM NRE Funding Agreement [Member]

Intel EUV NRE Funding Agreement [Member]

Agreement

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contribution of participating customers

€ 1,380,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of funding projects in Customer Co-Investment Program

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment in ordinary shares as percentage of issued share capital

'

'

'

'

'

'

'

'

23.00%

'

15.00%

'

5.00%

'

3.00%

'

'

15.00%

'

'

Shares issued under customer co-investment program

'

'

3,853,900,000

'

3,853,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fund for R&D project

'

'

'

'

'

'

'

'

'

'

829,000,000

'

'

'

'

276,000,000

276,000,000

'

553,000,000

276,000,000

Selling price of shares included in the customer co-investment program

'

'

€ 39.91

€ 39.91

€ 39.91

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity participation, amount

'

'

'

'

'

'

'

'

'

€ 2,513,000,000

'

€ 838,000,000

'

€ 503,000,000

'

'

'

'

'

'

Intel shareholders agreement date

'

'2012-09-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Suspension event voting restrictions percentage of issued share capital

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of restriction or exclusion of pre-emption rights

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase of shares, percentage

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorization to repurchase shares, period

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional purchases allowed anniversary

'

'6 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of acquisition of outstanding share capital Maximum

'

'

'

'

'

'

'

'

'

19.90%

'

'

'

'

'

'

'

'

'

'

Percentage of acquisition of outstanding share capital Minimum

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Permission to acquire outstanding shares

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

'

'

'

'

'

'

'

Additional Percentage of Outstanding shares acquired that should be held by the Intel Foundation

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

'

'

'

'

'

'

'

Percentage of outstanding share capital

'

'

'

'

'

'

'

5.00%

'

2.00%

'

1.00%

'

1.00%

'

'

'

'

'

'

Period of acquisition of shares

'

'

'

'

'

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

Transfer of ordinary shares restriction period

'

'

'

'

'

'

'

'

'

'2 years 6 months

'

'

'

'

'

'

'

'

'

'

Percentage of transfer of shares

'

'

'

'

'

'

'

'

'

4.00%

'

2.50%

'

1.50%

'

'

'

'

'

'

Transfer of shares, period

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

Percentage of votes in General Meeting

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

Term of depositary receipts exchanged for shares

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of funding agreements entered

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

Funding payable over the term

'

'

'

'

'

'2013

'2017

'

'

'

'

'

'

'

'

'

'

'

'

'

Termination period of NRE funding agreement

'

31-Dec-17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period forecasted to install lithography equipment

'

'2022

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (EUR €)	12 Months Ended				6 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jul. 09, 2012
				Any Director or Officer of ASML or any Associate Thereof [Member]	Intel [Member]	Intel [Member]	Intel [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'
Fund for R&D project	'	'	'	'	'	'	€ 829,000,000
Investment in ordinary shares as percentage of issued share capital	'	'	'	'	'	'	15.00%
Net sales	5,245,326,000	4,731,555,000	5,651,035,000	'	301,700,000	494,700,000	'
Outstanding balance to related parties	'	'	'	€ 0	€ 65,000,000	-€ 182,300,000	'

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent events evaluation date	11-Feb-14